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“An algorithm must be seen to be believed. The 
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ABSTRACT 
Genome-wide association studies have very successfully found highly significant 
disease associations with single nucleotide polymorphisms (SNP) in the Major 
Histocompatibility Complex for adverse drug reactions, autoimmune diseases and 
infectious diseases.  However, the extensive linkage disequilibrium in the region has 
made it difficult to unravel the HLA alleles underlying these diseases.  Here I present two 
methods to comprehensively predict 4-digit HLA types from the two types of 
experimental genome data widely available.  
The Virtual SNP Imputation approach was developed for genome scan data and 
demonstrated a high precision and recall (96% and 97% respectively) for the prediction 
of HLA genotypes.  A reanalysis of 6 genome-wide association studies using the HLA 
imputation method identified 18 significant HLA allele associations for 6 autoimmune 
diseases: 2 in ankylosing spondylitis, 2 in autoimmune thyroid disease, 2 in Crohn’s 
disease, 3 in multiple sclerosis, 2 in psoriasis and 7 in rheumatoid arthritis.  The EPIGEN 
consortium also used the Virtual SNP Imputation approach to detect a novel association 
of HLA-A*31:01 with adverse reactions to carbamazepine. 
 ix 
For the prediction of HLA genotypes from next generation sequencing data, I 
developed a novel approach using a naïve Bayes algorithm called HLA-Genotyper.  The 
validation results covered whole genome, whole exome and RNA-Seq experimental 
designs in the European and Yoruba population samples available from the 1000 
Genomes Project.  The RNA-Seq data gave the best results with an overall precision and 
recall near 0.99 for Europeans and 0.98 for the Yoruba population.  I then successfully 
used the method on targeted sequencing data to detect significant associations of 
idiopathic membranous nephropathy with HLA-DRB1*03:01 and HLA-DQA1*05:01 
using the 1000 Genomes European subjects as controls. 
Using the results reported here, researchers may now readily unravel the 
association of HLA alleles with many diseases from genome scans and next generation 
sequencing experiments without the expensive and laborious HLA typing of thousands of 
subjects.  Both algorithms enable the analysis of diverse populations to help researchers 
pinpoint HLA loci with biological roles in infection, inflammation, autoimmunity, aging, 
mental illness and adverse drug reactions. 
 
  
 x 
PREFACE 
When the first large scale genome wide association study of 7 common diseases 
was published in Nature by the Wellcome Trust Case Control Consortium in 2007, the 
HLA region stood out like a skyscraper in 3 of 7 the Manhattan plots.  Surprisingly, 
unlike the other regions of association, no HLA genes could be pinpointed in the Major 
Histocompatibility Complex region to provide insight into the underlying biological 
processes underlying these important diseases. Buried in the genome scan data 
somewhere, the information was hidden waiting to be tapped with new algorithms.   Here 
I describe two algorithms that were developed to unravel the HLA proteins encoded in 
this region from available genomic research data as well as the application of those 
algorithms to test for disease associations.  
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CHAPTER ONE Introduction 
Major Histocompatibility Complex (MHC) is a set of genes that encode proteins 
found on the cell surface that recognize foreign substances such as viruses or bacteria. In 
humans, the MHC is also known as the human leukocyte antigen (HLA) complex and is 
located on chromosome 6p21.31 (Figure 1.1).  Of the 200 genes in this region, 40 genes 
encode leukocyte antigens, which play a major role in the adaptive immune response to 
pathogens[1, 2].  
Figure 1.1 The location of important immune related genes in the MHC region on 
chromosome 6p21.31. The region is divided into 3 major areas (MHC Class I, MHC 
Class II, and MHC Class III). 
 
Reproduced with permission from Klein J, Sato A. New England Journal of 
Medicine 2000;343:702-709, Copyright Massachusetts Medical Society 
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The MHC region is divided into three major classes (MHC Class I, MHC Class II, 
and MHC Class III) [1, 2].  While there are 200 genes in the MHC region, the most 
important are the MHC I Class genes, HLA-A, HLA-B, and HLA-C; and the MHC Class 
II genes, HLA-DRB1, HLA-DQA1, and HLA-DQB1.  Together these six genes are 
called the Classical HLA genes.  
The MHC Class I HLA protein’s function is to present internal peptides (antigens) 
to the surface of the cell. The MHC I HLA protein bind antigens whose residue length is 
about 8-10 amino acids [3].  If the presented peptides are foreign (such as viral peptides), 
the cell will attract killer T-cells also known as CD-8, which will then kill the presenting 
cell.    
The Class II HLA system proteins include the HLA-DR, HLA-DQ, HLA-DM, 
HLA-DO, and HLA-DP[1].  Unlike the Class I HLAs, the antigens presented are 
originally from outside of the cell. The cell via endocytosis engulfs the extracellular 
proteins, breaks them down and eventually presents them to the cell surface, which 
triggers an immune response from CD4 cells. The Class II HLAs are most important for 
protection against bacterial infection.  
Since these proteins are important in recognizing a large number of potential 
viruses and bacteria, the protein pocket used to present the antigens on the cell surface are 
highly polymorphic in a population. Distinguishing between self and non-self peptides is 
an important part of the cell immune defense mechanism. When this mechanism goes 
awry, adverse reactions or autoimmune diseases can result with severe disease and health 
consequences.   
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The association of the MHC locus to over 100 diseases is well established [2, 4, 
5].  Recent Genome-Wide Association Studies (GWAS) have been very successful in 
finding a wide variety of diseases significantly associated with the MHC locus [6-11].  
While these GWAS have both discovered and confirmed associations of many diseases 
with single nucleotide polymorphisms (SNPs) within the MHC locus, the identification of 
the HLA risk alleles and haplotypes that may be driving many of these large signals has 
been more challenging. The MHC locus contains extensive linkage disequilibrium with a 
high concentration of polymorphisms and genes that makes unraveling the underlying 
disease etiology involving HLA alleles difficult. While the signals can often be resolved 
to areas of the MHC I or II region, the specific HLA gene and allele is often not clear 
from the results of present GWAS analyses.  Often additional HLA typing is necessary to 
identify the HLA alleles associated with the study disease [7, 12].    
The landmark Wellcome Trust Case Control Consortium (WTCCC) genome-wide 
association study [6] is the first example of the limitation of GWAS  to pinpoint HLA 
disease association.  When this first large scale genome wide association study of 7 
common diseases was published in Nature by the WTCCC in 2007, the MHC region had 
highly significant results in 3 of the 7 Manhattan plots of disease association results 
(Figure 1.2). 
The Manhattan plots show the level of association of the disease across the 
genome. Where a “skyscraper” appears above a certain height, there is evidence of an 
association of SNPs in that region to the disease. ).  The larger the –log(p-value), the 
greater is the disease association. A p-value is considered significant if the –log(p-value) 
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is greater than the cutoff of 5x10-8. 
Figure 1.2 Genome Wide Scan for 7 common diseases: bipolar disorder, coronary 
artery disease, Crohn’s disease, hypertension, rheumatoid arthritis, type 1 diabetes, 
and type 2 diabetes 
The X-axis is the position in the genome across the 22 autosomal chromosomes and the X 
chromosome. The Y-axis is the –log10 (P-Value) of the 7 disease associations. This WTCCC 
study found significant signals in the MHC region for 3 diseases: rheumatoid arthritis, type 1 
diabetes and Crohn’s disease. 
 
 
Reproduced with permission from: Genome-wide association study of 14,000 cases of seven common 
diseases and 3,000 shared controls, The Wellcome Trust Case Control Consortium, Nature 447, 661-678 
(7 June 2007), Copyright Nature Publishing Group 
 
However despite highly significant regions of association at the SNP level, no 
genes could be pinpointed in the MHC region to provide insight into the underlying 
biological processes underlying these important diseases.  Unlike other regions, the signal 
of association will travel across relatively long stretches of the genome. In Figure 1.3, 
this is seen in the plot of the WTCCC genome scan of the association with three diseases: 
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ankylosing spondylitis, autoimmune thyroid disease and multiple sclerosis. The signal of 
disease association in the MHC is not limited to a region of 10-20 kilobases as typically 
found in a genome wide association study but spans megabases of the MHC region.  This 
dissertation will reanalyze the WTCCC data from these two analyses [6] in Chapter 3 
with the Virtual SNP imputation method to pinpoint the HLA disease associations to a 
specific HLA allele. 
Figure 1.3 Genome Scan of ankylosing spondylitis (a), autoimmune thyroid disease 
(b) and multiple sclerosis (c) in MHC region. Signal of association with disease is 
spread over a wide locus spanning many genes making the disease-related gene 
difficult to pinpoint. 
 
Reproduced with permission from: Association scan of 14,500 nonsynonymous SNPs in four 
diseases identifies autoimmunity variants, Wellcome Trust Case Control Consortium & The 
Australo-Anglo-American Spondylitis Consortium (TASC) Nature Genetics 39, 1329 - 1337 
(2007) Published online: 21 October 2007, Copyright Nature Publishing Group 
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HLA genotyping (if completed at all for many of these studies) is often targeted to 
one Classical HLA locus and not comprehensive across all 6 Classical HLA loci.  This 
approach may provide an incomplete picture.  For example, the GWAS published in the 
NEJM “Risk HLA-DQA1 and PLA2R1 Alleles in Idiopathic Membranous Nephropathy” 
by Stanescu et al [13] did find a significant signal from a SNP in the intron of HLA-
DQA1 but no HLA genotyping was completed to further ascertain whether the signal 
really was coming from HLA-DQA1 or a near by gene.  A follow-up study by 
Kanigicherla et al [14] genotyped two HLA alleles (DQA1 and DQB1) but not the near 
by HLA-DRB1 gene with known associations with multiple autoimmune diseases.  This 
limited HLA typing occurred despite correspondence to the NEJM regarding the 
Stanescu article suggesting the signal may actually be coming from HLA-
DRB1*03:01[15].  The HLA associations of this disease are examined more 
comprehensively in Chapter 5 with a novel naïve Bayes HLA prediction method 
implemented in the software HLA-Genotyper. 
 
The linkage disequilibrium (LD) in the MHC region is extensive and is very 
different from other regions of the genome.  Linkage disequilibrium is defined as the 
occurrence of some combinations of SNP or HLA alleles greater than expected from a 
random formation of MHC haplotypes from alleles based on their frequencies in a 
population. The common A3-B7-DR15 haplotype primarily found in Western Europe is 
4.8 megabases. In Europeans, the HLA-B*07 allele is more likely to be on the same 
haplotype as HLA-DRB1*15 than is expected if these two alleles formed haplotypes 
randomly. This is the haplotype found in the MHC sequence in the GRCh37 human 
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genome reference.  This haplotype block contrasts with other regions of the genome 
where haplotype blocks are typically less than 60 kilo-bases. Fewer recombination events 
have occurred in this region than expected. As a result of this extensive LD, any highly 
significant association results in a GWAS will spread across much larger regions 
compared to the rest of the genome where LD blocks are much smaller.  This contrasts to 
outside of the MHC region where the “half-life” (|D’| falls below .5) of LD blocks was 
estimated to be 60 kb [16].  The significance of a signal will often rise and fall based on 
the SNP LD to a specific HLA protein.  The ability to impute and analyze all classical 
HLA associations in large-scale GWAS should provide greater power to understand the 
role of the MHC in these many diseases.  
An increasing available source of research data is whole genome, whole exome 
and RNA-Seq data.  Data from these various next generation sequencing approaches 
should allow even more accurate prediction of HLA genotypes that could be useful in not 
just research but clinical settings. Laborious and costly HLA typing is routinely 
completed for transplants patients and their donors so a more automated accurate 
approach would see wide adoption. HLA typing is also now used to screen susceptible 
individuals before prescribing certain medications for the prevention of adverse drug 
reactions.   
The primary AIMS of this dissertation are the following: 
1) Development and testing of an algorithm to predict HLA alleles from genome 
wide association study data based on the concept of a Virtual SNP, which 
represents the HLA allele as a proxy during SNP imputation. 
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2) Application of the virtual SNP imputation approach to multiple genome wide 
association data sets to both confirm previous associations with disease and to 
discover novel associations. 
3) Development and testing of an algorithm to predict HLA alleles from next 
generation sequencing data using a naïve Bayes approach.  This approach will be 
validated using an independent data set from the 1000 genome project to predict 
HLA genotypes from whole genome, whole exome and RNA-Seq datasets. 
4) Application of the naïve Bayes algorithm to predict and test association of HLA 
in case control study.  
 
As a result of the work toward the AIM 1 outlined above and described in detail 
latter, the EPIGEN consortium used the Virtual SNP imputation method to detect a novel 
association with adverse reactions to carbamazepine.  The research was published in the 
New England Journal of Medicine in 2011: McCormack, M., et al., HLA-A*3101 and 
carbamazepine-induced hypersensitivity reactions in Europeans.  Besides testing for 
associations with adverse drug reactions, the two approaches for in silico prediction of 
HLA genotypes should be useful in the large number of studies where association studies 
have found significant signals in the MHC region.  These approaches will also provide 
the tools to analyze HLA disease associations in non-European populations with data 
available from next generation sequencing and array-based genome scan technologies. 
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CHAPTER TWO Imputation of HLA Alleles from Genome Scan Data 
2.1 Introduction to HLA Nomenclature  
As the number of HLA alleles detected in populations throughout the world has 
increased, the HLA nomenclature was revised in 2010 to deal with the increased allele 
numbers [17].  Due to this, many of the research articles referenced use the nomenclature 
used prior to 2010. Previously a 4-digit code was used to identify different protein coding 
alleles.  The first two digits identified the allele family, which often matches the 
serological antigen.  The 3rd and 4th digit were assigned sequentially as they were 
discovered.  So as a HLA protein with a new amino acid sequence was discovered, a new 
4-digit HLA code would be assigned. Each 4-digit HLA allele must by definition differ 
by at least one amino acid.  To distinguish synonymous substitutions in the protein, the 
5th and 6th digits were added.  This worked well until 2002 at which time more than 100 
alleles for a family were detected for HLA-A*02 and HLA-B*15. As a work around to 
the limitation of the nomenclature, the new alleles in these families were then assigned to 
A*92 and B*95.  Eventually as additional allele families reached 100 different proteins, a 
further revision was necessary.  At this point, colons were added as delimiters to the HLA 
allele name. So HLA-DRB1*0301 would now be known as HLA-DRB1*03:01.  To 
distinguish between expressed protein product and the HLA allele gene sequence, HLA 
alleles are italicized and protein products are not italicized.  So the expressed protein 
product of the HLA-DRB1*03:01 allele is HLA-DRB1*03:01.   
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2.2 Prior work in HLA prediction from genome scan data 
 Two methods have previously been described to predict HLA alleles from SNP 
data [4, 18].  The first method described by de Bakker et al (2006) used a tag SNP 
approach to detect HLA alleles in an individual.  This approach utilized the Tagger 
method [4] to detect multi-marker SNP haplotypes that are most highly correlated with 
observed HLA alleles within four populations.  The approach demonstrated that 
population-based informative tags SNPs are a very useful method for identifying HLA 
alleles. However from a practical implementation level, the tag SNPs identified by this 
approach were often not found on the commercial SNPs arrays used in GWAS. As a 
result, subsequent SNP typing was often necessary to determine the HLA genotypes for a 
subject using multiple sets of tags.    
In a subsequent paper, Leslie et al [18] noted that the tagger method may have 
difficulties when trying to detect HLA alleles that are found on multiple haplotype 
backgrounds.   To deal with some the complexities of the HLA region not fully addressed 
by the tagging method, Leslie at al developed a statistical methodology for predicting 2 
and the more precise 4-digit HLA typing which uniquely identifies the HLA protein. The 
method utilizes a reference haplotype database. A set of 40 informative SNPs for each 
HLA allele are selected from the reference haplotype database to predict the HLA alleles 
for a given individual using a hidden Markov model. Using the 90 CEU HapMap samples 
as a reference, this method predicted the HLA-A, HLA-B, and HLA-DRB1 alleles for 2 
and 4 digit HLA predictions in 1500 individuals from the 1958 British Birth Cohort. For 
predicting 2-digit HLA types on the complete sample, the method had a recall of between 
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84% and 95% depending on the HLA locus and genotyping platform. For 4-digit typing, 
the true positive rate for this algorithm had a range of between 72% and 91% for the 4 
HLA types (HLA-A, HLA-B, HLA-DRB1, HLA-DQB1) tested in the 1958 British Birth 
Cohort.  The lowest accuracies were for the two HLA alleles with the greatest number of 
polymorphisms: HLA-DRB1 and HLA-B.  The analyses found that the accuracy 
improved significantly as the sample size of a reference HLA allele reached 10 or more 
in the reference training set.  
Using the HapMap samples as the training set, neither approach had the accuracy 
found in present SNP imputation software for SNPs which routinely has reached 
concordance rates greater than 97% using the same HapMap samples as a reference.  The 
main limitation of these two approaches is that the size of reference set of HapMap 
samples is underpowered given the relatively large number of HLA polymorphisms in 
several of the HLA types.  For example, HLA-B*27:05 allele is represented only once in 
the CEU HapMap samples and as a result had only a limited precision and recall of 0.82 
and 0.32 during the validation testing of the Leslie method.  Both these previous 
approaches suggest that a larger training data set with greater sample size for low 
frequency HLA types would be expected to significantly improve prediction accuracy.   
 
2.3 Description of Method 
Here a new method is presented for predicting HLA genotypes that leverages the 
fast and accurate SNP imputation algorithms offered in such software as MACH 1.0 [19], 
IMPUTE2[20] ,and BEAGLE [21].  These software use a hidden Markov model based on 
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a reference panel of phased SNP genotypes to impute missing genotypes in array-based 
genome scan data [22]. To deal with the size limitations of using the HapMap samples as 
the reference set, the SNP imputation software has been coupled with a much larger 
reference haplotype data set developed from approximately 1500 subjects from the 1958 
British Birth Cohort to predict HLA genotypes.  Using a phased reference training set of 
haplotypes, SNP imputation algorithms can infer genotypes of SNPs not in a study’s 
original genome scan. Such SNP imputation software has achieved very high genotype 
imputation accuracy using the reference data sets developed from the International 
HapMap Project and other genome-wide scan study data sets[19, 20, 23].  This work will 
measure the accuracy of SNP imputation software to accurately impute HLA genotypes 
using a much larger reference training set than those used previously. 
The application of SNP imputation software to impute HLA alleles has one notable 
implementation concept that needs to be addressed.  Each classical HLA gene is highly 
polymorphic and has many alleles encoding distinct proteins based on a unique 
combination of variants.  This is unlike an individual SNP, which is bi-allelic.  This is 
analogous to the APOE protein, which has 3 primary protein structures (APOE-2, APOE-
3 and APOE-3) corresponding to combinations of two SNP variants.  Unlike APOE, 
there are multiple SNPs in the HLA genes that are variant which result in 100s of proteins 
for a given HLA gene in the world’s population.  A population’s inventory of HLA 
proteins encoded by one gene helps protects it from the wide array of viral and bacterial 
diseases exposed to in a given geographic region.  
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SNP imputation software such as MACH 1.0 are optimized for bi-allelic SNPs and 
are not capable of directly imputing polymorphic markers as required by the HLA alleles.  
To adapt SNP imputation software such as MACH 1.0 to handle highly polymorphic 
HLA alleles, the concept of the “virtual SNP” has been implemented to represent the 
numerous alleles of each HLA gene.  Virtual SNPs are placed on the hyper-variable exon 
2 region of each HLA gene as a proxy for each respective HLA allele.  The genotype of 
each virtual HLA SNP represents the number of HLA alleles for a specific HLA gene. 
Table 2.0 Virtual SNP representation of HLA-DRB1*03:01 and HLA-DRB1*15:01 
A heterozygous HLA Allele is represented by an A/C genotype. So in the case of HLA-
DRB1*03:01/HLA-DRB1*15:01, those two Virtual SNPs are represented by an “A/C” at 
position chr6:32551889 and chr6:32551925. The two point mutations represent the 23 
different base pair differences that are present in exon 2 for these two alleles.  A 
homozygous HLA genotype would be represented as a “C/C”. The remaining alleles are 
simply set to “A/A” 
 
Exon 2 Position  HLA Allele  Genotype 
chr6:32551886  HLA‐DRB1*01:01  AA 
chr6:32551887  HLA‐DRB1*01:02  AA 
chr6:32551888  HLA‐DRB1*01:03  AA 
chr6:32551889  HLA‐DRB1*03:01  AC 
chr6:32551890  HLA‐DRB1*03:02  AA 
chr6:32551891  HLA‐DRB1*04:01  AA 
chr6:32551892  HLA‐DRB1*04:02  AA 
chr6:32551893  HLA‐DRB1*04:03  AA 
chr6:32551894  HLA‐DRB1*04:04  AA 
chr6:32551895  HLA‐DRB1*04:05  AA 
chr6:32551896  HLA‐DRB1*04:06  AA 
chr6:32551897  HLA‐DRB1*04:07  AA 
chr6:32551898  HLA‐DRB1*04:08  AA 
chr6:32551899  HLA‐DRB1*07:01  AA 
chr6:32551900  HLA‐DRB1*08:01  AA 
chr6:32551901  HLA‐DRB1*08:02  AA 
chr6:32551902  HLA‐DRB1*08:03  AA 
chr6:32551903  HLA‐DRB1*08:04  AA 
chr6:32551904  HLA‐DRB1*08:06  AA 
chr6:32551905  HLA‐DRB1*08:11  AA 
chr6:32551906  HLA‐DRB1*09:01  AA 
chr6:32551907  HLA‐DRB1*10:01  AA 
Exon 2 Position  HLA Allele         Genotype 
chr6:32551908  HLA‐DRB1*11:01  AA 
chr6:32551909  HLA‐DRB1*11:02  AA 
chr6:32551910  HLA‐DRB1*11:03  AA 
chr6:32551911  HLA‐DRB1*11:04  AA 
chr6:32551912  HLA‐DRB1*11:09  AA 
chr6:32551913  HLA‐DRB1*11:39  AA 
chr6:32551914  HLA‐DRB1*12:01  AA 
chr6:32551915  HLA‐DRB1*13:01  AA 
chr6:32551916  HLA‐DRB1*13:02  AA 
chr6:32551917  HLA‐DRB1*13:03  AA 
chr6:32551918  HLA‐DRB1*13:04  AA 
chr6:32551919  HLA‐DRB1*13:05  AA 
chr6:32551920  HLA‐DRB1*13:11  AA 
chr6:32551921  HLA‐DRB1*14:01  AA 
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chr6:32551922  HLA‐DRB1*14:04  AA 
chr6:32551923  HLA‐DRB1*14:06  AA 
chr6:32551924  HLA‐DRB1*14:07  AA 
chr6:32551925  HLA‐DRB1*15:01  AC 
chr6:32551926  HLA‐DRB1*15:02  AA 
chr6:32551927  HLA‐DRB1*15:03  AA 
chr6:32551928  HLA‐DRB1*16:01  AA 
chr6:32551929  HLA‐DRB1*16:02  AA 
  
Each HLA allele consists of a unique combination of amino acids, which are represented 
as a single point mutation for imputation purposes.  
 
2.4 HLA genotypes as a multi-class multi-label classification problem 
Prediction or the imputation of HLA genotypes can be described as a multi-class 
multi-label classification problem. Assume we have one multi-allelic HLA gene with 2 
alleles.  Let MGi denote the multi-allelic genotypes in the ith individual of N subjects 
where A1 and A2 denote the two alleles with L allele variants such that:  
 
For  i=(1,2,…N) 
MGi = (A1,A2)  
MGi1=A1 
MGi2=A2 
Where  A1  =(1,2….L), A2  = (1,2,…L) 
 
             
The prediction of MGi is considered a multi-class multi-label classification 
problem.  The multiple classes are the L HLA alleles and the multi-labels are the 2 alleles 
per individual. 
 
2.5 Transformation of Multi-Class Multi-Label Classification Problem into 
Multi-targeted Multi-class Classification Problem 
 
Multi-class multi-label classification problem may be transformed to a multi-
targeted multi-class classification problem for which many algorithms are available to 
solve.  To transform the multi-allelic genotype into the multi-target multi class problem, a 
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vector of virtual SNP allele counts (dosages) are generated with the follow 
transformation: 
 
A vector of virtual SNPs dosages are defined as Gij where i is the ith individual of 
N subjects and j is the jth SNP dosage of the L bi-allelic virtual SNPs.Gij =(0,1,2) where 
Gij denotes allele count of the jth allele in the ith individual.  
 
The multi-allelic genotype MGi is transformed to L bi-allelic virtual SNP Gij 
dosage with the following: 
 
  if MGi1 ≠ j  and   MGi2 ≠ j    then allele count =0  
Gij =        if MGi1 = j  and   MGi2 ≠ j     then allele count =1 for   (j=1,2..L; i=1,2…N) 
  if MGi1 = j  and   MGi2 = j     then allele count =2               
 
 
Table 2.1 HLA Genotype Conversions to HLA Dose Vector  
The set of HLA genotypes are converted into vector of doses. Each dose represents the 
dose of a unique HLA protein encoded by the HLA allele. For example, the N=9 
individuals, the HLA alleles would be transformed in the following doses for each of the 
L=3 alleles. 
 
HLA Genotype MGi for 
individuals 1 to 9 
Individual
i=1 to 9 
Gi1 
Dose 
Gi2 Dose Gi3 
Dose 
HLA-A*01, HLA-A*01 1 2 0 0 
HLA-A*01, HLA-A*02 2 1 1 0 
HLA-A*01, HLA-A*03 3 1 0 1 
HLA-A*02, HLA-A*01 4 1 1 0 
HLA-A*02, HLA-A*02 5 0 2 0 
HLA-A*02, HLA-A*03 6 0 1 1 
HLA-A*03, HLA-A*01 7 1 0 1 
HLA-A*03, HLA-A*02 8 0 1 1 
HLA-A*03, HLA-A*03 9 0 0 2 
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2.6 Transformation Example 
 
For example, assuming L=3 HLA alleles in a gene (HLA-A*01, HLA-A*02, and 
HLA-A*03) for N=9 individuals representing the 3 x 3 combinations of these alleles.  
Each of these 3 alleles represents a different protein (HLA-A*01, HLA-A*02, HLA-
A*03).  The following HLA genotype vector MGi would be transformed to the following 
virtual SNP dosage Gij such that MGij   Gij  as seen in Table  2.1. 
 
 
2.7 Transformation of multi-targeted multi-class problem into multi-targeted 
binary classification problem 
 
Once the HLA genotypes are transformed into a multi-targeted multi class set 
represented by the virtual SNP vector of allele counts, the classification problem can be 
further reduced to a multi-targeted binary classification problem by the phasing of Gij 
allele into virtual SNP binary representation on 2 chromosomal strands as seen in Table 
2.2.  The phasing of the genotype doses are completed by MACH 1.0 to produce the 
phased reference panel which can then be used to impute these virtual HLA SNPs in a 
study data set of SNP genotypes from the MHC region. 
Essentially each of these virtual SNPs is then assigned a genotype that represents 
the number of HLA alleles assayed in that individual (Table 2.0).  To represent 0 dose, 
the “A/A” genotype is assigned.  To represent a single dose, an “A/C” genotype is 
assigned.  To represent 2 doses of an HLA allele, a homozygous “C/C” dose is assigned.  
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 For example, a subject that was heterozygous for HLA-DRB1*03:01/DRB1*15:01 
would have those two virtual SNPs assigned “A/C”. So to indicate a dose of 1 allele for 
each of the 2 HLA alleles, HLA-DRB1*03:01 and DRB1*15:01 would be assigned 
“A/C” and the remaining HLA DRB1 virtual SNPs would be assigned “A/A” [Table 2.0].  
An individual homozygous for HLA-DRB1*03:01 or HLA-DRB1*15:01 would be 
represented by “C/C” for that virtual HLA SNP to indicate 2 doses of the HLA protein. 
For each individual, the 5 HLA genes would each have a vector of virtual HLA SNPS to 
indicate the dose of that particular HLA protein.  These virtual SNPs would then be used 
for imputation along with MHC SNP genotypes available for the British 1958 Birth 
Cohort.  
Table 2.2  Phasing of HLA Allele Dose to Create Binary HLA SNP  
The dose of the HLA genotype is represented as a single point mutation in a phased 
chromosome after phasing.  
 
HLA Genotype MGj Chromosome 
Strand 
SNP 
HLA*A1 
SNP 
HLA*A2 
SNP 
HLA*A3 
HLA*A1, HLA*A1 A 1 0 0 
B 1 0 0 
HLA*A1, HLA*A2 
 
A 1 0 0 
B 0 1 0 
HLA*A1, HLA*A3 
 
A 1 0 0 
B 0 0 1 
HLA*A2, HLA*A1 
 
A 0 1 0 
B 1 0 0 
HLA*A2, HLA*A2 
 
A 0 1 0 
B 0 1 0 
HLA*A2, HLA*A3 
 
A 0 1 0 
B 0 0 1 
HLA*A3, HLA*A1 
 
A 0 0 1 
B 1 0 0 
HLA*A3, HLA*A2 A 0 0 1 
B 0 1 0 
HLA*A3, HLA*A3 
 
A 0 0 1 
A 0 0 0 
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2.8 Validation of Virtual SNP HLA Prediction Method 
To assess the accuracy of the Virtual SNP imputation method to predict HLA 
genotypes with a larger reference data set, the predicted and assayed HLA genotypes 
available from 1963 WTCCC type 1 diabetes study cases were compared to validate the 
approach. While previous validations of HLA imputation have used population-based 
subjects, a disease sample was chosen to test that a population based control sample 
could accurately impute HLA alleles with a very different HLA allele and haplotype 
frequency. 
2.9 Imputation Reference Training Set 
The imputation of the HLA alleles in the cases and control subjects were 
completed with the software program MACH 1.0.  The reference training set consisted of 
a merged set of 130 HLA alleles and 3808 MHC SNP genotypes available from the 1488 
British 1958 Birth Control subjects.  The SNPs selected were within the extended MHC 
region chr6:25,760,407 - 33,529,443 (NCBI v36).  The genotypes available were assayed 
on the Affymetrix GeneChip Mapping 500K array, Illumina Infinium HumanHap550 
array, and an Illumina Infinium array customized for 14,458 mostly non-synonymous 
SNPs. Any discordant SNP genotypes were dropped on the merge.  The dataset was then 
phased and any missing SNP and HLA genotypes imputed to create complete reference 
haplotypes targeting the MHC region.   
For the first step, the SNP imputation software, MACH 1.0, first phased and 
imputed any missing HLA and SNP genotypes in 1488 subjects from the 1958 British 
Birth Cohort to create the reference training set used for HLA imputation.  The resulting 
  
19
reference data set of 2976 phased haplotypes contained 3808 SNPs from the extended 
MHC region and 130 HLA alleles from the HLA-A, HLA-B, HLA-C, HLA-DRB1 and 
HLA-DQB1 loci. For several assayed 4-digt HLA types with ambiguity or multiple low 
allele frequencies below 1%, the HLA types were binned into the corresponding 2-digit 
HLA type to maximize overall accuracy and number of HLA alleles with frequencies 
greater than 1%.   
2.10 Method to Assess Precision and Recall of HLA Allele Prediction 
For the validation of the imputed HLA genotypes, the HLA genotypes were 
imputed for the approximately 2000 WTCCC Type 1 diabetes cases using the software 
package MACH 1.0.  The predicted HLA genotypes were compared with all assayed 
HLA genotypes available for these subjects (Table 2.3 and Table A.1).  
Table 2.3  Disease and control data sets selected for HLA imputation and analyses 
Data Sets Genotyping Platforms 
Research 
Consortium
SNPs 
Assayed 
MHC 
SNPs Subjects
British 1958 Birth Cohort 
Reference Haplotypes 
Illumina 
Affymetrix WTCCC 469,557 3808 1488 
Type 1 Diabetes Cases 
Validation Data Set Affymetrix WTCCC 469,557 1313 1963 
Ankylosing Spondylitis 
Cases Illumina WTCCC 12,701 779 900 
Autoimmune Thyroid Disease 
Cases Illumina WTCCC 12,572 785 913 
Crohn’s Disease Cases Affymetrix WTCCC 469,557 1265 1748 
Multiple Sclerosis Cases Illumina WTCCC 12,374 791 975 
Rheumatoid Arthritis Cases Affymetrix WTCCC 469,557 1265 1860 
UK NBS WTCCC Controls Affymetrix WTCCC 469,557 1235 1458 
Psoriasis Cases Perlegen GAIN 599,171 1358 1299 
Psorasis Controls Perlegen GAIN 599,171 1358 1343 
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The precision and recall of the HLA imputation predictions were used to measure 
the performance of this method which are also referred to as sensitivity and specificity by 
Leslie et al paper on HLA imputation[18].  Precision is the total number of correct calls 
divided by the total number of calls for each HLA allele. Recall is the total number of 
correct calls divided by the total tested for each HLA allele.  As the minimum criteria for 
making a call is decreased, the recall will increase at the expense of the precision. The 
more stringent the criteria for a call, the higher the precision will be and the lower the 
recall will be.  
Using a 3 x 3 table (Table 2.4) to count the 9 HLA genotype assay-prediction 
combinations, the following equations were used to obtain precision and recall. Recall is 
also known as the true positive rate (TPR): 
 Total correct=E+F+H+2I 
 Total number of calls=B+E+H+2C+2*F+2I 
 Total number of tests=D+E+F+2G+2H+2I 
 Precision= Total correct / Total number of calls 
 Recall=True Positive Rate=TPR== Total correct / Total number of tests 
 
Table 2.4 HLA Genotype Assay-Prediction Assessment Matrix  
 
HLA Genotype 0 Alleles Predicted 1 Allele Predicted 2 Alleles Predicted 
0 Alleles Assayed A 
NA 
B 
0 correct 
1 incorrect 
C 
0 correct 
2 incorrect 
1 Allele Assayed D 
0 correct 
1 incorrect 
E 
1 correct 
0 incorrect 
F 
1 correct 
1 incorrect 
2 Alleles Assayed G 
0 correct 
2 incorrect 
H 
1 correct 
1 incorrect 
I 
2 correct 
0 incorrect 
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The terms precision and recall are commonly used in information retrieval to 
measure document classification.  Document classification has similarities with HLA 
classification. Classification of both HLA alleles and documents both require 
classification into one more categories. As a result, similar measures work well to assess 
performance of these algorithms.   
2.11 Precision and Recall Results for HLA Imputation Method 
The validation dataset of 1963 T1 Diabetes cases shared 1313 common SNPs 
genotyped on the Affymetrix platform within the MHC region.  Using the British 1958 
Birth Cohort reference-training data set, MACH 1.0 was then used to predict the 130 
HLA alleles assayed in the Type 1 Diabetes cases.   Of these 130 HLA alleles, 117 were 
in common with the British 1958 Birth Cohort. A total of 90 HLA alleles typed in the 
Typed 1 Diabetes had allele frequencies greater than 1%. 
Table 2.5 Validation results for HLA Virtual SNP Imputation Method 
The imputation of HLA alleles in the WTCCC Type 1 Diabetes was quite accurate.  The 
precision and recall overall were near the accuracy of HLA lab based approaches used in 
the generation of the HLA reference panel.  The most polymorphic HLA loci HLA-B and 
HLA-DRB1 have the lowest Precision and Recall 
 
Locus 
Alleles 
per 
Locus 
Total 
Alleles 
Tested 
Total 
Called 
Total 
Correct Precision Recall 
HLA-A 25 3016 3012 2966 0.98 0.98 
HLA-C 21 2468 2445 2300 0.94 0.93 
HLA-B 43 2460 2439 2371 0.97 0.96 
HLA-DRB1 24 3838 3728 3541 0.95 0.92 
HLA- DQB1 17 3828 3809 3751 0.98 0.98 
Overall 130 15610 15433 14929 0.97 0.96 
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The predicted HLA calls in the WTCCC Type 1 Diabetes Cases were then 
compared to the actual HLA genotypes that were previously assayed in the test data set. 
The overall results were highly accurate with an overall precision and recall of 0.96 and 
0.97 for the 5 HLA loci genotyped in the Type 1 Diabetes WTCCC data set as seen in 
both Table 2.5 and Appendix Table A1.1.  The frequency of the 130 predicted HLA 
alleles were also compared with the actual HLA alleles assayed in the type-1 diabetes test 
cases.  Using a linear regression model, the predicted and actual HLA frequencies were 
found to be highly correlated with an r-squared equal to 0.998  (P-value <1 x 10-16) as 
seen in Figure 2.1.  
Overall the method was very accurate for the HLA alleles frequencies greater than 
1% and imputation R2 >0.30 in the type 1 diabetes cases (Figure 2.2a and 2.2b).  
However, there were two primary sources of misclassification. One source of 
misclassification is the ambiguous 4-digit HLA calls in the original HLA assays that were 
assigned a 2-digit HLA type.  Typically, the virtual SNP imputation method 
“misclassified” these 2-digit HLA types representing ambiguous calls to a more precise 
4-digit type. For example, 25 individuals typed as HLA-C*07 due to ambiguity at the 4 
digit level were imputed to be the higher resolution HLA-C*07:03.  This suggests many 
of these ambiguities are resolvable with the Virtual SNP imputation method. Further SBT 
typing may confirm the more precise HLA genotype call. 
Another source of incorrect HLA allele calls were those HLA alleles with very 
low frequency in the reference training set that have a higher frequency in the type 1 
diabetes cases used as validation.  This type of error for the type 1 diabetes cases were for 
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the HLA DRB1*04:02 allele. While the allele frequency is only 0.23% (8 individuals) in 
the British 1958 Birth Cohort, there were 44 T1 Diabetes cases (1.1%)  that were typed as 
HLA DRB1*04:02.   The MACH 1.0 imputation r2 quality measure was only 0.14 in 
these cases, which is well below the recommended cut-off of 0.30 for the imputation to 
be included in an analysis.  To address these types of imputation quality issues, 
increasing the total number of these low frequency HLA alleles in the reference training 
set would be expected to substantially increase the quality of the imputation of these rarer 
alleles. Merging the Type 1 Diabetes cases into the reference panel should resolve this 
type of error for future imputation of research data sets.  These rare HLA variants could 
also be easily flagged for HLA genotyping given the low MACH r2 quality measure.  
The precision and recall of the HLA allele prediction is positively correlated with 
the number of HLA alleles in the reference training set (Figure 2.1).  The precision and 
recall increase sharply as the number of HLA alleles in the reference training set 
increases.  In general, HLA allele imputation with allele counts greater than 10 had very 
good recall.  The exceptions were several 2-digit HLA assays (HLA C*03, DRB1*04) 
that due to ambiguity were given a less precise 2-digit HLA type for some subjects in the 
original assays.  These ambiguous HLA alleles were often assigned a more precise 4-digit 
HLA allele by the imputation method and resulted in these ambiguous 2-digit HLA 
alleles having poor scores for precision and recall. In all cases, the MACH r2 detected the 
lower imputation quality of the sample with values below 0.50.   
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Figure 2.1 Plot comparing the frequency of 118 assayed and predicted HLA-A, 
HLA-B ,HLA-C, HLA-DRB1 , and HLA-DQB1 alleles among the individuals typed 
in 1963 WTCCC T1 diabetes cases.  
The predicted and assayed HLA allele frequencies are highly correlated with the linear 
regression model with an r2 = 0.997 and a p-value < 5e-16.  Frequencies were highly 
correlated for frequencies above 1%. GWAS typically exclude SNPs with frequencies 
below 1 to 3%. 
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Figure 2.2a Plot of the precision of HLA imputation quality versus Mach r2 quality 
measure for 90 imputed HLA alleles. HLA alleles plotted were filtered to have a 
frequency greater than 1% in the Type 1 diabetes cases.  Precision is measured as 
the Total Correct Calls /Total Number of Calls.   
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Figure 2.2b Plot of the recall of HLA imputation quality versus Mach r2 quality 
measure for 90 imputed HLA alleles. Recall is measured as the Total Correct 
Calls/Total Number of Assays. HLA-DRB1*04:02 was not correctly imputed due to 
the low frequency in the reference panel of 0.23% for this allele.  The Type 1 
Diabetes cases which actually had a 1.1% allele frequency.  In general, HLA allele 
imputation with allele counts greater than 10 in the reference had very good recall. 
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CHAPTER 3 Testing of Disease Association with Virtual SNP Imputation Method 
3.1 Auto-immune Disease Subjects 
Subjects with 6 autoimmune related diseases were selected from the WTCCC and 
Genetic Association Information Network (GAIN) data sets. All subjects were of 
European ethnicity.  The ascertainment protocol, diagnostic criteria and genotyping 
details are available from previous published reports analyzing the 6 auto-immune 
diseases: ankylosing spondylitis (AS) [24], autoimmune thyroid disease (ATD) [24], 
Crohn’s disease (CD) [6],  multiple sclerosis (MS) [24], psoriasis (PS) [11] and 
rheumatoid arthritis (RA) [6].  A total of 7723 cases were analyzed for these 6 diseases 
(Table 2.3). For the WTCCC cases (AS, AITD, CD, MS, and RA), a common set of 1458 
UK Blood Services subjects recruited for the WTCCC study[6] were used for the 
controls.  The control data set for the psoriasis analysis consisted of 1363 subjects. For 
the reference training data set used for imputation of the HLA genotypes in these disease 
subjects, I used MACH 1.0 to imputed and phase 1488 British 1958 Birth Cohort 
subjects.  
 
3.2 HLA Typing of Auto-immune Disease Subjects 
The HLA genotyping for the British 1958 subjects were deposited by Prof John 
Todd, University of Cambridge and made available through the British 158 Birth Cohort 
DNA collection. Genotyping of the HLA-DQB1, HLA-DRB1, HLA-A, HLA-B and 
HLA-C genes had been completed with the Dynal RELI SSO assays (Invitrogen Ltd, 
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Paisley, UK).  For the finer resolution of the HLADRB1*04 subtypes that were 
ambiguous, the sample was re-genotyped using the specific Dynal AllSet SSP assay.  
 
3.3 Statistical Analyses 
The tests of association were based on a step-wise logistic regression analyses 
using an additive model of the imputed dosage of the HLA alleles.  The logistic 
regression analyses were conducted with general linear model module (glm) from the R 
statistical package version 2.9.2. One hundred and thirty HLA allele dosages were 
imputed with MACH 1.0 and assigned a value between 0 and 2 to reflect the estimated 
number of allele copies for a specific individual. For the step-wise logistic regression 
method, all models included gender which has previously been established as a 
significant covariate for these autoimmune diseases.   
To avoid potential bias in the analysis of the WTCCC cases and controls, only 
HLA alleles imputed from the UK Blood Services controls were used in the analysis with 
none of the original assayed HLA alleles included from the British 1958 Birth Cohort 
control samples used in the reference data set for imputation.  For the case-control 
analysis, all models to test for association were all based on imputed HLA genotypes. 
The imputed HLA genotypes were not supplemented with the control samples that had 
wet-lab HLA assays since no cases were available with wet-lab HLA based genotypes.  
All the significantly associated imputed HLA genotypes in Table 3 have a MACH r2 
greater than 0.60. For SNP imputation with MACH 1.0, the recommended threshold for 
imputation quality is 0.30. 
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Within the GAIN psoriasis data set, population substructure was examined using 
the EIGENSTRAT software package. A total of 49 outliers (24 cases, 25 controls) were 
removed during 5 iterations of excluding those subjects whose ancestry were greater than 
6 standard deviations from the mean.  For the psoriasis logistic regression analyses, 3 
principle components were then included as covariates to adjust for ancestry differences 
between cases and controls.  As only minor population substructure was detected in the 
original analyses of the WTCCC UK subjects, no adjustment for population substructure 
was included in the analyses of the WTCCC data sets. 
Only HLA alleles with MACH r2 quality scores > 0.5 and an allele frequency 
greater than 1% were included in the step-wise logistic regression analysis. This was 
based on the plot of recall and precision plots versus r2 quality scores and is higher than 
the recommended cut-off of 0.3. This cut-off provided a precision and recall greater than 
0.80.  A forward stepwise logistic method was used to select HLA alleles to add to the 
model.  The HLA allele with the lowest p-value for association that was significant after 
adjusting for multiple testing was then added to the model.  The p-value cut-off for 
multiple testing was based on a conservative Bonferroni correction.  The number of 
multiple tests adjusted for were the number of HLA alleles imputed with allele 
frequencies greater than 1% in the specific case/control data set.  
 
3.4 Disease Association Test Results for 6 Auto-Immune diseases  
To demonstrate the usefulness of the HLA imputation method to detect primary 
and secondary HLA disease associations, HLA genotypes were imputed in genome wide 
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association studies for 6 autoimmune diseases: ankylosing spondylitis, autoimmune 
thyroid disease, Crohn’s disease, multiple sclerosis, psoriasis, and rheumatoid arthritis.  A 
step-wise logistic regression using an additive genetic model was then employed to test 
for association with each of the HLA alleles.  These diseases have previously been shown 
to be associated with gender and so this covariate was included in all the initial starting 
models.  To correct for multiple testing, a Bonferroni correction based on the number 
HLA alleles greater than 1% in the each case-control sample was applied.  A total of 18 
significant HLA alleles were identified for these autoimmune diseases (see Table 3.1). 
Many of these confirmed well-established associations but also detected several novel 
secondary associations after conditioning.   
Ankylosing Spondylitis (AS) 
Ankylosing spondylitis is a chronic inflammatory autoimmune disease, which 
affects the spine.  The step-wise HLA model detected the very strong genetic effect of 
HLA B*27:05 (OR=86.55, p-value=1.60e-193) with this disease.   The extremely high 
odds ratio is consistent with previous high estimates for this disease.  The HLA B*27:05 
allele is found in 86% of the AS cases compared to 8% of the population based controls. 
With the model conditioning for HLA B*27:05 and gender, a significant signal was also 
detected in the MHC II region for HLA DQB1*06:04 (OR=2.54, p-value=4.79e-04).  
Results also confirmed that gender is highly associated with AS (OR=0.40, p-
value=8.20e-11) with females at decreased risk relative to males.  
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Autoimmune Thyroid Disease (AITD) 
Autoimmune Thyroid disease or Graves disease is an autoimmune disease which 
results in a hyperactive thyroid.  Two significant HLA alleles were identified as 
associated with autoimmune thyroid disease.  The analysis confirmed the previous reports 
of an AITD association with HLA DRB1*03:01 (OR= 2.58, p-value= 9.83x10-26). A 
significant novel association of HLA DRB1*11 (OR=1.84, p-value=4.28 x 10-6) was also 
observed with AITD.  
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Table 3.1 Significant HLA Allele Associations for 6 Auto-immune Diseases  
Disease Model Cases Controls
Logistic Regression 
Model Variables 
Cases 
Frequency
Controls 
Frequency 
Crude Odds
Ratio 
Nominal 
P-Value 
Adjusted Odds
Ratio# 
Adjusted 
P-Value# 
Ankylosing spondylitis  900 1458 Gender  0.331 0.517 0.46 2.59e-18 0.40 8.20e-11
   HLA B*27:05 0.447 0.041 77.89 1.12e-205 86.55 1.60e-193
   HLA DQB1*06:04 0.025 0.028 0.92 0.066 2.54 4.79e-04
Autoimmune Thyroid 
Disease 913 1458 Gender 0.150 0.517 5.21 9.95e-55 5.22 4.02e-52
   HLA DRB1*03:01 0.262 0.138 2.44 1.11e-26 2.58 9.83e-26
     HLA DRB1*11 0.081 0.060 1.43 0.0031 1.84 4.28e-06
Crohn's Disease 1748 1458 Gender 0.611 0.517 1.47 7.82e-08 1.48 4.47e-08
   HLA DQB1*06:02 0.112 0.147 0.73 5.13e-05 0.71 1.06E-05
    HLA DRB1*04:04 0.037 0.055 0.59 2.91e-04 0.56 6.02E-05
Multiple Sclerosis 975 1458 Gender 0.722 0.517 2.43 1.15e-23 2.22 1.39e-17
   HLA DRB1*15:01 0.324 0.150 3.07 6.62e-46 3.16 4.74e-43
    HLA A*02 0.225 0.293 0.69 8.43e-08 0.71 3.90e-06
   HLA DRB1*03:01 0.142 0.138 1.06 5.10e-01 1.42 2.45E-04
Psoriasis 1299 1343 Gender 0.451 0.549 0.87 0.069 0.802 7.65e-03
49 dropped with 
eigenstrat   HLA C*06:02 0.254 0.092 3.85 2.14e-53 3.87 9.72e-53
    HLA DQB1*06:04 0.019 0.040 0.41 2.51e-06 0.46 9.13e-05
Rheumatoid Arthritis 1860 1458 Gender 0.747 0.517 2.77 3.14e-42 2.70 2.40e-34
   HLA DRB1*04:01 0.276 0.114 3.70 8.26e-60 4.60 9.60e-66
      HLA  DRB1*01 0.147 0.112 1.37 3.40e-05 2.25 9.45e-20
      HLA DRB1*04:04 0.099 0.055 2.35 8.79e-12 2.98 1.12e-15
      HLA C*07:01 0.185 0.173 1.07 0.280 1.47 3.53e-07
      HLA DRB1*10:01 0.013 0.005 2.92 0.001 4.55 1.13e-05
   HLA DRB1*09:01 0.013 0.009 1.69 0.04 3.04 5.01e-05
   HLA DRB1*13 0.045 0.111 .37 3.14e-22 0.67 3.59e-04
*Frequencies are the percentage of females in each case and control group. Male is the referent group for the gender odd ratios.# For all models listed, 
the adjusted OR and P-value were calculated using forward step-wise logistic regression. For the psoriasis model, two principle component variables 
were also included to adjust for geographic substructure. 
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Crohn’s Disease (CD) 
Crohn’s disease is an inflammatory disease of the intestines. Previous studies 
have shown an association with HLA DRB1*07[25]. Using the step-wise logistic 
regression model, HLA DQB1*06:02 (OR=0.71,p-value= 1.06x10-05) and DRB1*04:04 
(OR=0.56, p-value=6.02x10-05) were found to be associated with a decreased risk of 
Crohn’s disease. No significant HLA alleles were found to be associated with increased 
risk of Crohn’s disease (CD) in this analysis after adjusting for multiple testing.  This is 
the only disease of the 6 examined for which analyses did not detect an association of an 
HLA allele and increased risk.  
 
Multiple Sclerosis (MS) 
The step-wise logistic regression model confirmed a primary risk association with 
HLA DRB1*15 (OR=3.16, p-value=4.74 x 10-43).  This allele is also in strong LD with 
HLA DQB1*06:02 which also had a very significant association.  The DRB1*15 based 
model had a slightly better fit than the DQB1*06:02 conditional model (AIC: 3013 
versus 3018).  The most significant secondary signal was a protective affect for the HLA 
A*02 allele (OR=0.71, p-value=3.90 x 10-6).  This confirms previous case-control studies 
that also found that HLA*02:01 had a protective effect[26].  With the conditioning of the 
HLA DRB1*15 and HLA A*02 alleles, a positive association with HLA DRB1*03:01 
(OR=1.42, p-value=2.45x10-4) was also detected.  This moderate HLA DRB1*03:01 
association with MS in this UK population confirms previous suggestions from small 
studies in African-Americans (OR 1.7, P=0.01) [27] and transmission disequilibrium 
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analyses in Sardinians (p-value=0.05) [28].  In both the Sardinian and African-American 
populations, the HLA DRB1*15 allele has relatively low frequency in both populations 
and not the primary signal associated with the disease.  In these two populations, the 
HLA-DRB1*15 risk allele would not mask other HLA signals associated with the disease 
in those populations.  In Europeans, detecting an association with HLA-DRB1*03:01 
would only be detected after adjusting for the HLA-DRB1*15:01 risk. After adjustment 
for HLA*DRB1*15:01 and HLA-A*02, this analysis in European case-control subjects 
detects a third population where the HLA DRB1*03:01 allele is associated with increased 
risk of MS. 
 
Psoriasis 
The association analysis for psoriasis confirmed HLA C*06:02 (OR=3.87, p-
value= 9.72 x 10-53) as the most significant association in the MHC region. It has 
previously been suggested that highly significant SNPs flanking the HLA C gene in the 
PSORC1 and -32c loci may be the location of the psoriasis functional polymorphism. 
While SNPs in this region were highly significant, their p-values were all lower than the 
HLA C*06:02 results.  The model also detected a novel protective signal in the MHC II 
region for HLA DQB1*06:04 (OR=0.46, p-value=9.13 x 10-5).   
To confirm that HLA alleles in the models captured the entire signal in the region, 
the association of SNPS with PS was examined after adjusting with gender, these 2 HLA 
alleles and 3 principle components for population substructure. While no imputed SNPs 
reached genome-wide significance after conditioning, there were two regions of elevated 
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risk.  The most interesting results were for two non-synonymous SNPs in the MICA gene 
and suggest further follow-up is important in independent samples.  
 
Rheumatoid Arthritis (RA) 
Rheumatoid arthritis is an autoimmune disease that results in the inflammation of 
the synovial joints.  The shared epitope hypothesis (SE) originally proposed by 
Gregerson et al [29] suggested that a common set of amino acid sequences shared on 
several HLA DRB1 alleles explained the association[29].  The HLA DRB1 alleles at 
increased risk under this hypothesis are the SE alleles: HLA-DRB1*04:01, HLA-
DRB1*04:04, HLA-DRB1*04:05, HLA-DRB1*04:08, HLA-DRB1*01:01, HLA-
DRB1*01:02, HLA-DRB1*14:02, HLA-DRB1*09 and HLA-DRB1*10:01 [30].  We 
confirmed 5 “shared epitope” HLA alleles to be significantly associated with RA in the 
UK WTCCC samples (Table 2). The HLA DRB1*04:01 (OR=4.60, p-value=9.60 x 10-66) 
had the largest odds ratio and the most significant association with RA.  The 2 other 
common “shared epitope” HLA risk alleles with more moderate risk were HLA-
DRB1*01 (OR=2.25, p-value=9.45x10-20) and DRB1*04:04 (OR=2.98, p-value 
=1.12x10-15).  The step-wise logistic regression model also detected the lower frequency 
“shared epitope” alleles HLA DRB1*10:01, and DRB1*09:01 to also be associated with 
increased risk of RA in this UK sample.  The analysis also found an unexpected novel 
association of RA with HLA alleles: an increased risk of RA with HLA C*07:01 
(OR=1.47, p-value=3.53 x 10-7) and a protective association with HLA DRB1*13 
(OR=0.64, p-value=3.77 x 10-5).  This novel association of HLA C*07:01 with RA is the 
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first significant risk signal detected in the MHC I region that is independent of the risk 
associated with the “shared epitope” found in the HLA DRB1 gene.  
 
3.5 Using HLA Imputation to Test for Association with Adverse Reactions  
Background 
Adverse reactions (ADRs) to medications are a serious health concern. In a 
prospective study, adverse drug reactions accounted for 6.5% of hospitalization and 4% 
of hospital bed capacity in the National Health Service in England [31].  The projected 
estimated costs of these admissions were over $800 million.  It is estimated that about 
15% of ADRs are hypersensitivity reactions.  The efficient pre-screening of individuals 
with hypersensitivity reactions to medications could have major benefits to decrease 
health costs and improve an individual’s treatment outcomes for many diseases. 
Carbamazepine is a common prescription for the treatment of epilepsy, bipolar 
disorder and trigeminal neuralgia.  The use of this medication has been found to be 
associated with a variety of hypersensitivity reactions of various severities.  
Maculopapular exanthema (MPE), a relatively mild rash, occurs between 5 to 10% of 
European ancestry patients taking this medication.  The more severe drug induced 
hypersensitivity syndrome has estimated mortality rate of near 10%. Steven-Johnson 
Syndrome  (SJS) and toxic epidermal necrolysis (TEN) are diseases with a severe 
blistering rash that are also induced by carbamazepine with a rate of 1-6 cases per 10,000 
drug exposures.  
  
37
Methods and Results 
To test the association of HLA alleles with hypersensitivity reactions to 
Carbamazepine, the EPIGEN consortium utilized the Virtual SNP imputation method in a 
genome wide association study.  The HLA imputation was completed using genotypes 
assayed with an Illumina 610K chip completed on 49 MPE case subjects and 257 
Carbamazepine-exposed control subjects. In the discovery analysis of 49 MPE cases and 
1296 controls from the WTCCC, HLA-A*31:01was the most strongly associated allele 
(P=1.11x10-6) as seen in the Manhattan plot in Figure 3.1.  An additional 63 MPE cases 
were then typed for HLA-A*31:01.  The combined analysis of 106 cases and 257 
controls showed a significant association (OR=8.33, P=8.0x10-7).  
This result was then followed up in subjects with the more severe adverse 
reactions.  The typing of HLA-A*31:01 in 12 SJS- TEN cases found 5 (43%) with the 
allele. In contrast, only 10 (4%) of the 257 CBZ-exposed controls carried HLA-A*31:01.  
The association of SJS-TEN with HLA-A*31:01 is significant (OR=9.12, P=8x10-5).  
Validation of HLA-A*31:01 Imputation 
To confirm the association of the imputed HLA A*31:01 in the analyses, high 
resolution HLA typing was completed across all 49 sample cases with maculopapular 
exanthema (MPE) and the 213 CBZ-exposed controls from the EPIGEN consortium. 
Using sequence-specific polymerase-chain-reaction (SSP) assay primers, 4-Digit HLA 
typing was completed (Figure 3.2).  The direct genotyping of HLA-A*31:01 in these 
samples showed 100% concordance with the HLA-A*31:01 alleles that were imputed 
with the Virtual SNP imputation method.  
  
38
Figure 3.1 Results of a genome wide association study of carbamazepine-induced 
MPE.  The HLA-A*31:01 genotypes were imputed in 43 MPE Cases with the virtual 
SNP Imputation Method.  The controls were from 1296 controls with HLA typing 
from the 1958 British Birth Cohort.  HLA A*31:01 was the most strongly associated 
variant (P=1.11x10-6) 
 
 
Reproduced with permission from: McCormack M et al. New England Journal of 
Medicine 2011;364:1134-1143,  Copyright Massachusetts Medical Society 
 
 
 
 
  
HLA-A*31:01 
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Figure 3.2 Gel bands of PCR amplification of sequence specific primers for HLA-
A*31:01 to compare 4 samples carrying imputed HLA-A*31:01 allele and an 
imputed negative sample.  
A gel band in sample lanes 1-4 confirm the presence of the imputed HLA-A*31:01 allele.  
The lack of a band in lane 5 confirms the imputed negative sample.  These experiments 
confirmed all predicted HLA-A*31:01 alleles predicted by the Virtual SNP imputation 
method.  
 
 
Reproduced with permission from: McCormack M et al. New England Journal of 
Medicine 2011;364:1134-1143,  Copyright Massachusetts Medical Society 
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3.6 Discussion  
The above results demonstrate that the unraveling of the HLA disease 
associations from genome scan SNP data is now feasible using readily available SNP 
imputation software joined with a large reference data set using the virtual SNP 
imputation method.  The virtual SNP imputation approach is capable of accurately 
imputing HLA genotypes with an overall level of precision and recall of 0.96 and 0.97 
with the use of approximately 1500 subject reference data set phased with both actual and 
virtual HLA SNPs.  The validation of the imputation in a Type 1 Diabetes data set 
demonstrates the imputation will also be accurate in a sample with an extreme genetic 
effect with very different allele frequencies.  The validation results demonstrated that 
HLA imputation is accurate in a case sample with a much difference allele frequencies 
than the population based reference set (T1 Diabetes versus the 1958 British Birth 
Cohort).  
This use of widely available SNP imputation software may now be extended to 
predict HLA genotypes with a high level of precision for common HLA alleles found in a 
large reference data set of 1500 subjects.  The use of SNP imputation as the 
computational method provides a straightforward approach for the efficient examination 
of the role of the HLA in large-scale genome scans.    The HLA alleles can be identified 
without the expensive and laborious HLA typing of these large data sets for many 
common HLA alleles. 
The analysis of 6 autoimmune diseases demonstrates the usefulness of the virtual 
SNP Imputation method to unravel the HLA associations.  The analyses detected 18 
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significant disease associations after adjusting for multiple testing.  The results 
reassuringly confirmed many previous established HLA associations and detected 
multiple novel secondary signals in the MHC region.  The analysis found highly 
significant primary risk signals of AS with HLA B*27:05, AITD with HLA 
DRB1*03:01, MS with HLA DRB1*15, PS with HLA C*06:02, and RA with the “shared 
epitope” grouping of HLA alleles.  Protective associations were found with CD (HLA 
DQB1*06:02), MS (HLA A*02), PS (HLA DQB1*06:04) and RA (HLA DRB1*13).  
The analysis of adverse reactions to carbamazepine demonstrated the usefulness 
in detecting associations in this class of diseases with a very small sample size. In the 
discovery data set, the HLA risk alleles were quickly narrowed to HLA-A*31:01, which 
allowed further testing in additional samples of the MPE phenotype and related 
phenotypes to further confirm the association.   
 
The availability of accurate HLA typing from genome scan data may also prove 
useful in a number of new areas.  With the development of genome scan databases for 
personal genomics, this technique would be useful for more accurately measuring the risk 
of the large number of diseases associated with the MHC region and HLA alleles.  The 
use of these databases could be extended to potential clinical applications such as the 
rapid screening of potential transplant donors. Since drug adverse reactions to specific 
medications have been found associated with specific HLA types, personal genetic 
profiles may also be developed to more accurately assess an individual’s risk to 
maximize the safety of prescribed medications.  The availability of accurately predicted 
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HLA genotypes will also allow the rapid examination of the association of HLA types to 
the host susceptibility or resistance of infectious diseases such as HIV, influenza, malaria, 
tuberculosis and other infectious diseases.  The imputation of a comprehensive set of the 
classical HLA types for the expanding list of diseases and phenotypes associated with the 
MHC region should become an important follow-up step in the understanding of the 
underlying immunological response and proteins driving this region.  
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CHAPTER 4 Prediction of HLA alleles from next generation sequencing 
4.1 Background 
The cost of sequencing a genome has undergone rapid decreases in the last decade 
due to improving technology. As seen in figure 4.1 prepared by the National Human 
Genome Institute, the costs per sample at 30x coverage on the Illumina and Solid 
platforms has dropped to approximately $5,800 in April 2013.   These costs do not 
include storage and downstream analysis of the generated sequences.  
Figure 4.1 Decreasing Costs of Whole Genome Next Generation Sequencing 
Genome sequencing costs are dropping faster than Moore’s Law. In January 2014, 
Illumina announced the new systems that reached the $1000 barrier. 
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Whole exome sequencing is now under $800 per sample. As these costs continue 
to rapidly decrease, these new technologies will become an important tool in biomedical 
research and clinical settings.  Presently HLA typing using SSOP and SBT is a labor-
intensive process whose costs have not seen significant cost reductions with 4-digit HLA 
typing approximately $500 per sample.  As next generation sequencing costs continue to 
drop dramatically, this will become a viable and economical approach to HLA 
genotyping of samples.  Illumina has recently announced the HiSeq X Ten which can 
sequence 18,000 genomes a year and breaks the $1000 barrier [32].  Very affordable 
whole genome sequencing is not far off.   
However, a roadblock for using next generation sequencing for HLA related 
research and clinical applications is the ability to call HLA genotypes from next 
generation sequencing data. Given the increasing availability of whole genome, whole 
exome and RNA-Seq datasets, a toolkit that could accurately and rapidly predict HLA 
genotypes would be an important downstream analysis useful in many biomedical and 
clinical applications.  For the 3rd AIM, the algorithm for a novel naïve Bayes algorithm 
will be described to predict HLA genotypes from next generation sequencing data.  The 
algorithm will be implemented in Python (HLA-Genotyper) and validated across whole 
genome, whole exome and RNA-Seq data sets available in European and Yoruba 
populations.   
4.2 Present approaches for HLA genotyping  
Based on a survey of the literature, 5 other algorithms were found that have implemented 
software for HLA genotyping from next generation sequencing data (Table 4.0).    
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Table 4.0 Software developed for HLA genotyping from next generation sequencing 
 
Three of these 5 have the software freely available for researchers to download.  
Those freely available include the packages: HLAminer, seq2HLA, and ATHLATES.  
HLA-Caller developed by Broad Institute is no longer supported although it is available 
for download. It is presently not compatible with the most recent human reference 
sequence.  The implementation of the algorithm described in PNAS [33] has not been 
Software Author Institution Approach 
HLA-Caller Xiaoming Jia, 
Paul de Bakker, 
GATK Team 
Broad Institute Uses genotypes/phase/Allele 
Frequency in Bayesian model 
HLAminer Warren Michael Smith 
Genome 
Science Center 
De Novo Assembly (Large 
memory and computational 
requirement) 
seq2HLA Boegel et al. Gutenburg 
University 
Iterative Counting of aligned 
reads 
Not Available Wang et al. Stanford 
University 
Very deep coverage, long reads 
(150 bp), custom targeted 
sequencing, counting aligned 
reads 
ATHLATES Lui et al. Broad Institute De Novo Assembly (Large 
memory requirements) 
HLA-
Genotyper 
Farrell Boston 
University 
Naïve Bayes Classification
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made freely available although a commercial company has implemented its algorithm for 
commercial purposes.  
To increase the accuracy of the HLA genotyping, several of the approaches 
utilized sequencing with longer reads of 150 bp to 250 bp combined with custom capture 
probes.   Longer uniquely matched reads are more likely to distinguish alleles at the 
protein level.  The use of de novo assembly is used by two of the approaches: HLAminer 
and ATHLATES.  Counting of HLA aligned reads is used by seq2HLA as well as the 
Stanford research group of Wang et al.  The Naïve Bayes HLA genotyping approach is 
novel and the validation results of the implemented algorithm will be presented later in 
this chapter. 
Dr. Xiaoming Jia at the Broad Institute developed the HLA Caller algorithm [34] 
to call 4-digit HLA genotypes.  The software was implemented in Java and utilizes the 
GATK Toolkit.  This algorithm calculates the posterior probabilities of all pairs of HLA 
genotypes based on genotypes, phase and HLA frequency.  The posterior probability is 
calculated with the following equation: 
 
௣ܲ௢௦௧௘௥௜௢௥ሺܣ݈݈݈݁݁1, ܣ݈݈݈݁݁2|݀ܽݐܽሻ ൌ ௚ܲ௘௡௢௧௬௣௘௦	 ௣ܲ௛௔௦௘ ௙ܲ௥௘௤௨௘௡௖௬ 
Where ௣ܲ௢௦௧௘௥௜௢௥ሺܣ݈݈݈݁݁1, ܣ݈݈݈݁݁2|݀ܽݐܽሻ is the likelihood of the HLA genotype 
(Allele1, Allele2) given the sequence read data 
௚ܲ௘௡௢௧௬௣௘௦	 is  probability of the (SNP genotypes | (Allele 1, Allele 2)) 
௣ܲ௛௔௦௘	 is the probability of  (nearby phase | (Allele 1, Allele 2)) 
୤ܲ୰ୣ୯୳ୣ୬ୡ୷	 is the probability of  (allele frequencies | (Allele 1, Allele 2)) 
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This algorithm has not undergone extensive validation on commonly available 
next generation sequencing data.  The HLA calling algorithm was applied in the typing of 
Class I HLA typing for the Erlich et al demonstration of HLA genotyping of Class I loci 
with the 454 sequencing instrument[35].  The instrument was chosen to take advantage of 
the long read lengths generated by that technology.  On October 2013, Roche Diagnostics 
announced that the 454 sequencing technology would be shut down.  The HLA Caller 
software is presently no longer supported by Broad and is not undergoing active 
development.  One weakness of the algorithm is that it did not address the poor coverage 
in the HLA region, which is an issue discussed in more detail later in this chapter. 
 
 
In PNAS, Wang et al. demonstrated a high throughput HLA genotyping approach 
using very high coverage deep sequencing with a custom capture kit for the HLA region 
[33].  The approach requires specialized PCR primers to enable amplification of the 
polymorphic exons. Exons 2-5 in Class I genes HLA-A, HLA-B, HLA-C were captured 
and amplified. Exons 1-7 were captured and amplified in the Class II HLA gene HLA-
DRB1. Paired-end reads were used with read-lengths of 150 bases. Coverage was very 
high with median coverage near 1000x. Reads were aligned against all HLA allele 
sequences in the IMGT/HLA database. A number of filters were employed including a 
best-match filter, a mismatch filter, a length filter and a paired-end filter.  This approach 
demonstrated high accuracy.  The HLA genotype was assigned to the genotype with the 
maximum number of distinct reads for a given HLA genotype. Homozygous genotypes 
were adjusted by the empirical value of 1.05.  The approach was very accurate for the cell 
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lines and clinical samples that were utilized. However, the software and probes used were 
not made available and the validation of the algorithm on whole genome, whole exome 
and RNA-Seq data that are typically employed in research experiments was not part of 
the analysis.  The approach did demonstrate that with very high coverage and longer read 
lengths high quality HLA genotyping at could be completed with next generation 
sequencing data. A commercial software company, Omixon Biocomputing Solutions, has 
recently developed a software product based on this algorithm with some modifications. 
Based on results from a poster presented at Bio-IT World 2012, Vienna, HLA typing 
using whole genome sequencing yielded 85% precision and 75% recall using a 
RainDance HLAseq kit. 
In Genome Medicine, Warren et al describe a computational method to derive 
HLA allele predictions from next generation sequencing [36].  The software called 
HLAminer is available for download at 
http://www.bcgsc.ca/platform/bioinfo/software/hlaminer.  The approach uses targeted de 
novo assembly of the reads found in the HLA gene region.  The HLA genotypes are 
called based on a comparison of the assembled sequence contigs to the known HLA 
sequences found in the IMGT/HLA database.  The best BLAST alignment of the contig 
is used to develop a score based on the size, depth and percent of sequence identity.  
Using simulated next generation data (1% error rate) with a read length of 100, the 
method achieved 87% precision and 88% recall. Lower error rates, increased read lengths 
and higher depth of coverage, improved the precision and recall in the simulations. In the 
simulation, read lengths of less than 75 and error rates greater than 1% negatively 
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impacted the algorithm. Application of the algorithm to real datasets from RNA-Seq, 
whole genome sequencing and whole exome capture experiments had similar precision 
and recall to the analysis based on the simulated data.  
Seq2HLA[37] which used an iterative counting approach also had issues with 
ambiguities with the prediction of 4-digit HLA predictions and achieved only 32% 
accuracy. This approach counted the reads that aligned with sequences available in the 
IMGT/HLA database and then used an iterative approach to narrow the choices for the 
final HLA genotype called.  
 
 
4.3 Solving coverage problems in the HLA Region 
A major problem that will need to be addressed in order to predict HLA 
genotypes from next generation sequencing data is the poor coverage that occurs in the 
HLA region with the very fast alignment algorithms typically used to analyze next 
generation sequencing data.  There is often poor alignment of the reads to the HLA genes 
in the region.  The large number of paralogous genes in the region also complicates 
alignment in the MHC region.  This will result in alignments of many reads to multiple 
locations and poor mapping quality. For example, the HLA-DRB1 has gene paralogs 
HLA-DRB3, HLA-DRB4, and HLA-DRB5 and pseudogenes HLA-DRB2, HLA-DRB6, 
HLA- DRB7, HLA-DRB8 and HLA-DRB9.   
Additionally, the HLA genes often have hundreds of alleles due to the high rates 
of polymorphism in the genes. Often reads from the HLA genes are not mapped to the 
human reference genome due to mismatches with the reference. When the number of 
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mismatches reaches a certain threshold, the read is not aligned.  This results in low 
uneven coverage.  Typically an alignment software program such as bwa [38] has a 
maximum number of mismatches that is allowed per read. For bwa alignments, the 
default maximum edit distance is 0.04. So for a 101 base read, mismatches to the 
reference of greater than 5 would not align.  
For example, hg19/GRCh37 human reference has the HLA-DRB1*15:01 allele 
sequence for the HLA-DRB1 gene.  Individuals with this HLA allele will align accurately 
as there will be few if any mismatches. As the evolutionary distance of other HLA-DRB1 
alleles increase, the read alignment will suffer with the increase in mismatches.  Simply 
increasing the maximum edit distance however could potentially align reads that align to 
other paralogous genes in the MHC region. As seen in Figure 4.2, there are a total of 23 
mismatches observed between HLA-DRB1*15:01 (found in the reference) and the HLA-
DRB1*03:01.    
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 Figure 4.2 Alignment of HLA*DRB1*15:01 to HLA*DRB1*03:01 using the IMGT/HLA Alignment Tool 
HLA-DRB1*15:01 is the locus found in the GRCh37 human reference. 23 mismatches are found between the HLA-
DRB1*03:01 and the reference sequence in exon 2.  The high number of mismatches makes alignment difficult using 
standard genome alignment tools such as bwa. 
 
AA Codon                                10                  15                  20                  25                  
 DRB1*03:01:01:01    CA CGT TTC TTG GAG TAC TCT ACG TCT GAG TGT CAT TTC TTC AAT GGG ACG GAG CGG GTG CGG TAC CTG GAC AGA  
 DRB1*15:01:01:01    -- --- --- C-- TG- C-G C-- -A- AGG --- --- --- --- --- --- --- --- --- --- --- --- -T- --- --- ---  
AA Codon            30                  35                  40                  45                  50                  
 DRB1*03:01:01:01   TAC TTC CAT AAC CAG GAG GAG AAC GTG CGC TTC GAC AGC GAC GTG GGG GAG TTC CGG GCG GTG ACG GAG CTG GGG  
 DRB1*15:01:01:01   --- --- T-- --- --- --- --- TC- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---  
  
 AA Codon           55                  60                  65                  70                  75              
 DRB1*03:01:01:01   CGG CCT GAT GCC GAG TAC TGG AAC AGC CAG AAG GAC CTC CTG GAG CAG AAG CGG GGC CGG GTG GAC AAC TAC TGC  
 DRB1*15:01:01:01   --- --- --C --T --- --- --- --- --- --- --- --- A-- --- --- --- GC- --- -C- GC- --- --- -C- --- ---  
  
 AA Codon           80                  85                  90                    
 DRB1*03:01:01:01   AGA CAC AAC TAC GGG GTT GTG GAG AGC TTC ACA GTG CAG CGG CGA G           
 DRB1*15:01:01:01   --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- -  
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To accurately predict both rare and common HLA alleles from next generation 
sequence data, it is critical to capture reads that map to any of the 1000s of known HLA 
allele sequences.  The impact of the poor alignment in this region can be seen in the depth 
of coverage seen found in pilot 2 of the 1000 genomes project using the GATK pipeline 
[39].  There are clear dips in the depth of coverage in the MHC 1 and MHC 2 regions. 
Figure 4.3 MHC depth of coverage in JPT samples of the 1000 Genomes Project  
Using the low coverage pilot 2 whole genome data, the depth was calculated using 
the GATK depth of coverage tool,  
 
 
 
 
 
 
 
 
 
 From McKenna A et al. Genome Res. 2010;20:1297-1303 licensed under CC 4.0 
 
The reason for these dips in coverage is the increased level of mismatches when 
aligning reads to a single standard reference.  The alignment to these highly polymorphic 
regions will be poor even with high coverage sequencing.  The Figure 4.4 displays the 
read alignment for the HLA DRB1 loci for two genomes sequenced at 40x coverage for 
two Saudi individuals with different HLA genotypes.  Despite the high genome coverage, 
MHC I MHC II 
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the top individual has poor coverage in the HLA-DRB1 loci exon 2 region. Neither of 
this individual’s HLA alleles matches the reference so a large number of mismatches 
result with the bwa alignment.  As a result, the reads are left unmapped in that region.  
The bottom individual has alleles HLA-DRB1*15:03 and HLA-DRB1*13:03. In the 
bottom individual, there is much better coverage with the near match of one allele with 
the reference. 
 
Figure 4.4 Bias to the reference for bwa alignment at HLA-DRB1 loci aligned to 
GRCh37 reference 
 The Integrative Genomic Viewer (IGV) display of reads from two bam files show 
contrasting coverage in the HLA-DRB1 exon 2 region. Each sample has 40x 
coverage.  The top read alignment to HLA-DRB1 loci is from an individual with 
genotype HLA-DRB1*10:01/11:04.  The bottom alignment is from an individual 
with HLA-DRB1*13:03/15:03.  As expected, the alignment for the exon 2 region 
is much higher for the individual with the HLA-DRB1*15 allele.  The allele is 
similar to the GRCh37 reference that bwa is aligning to HLA-DRB1*15:01. 
 
 
Exon 2 region 
with relatively 
few bwa 
aligned reads  
DRB1*10:01/11:04 
DRB1*13:03/15:03 
GRCh37 reference uses the HLA-DRB1*15:01 sequence 
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This depth of coverage issue will be addressed with the following approach.  To 
rapidly find overlaps with all HLA gene sequences, all unmapped reads will be matched 
searched in all known HLA alleles found in that individual’s ethnic population. Samtools 
will be first used to select all unmapped reads from the unaligned reads in the BAM file. 
Each of those unmapped reads will be scanned for exact matches for all known HLA 
sequences.  To implement this, the HLA sequences in the IMGT/HLA database that are 
found in the population will be split into overlapping N-mers where N corresponds to the 
reads length of the next generation sequencing reads.  To speed the search process, each 
N-mer generated from the IMGT/HLA database will be stored in a hash. With this data 
structure, whether a read has an exact match to a specific HLA allele is quickly 
determined.  This will be an important step in the HLA calling pipelines developed for 
the naïve Bayes classifier for processing next generation sequencing data (DNA and 
RNA-Seq).  This is essentially creating a virtual capture of HLA reads from all the non-
mapped reads.  
Another coverage problem is specific to whole exome sequencing and the baits 
used to capture this highly polymorphic region.  To assess the two bait kits used in the 
1000 Genomes Project’s whole exome sequencing, the precision and recall of the naïve 
Bayes HLA prediction classification algorithm will be compared.  The increased capture 
of the HLA exon 2 and exon 3 by a kit would be expected to result in better classification 
of the HLA genotypes in the samples.  Those kits with poor capture in the exon regions 
will result in poor HLA prediction because of the poor coverage. 
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4.4 Introduction to naïve Bayes approach 
Intuitively, the reads in a next generation sequencing experiment can be 
considered a collection of words e-mailed to us for classification.  Like an incoming e-
mail, the set of words (100 bp reads) need to be classified. While an e-mail message 
would be classified as spam or not spam, the genomic words (RNA or DNA 100 bp 
reads) need to be classified instead as a specific HLA genotype.  Given that a naïve 
Bayes classifier [40] is considered the best approach for classifying e-mails [41], one 
would expect that an adaption of such a classifier to next generation sequencing reads 
should show promise in successfully classifying next generation sequencing reads if an 
appropriate training data set could be developed.  The naïve Bayes classifier is a 
supervised machine learning method based on Bayes' theorem with independence 
assumptions of the features used to predict the class, which in this case will be the HLA 
genotype.  This independence assumption among the features (reads from the next 
generation sequencing experiment) is not typically true in real life examples and therefore 
somewhat naïve. The naïve Bayes classifier approach is most apt when the feature space 
(in this case: large numbers of unique individual reads) is high and will often outperform 
more sophisticated approaches used for classification [40, 42].  
So rather than attempting to apply iterative alignment or de novo assembly 
methods using next generation sequencing reads to predict a given HLA genotype, a data 
mining approach based on the naïve Bayes classifier will be implemented for solving the 
HLA prediction problem.  The following diagram (Figure 4.5) provides an overview of 
  
56
the naïve Bayes approach and bioinformatics data used to classify using the python 
implementation HLA-Genotyper. 
 
Figure 4.5 Data flow diagram for HLA-Genotyper software to implement naïve 
Bayes method to predict HLA genotypes 
The reads aligned to the HLA genes and unmapped genes are matched to all known HLA 
4-digit sequences from IMGT/HLA database.  HLA frequencies for the specific ethnic 
population are used as priors.  The posterior probabilities of the 4-digit HLA genotypes 
are estimated using the naïve Bayes algorithms implemented in HLA-Genotyper. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Posterior 
Probability of  
4-Digit HLA 
Genotypes 
 
BAM File with 
aligned reads 
 
BAM File with 
unaligned reads 
HLA-Genotyper Priors: HLA Allele 
Frequencies in 
Ethnic Population  
IMGT/HLA 
database of 4-Digit 
HLA Sequences 
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4.5 Naïve Bayes classification method to predict HLA genotypes from Next 
Generation Sequencing Data 
To call HLA genotypes from next generation sequencing reads from an 
individual’s genome, a multi-class Naïve Bayes classifier approach has been developed.  
The algorithm assumes the DNA reads that have been sequenced are randomly 
distributed across the HLA gene.  This assumption should generally apply for whole 
genome sequencing technology. However, we recognize that for whole exome 
sequencing using capture technology, this may be violated by the specific bait designs 
used for the HLA genes being captured. Such designs may result in uneven coverage over 
the exon sequences of the numerous alleles in a specific HLA gene.  We examined this in 
more detail with the validation on the 1000 genomes samples and compare two different 
bait designs used in that project. Another source of bias that will need to be addressed is 
that the alignment match of the reads will be higher for any HLA alleles found in the 
reference used for alignment.  The greater the phylogenic distance of an HLA allele to the 
HLA allele found in the reference, the more mismatches can be expected. Depending on 
the alignment algorithm, this relative increase in mismatches may in turn result in lower 
coverage for specific HLA alleles and introduce bias in subsequent HLA genotyping 
methods.  
 
There are 6 major HLA genes (HLA-A, HLA-B, HLA-C, HLA-DQA1, HLA-
DQB1, HLA-DRB1). Each of these HLA genes has multiple alleles whose protein 
structure varies based on the encoding of exon 2 and sometimes exon 3.  The high level 
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of polymorphism in exon 2 and 3 encodes the protein pocket used for antigen binding.  
The high polymorphism makes the design of SNP assays difficult, as the technology 
requires non-varying flanking regions to bind. 
 
The HLA genotype, H, is the class to be assigned with the algorithm.  The HLA 
genotype that is assigned is the one that presents the maximum posterior probability 
based on the likelihood of the available reads generated in the next generation sequencing 
experiment.  The classification model is a conditional model such that: 
               ݌ሺܪ|ܴଵ, … . , ܴ௡) 
where the Class H represents the dependent classification variable for the HLA 
genotype outcomes.  This is conditional on the sequencing reads R1 to Rn where n is the 
number of reads that align to the specific HLA gene whose genotype is to be classified.  
To capture those reads, the algorithm looks for an exact match of the read to any known 
HLA allele sequences that are found in that individual’s ethnic population. 
 
Using Bayes Theorem, ܲ݋ݏݐ݁ݎ݅݋ݎ ൌ 	 ೛ೝ೔೚ೝ	∗	೗೔ೖ೐೗೔೓೚೚೏೐ೡ೔೏೐೙೎೐ , we arrive at the following: 
  
݌ሺܪ|ܴଵ, … . , ܴ௡ሻ ൌ ௣ሺுሻ௣ሺோభ,….,ோ೙|ுሻ௣ሺோభ,….,ோ೙ሻ  
݌ሺܪ|ܴଵ, … . , ܴ௡ሻ ൌ ݌ሺܪሻ		݌ሺܴሺଵሻ|Hሻ݌ሺܴሺଶሻ|Hሻ… . ݌ሺܴሺ௡ሻ|Hሻሻ ൌ ܲሺܪሻෑ݌ሺܴሺ௝ሻ
௡
௝ୀଵ
|Hሻ 
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Where ݌ሺܪ|ܴଵ, … . , ܴ௡ሻ is the posterior probability of the HLA genotype and 
p(R(j) |H) is the likelihood of the jth read aligning to either of the 2 HLA alleles(a,b) found 
in the HLA genotype so that : 
݌ሺܴ௝|Hሻ ൌ ݌ሺܴሺ௔,௕ሻ|Hሻ ൌ 1 െ ሺሺ1 െ ݌ሻሺ1 െ ݍሻሻ 
 
Where: 
             p(H) is the likelihood of the genotype in the specific ethnic population 
from which the specific individual is a member.  This is calculated assuming Hardy-
Weinberg equilibrium where A is the probability of HLA allele a and B is the probability 
for HLA allele b: 
݌ሺܪሻ ൌ 	ܣଶ ൅ 2ܣܤ ൅ ܤଶ 
p(R(a,b) |H) ݅ݏ the likelihood of HLA genotype a,b  for read j 
p is a measure of the mapping quality based on the likelihood of read j aligning to 
HLA allele a  
q is a measure of the mapping quality based on the likelihood of read j aligning to 
HLA allele b  
Both p and q are measures of the mapping quality of the read based on the M 
number of exact matches to HLA alleles in the HLA gene. 
If the read aligns exactly in HLA allele a:  
݌ ൌ 1/ܯ௔ 
If the read does not align to HLA allele a, p is set to the estimated machine 
sequencing error rate: 
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݌	 ൌ 	݁ 
Likewise if the read aligns exactly in HLA allele b: 
ݍ ൌ 1/ܯ௕ 
If the read does not align to HLA allele a, q is set to an estimated machine 
sequencing error rate:  
ݍ	 ൌ 	݁ 
M is the total number exact matches of the read sequence among the known HLA 
allele sequences in the IMGT database for the HLA gene.  The probabilities of p and q 
are set to a minimum value for non-matches to reflect the possibility of machine error in 
the read that results in the non-match.   
 
Effectively a single read that is unique to a specific HLA allele will have a 
probability (p or q) set to 1.0 for that allele read. A read that is common in multiple HLA 
alleles for that gene will be have a probability that is the inverse of the number of exact 
matches.  Reads without a match in the sequence of a specific HLA allele will have the 
likelihood set to a value above 0 to reflect the potential of machine error.   Since it is 
possible the read is from a sequence that could align but has one or more errors in the 
read, a non-mapped read’s likelihood is set to an estimated sequencing error rate.  If 
instead p(Rj |H) was set to 0 for any mismatches, an error in a read would in turn set the 
likelihood of a genotype incorrectly to 0. 
The likelihood of each HLA genotype is calculated by multiplication of each 
read’s probability of aligning to a specific HLA genotype.  The model assumes each read 
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aligns to either one or two HLA alleles in the same gene. Reads that align to different 
HLA genes are excluded.  The algorithm assumes reads of same length are generated 
from across the region randomly. Programmatically this is computed by summing the log 
probabilities to avoid underflow (computer issue caused by very small numbers). 
 
4.6 The Prior Based on Ethnic Specific HLA Probabilities. 
For the ethnic specific prior probabilities, the algorithms used HLA allele 
frequencies determined from the National Marrow Donor Registry [43] and the Allele 
Frequency Net Database (AFND) [44].  The source of the HLA allele frequencies were 
primarily from the National Marrow Donor Program databases which grouped the 
frequencies by the four major U.S. census categories of race and ethnicity: African-
American (AFA), Asian-Pacific Islander (API), European (EUR), and Hispanic (HIS). 
HLA alleles found in the HLA population-based high-resolution HLA frequencies 
defined on the basis of from one to five loci are presented and made available online.  
The prior in the algorithm is to set to 0 for those HLA alleles not found in the ethnic 
population.  In a genome where the allele frequencies are not known such as in an archaic 
human genome, a uniform probability distribution of all HLA alleles found in all 3 
populations could be used. With Neanderthal introgression estimated at 2-4% in non-
Africans, an increased weight for non-African HLA alleles may also be considered.  The 
ethnic priors for each 4-digit HLA allele for the naïve Bayes algorithms can be found 
Table A.2 of the Appendix. 
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4.7 Training Data Set the Naïve Bayes Algorithm 
To use the naïve Bayes algorithm to predict HLA genotypes, an appropriate 
training data set is necessary to assign the probability of a read mapping to a specific 
HLA allele sequence. The probability of read sequences mapping to HLA alleles will be 
generated for the specific read length (k) found in the sequencing experiment for the 
ethnic group the sequence is from.  So to predict the HLA genotypes in a next generation 
sequencing run which has 101 base-pair reads, a probability distribution for all possible 
101 base-pair reads in the specified exons are calculated for the specific ethnic 
population. The naïve Bayes algorithm then uses these set of probabilities obtained from 
the training data to calculate the posterior probability of the HLA allele along with the 
prior. The training data set must include all known sequences in the HLA loci. For every 
k-mer read generated from the training database, the number of HLA alleles a specific 
read is mapped to is tracked. The mapping probabilities are then calculated using the 
mapping totals.  
The data set selected for training the naïve Bayes algorithm is the IMGT/HLA 
database [45], which is part of the International ImMunoGenTics (IMGT) project.  This 
database houses the official sequences of the WHO nomenclature Committee For Factors 
of the HLA System. The database presently holds 10,691 allele sequences.  Typically, in 
most parts of the genome, a gene has a single sequence with a minor set of variations that 
results in protein coding changes. For example, the protein APOE has 3 protein versions 
(APOE-2, APOE-3 and APOE-4) generated by changes in two SNPs.  In contrast, the 
HLA-A gene consists of not three protein possibilities but over 300.  A single HLA gene 
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across a population may encode hundreds of different proteins. Each of these different 
proteins is assigned a different 4-digit HLA code.  This database provides the sequences 
of all known HLA alleles. Many of these are not full sequences but often just the critical 
sequences of the exons that distinguish the specific HLA proteins and corresponding 4-
digit HLA code. Many of these sequences are from RNA-Seq experiments and do not 
include the sequences for introns. This is taken into account when training. When training 
for an RNA-Seq experiment, the exons will be spliced together before generating the 
reads and the mapping probabilities. When training for a targeted, whole exome or whole 
genome experiment, the abutting intronic regions will instead be included when 
generating the reads and corresponding mapping probabilities used in the classification of 
HLA genotypes. 
For example in table 4.1, Training Read 1 maps to the two HLA alleles A*01 and 
A*02 for which the read exactly matches. This training read would simply be assigned a 
probability of 0.50 each for those two HLA alleles. For the HLA alleles where there is 
not an exact match in the alignment, the read (HLA-A*03,A*04,A*05,A*06) is set to a 
low probability.  As errors will be possible in these sequences and result in a mismatch, 
the HLA allele mapping probability with 0 matches are set to 0.01 to reflect the 
possibility of such a sequencing error. 
Likewise, Training Read 2 maps to 3 different HLA alleles and would be assigned 
a probability of 0.33 (1/3). Training Read 3 only maps to one HLA allele and would be 
assigned a training probability of 1.0. Essentially the more unique the mapping of a read, 
the higher the probability assigned for the HLA allele that it maps to.   
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Table 4.1 Example Training Data for Naïve-Bayes Algorithm to Classify HLA 
Alleles 
 
Read Mapping 
Number of 
Alleles the 
Read 
Matches 
HLA 
Allele 
A*01 
HLA 
Allele 
A*02 
HLA 
Allele 
A*03 
HLA 
Allele 
A*04 
HLA 
Allele 
A*05 
HLA 
Allele 
A*06 
Training Read 1 
Maps to Alleles 
A*01, A*02 
2 0.5 0.5 0.01 0.01 0.01 0.01 
Training Read 2 
Maps to HLA-
A*01,A*02,A*03 
3 0.33 0.33 0.33 0.0 0.0 0.0 
Training Read 3 
Maps to HLA-
A*02 
1 0.01 1.0 0.01 0.01 0.01 0.01 
Training Read 4 
Maps to HLA-
A*05 
1 0.01 0.01 0.01 0.0 1.0 0.01 
Training Read 5 
Maps to HLA-
A*04,A*05 
2 0.01 0.01 0.01 0.5 0.5 0.01 
Training Read 6 
Maps to HLA-
A*02,A*03, 
A*04,A*05 
4 0.01 0.25 0.25 0.25 0.25 0.01 
 
4.8 Capturing HLA reads to use in the algorithm  
Reads from next generation sequencing runs are aligned against one reference 
genome.  This can be problematic in regions of the genome that are highly polymorphic 
such as the HLA genes in the MHC. Alignment algorithms often have a mismatch cutoff.  
The HLA region is among the most polymorphic regions in the genome and exon 2 is the 
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most polymorphic among the HLA exons as seen in Figure 4.2.  Those allele sequences 
with more differences from the reference are less likely to align in lower coverage.  The 
alleles that match the reference will have higher coverage in general than those more 
distant.  
Table 4.2  Haplotypes from the MHC Haplotype Project.   
The MHC region from the PGF Cell line is the sequence contained in the GRC 
human reference.  The other 7 cell lines are included as alternate loci in the 
reference.  The A3-B7-DR15 haplotype is most common in western Eurasia with the 
highest frequency found in Ireland. 
Cell 
Line Haplotype HLA-A HLA-B HLA-C 
HLA-
DRB1 
HLA-
DQB1 
PGF* A3-B7-DR15 03:01 07:02 07:02 15:01 06:02 
COX A1-B8-DR3 01:01 08:01 07:01 03:01 02:01 
APD A1-B60-DR13 01:01 40:01 06:02 13:01 06:03 
DBB A2-B57-DR7 02:01 57:01 06:02 07:01 03:03 
MANN A29-B44-DR7 29:02 44:03 16:01 07:01 02:02 
SSTO A32-B44-DR4 32:01 44:02 05:01 04:03 03:05 
QBL A26-B18-DR3 26:01 18:01 05:01 03:01 02:01 
MCF A2-B62-DR4 02:01 15:01 03:04 04:01 03:01 
 
 For example, the cell line PGF was incorporated into the HG19/v37 reference 
sequence.  This cell line’s MHC region represents one of the eight common haplotypes 
sequenced by the MHC Haplotype Project (see Table 4.2)[46].  The PGF cell line is 
homozygous for the A3-B7-DR15 haplotype.  This HLA haplotype consists of HLA-
A*03:01,HLA-B*07:02,HLA-C:07:02, HLA-DRB1*15:01,HLA-DQB1:06:02. It is 
considered one of the longest haplotypes with a length of 4.8 MB.  While found in 
Western European populations, the haplotype is found rarely in Asian populations.  The 
HLA-B*07:02 allele found in the haplotype reaches frequencies of greater than 13% in 
North West Europe and drops to approximately 1% in Southeast Asia [47].  Reads from a 
genome with the matching haplotype will align more readily with the reference.  Those 
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HLA haplotypes whose sequences are more distant from PGF haplotype will have greater 
number of mismatches resulting in relatively poor alignment and poor coverage.  
This coverage is influenced by an aligner’s cutoff for the number of mismatches 
tolerated for a successful match. For example, bwa uses a default cutoff of 4% of the read 
length. A read with more than 4 mismatches in a 100 base read is left unmapped by bwa.  
This will show up as reduced coverage in these regions.  So a particular HLA allele may 
have more than 4 mismatches to the reference but still have an exact match with an 
alternative allele. 
To address this issue, the HLA-Genotyper software includes an option to search 
among all unmapped reads for any exact matches to known HLA sequences in the HLA-
IMGT database.  So if a read can not be aligned by bwa to the single reference, that read 
is then checked by HLA-Genotyper to see if it matches any of the thousands of known 
HLA sequences in the larger IMGT/HLA database.  
If an exact match is found in the IMGT/HLA database, the HLA-Genotyper 
software will then use the read in the naïve Bayes algorithm.  If it is not found, it is 
discarded and not used in the naïve Bayes algorithm. This search among unmapped reads 
has been implement in the HLA-Genotyping software to increase the number of reads 
used to calculate the posterior probability of an HLA genotype.  These unmapped reads 
have the highest level of mismatches relative to the reference and are among the reads 
most critical for distinguishing between the 4-digit HLA alleles. For bwa created bam 
files, the HLA-Genotyper software searches all unmapped reads to find any reads that are 
an exact match to any known HLA allele sequence. As bwa will not match a read because 
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of mismatches, often additional reads that were an exact match to one or more HLA 
alleles are found with the HLA-Genotyper software.  
In Table 4.3, the Europeans with HLA-DRB1*15:01 HLA allele are listed. As 
expected, all the HLA-DRB1*15:01 reads aligned with bwa and none were found among 
the unmapped reads (see Table 4.3 in bold).  So all of the HLA-DRB1*15:01 reads were 
successfully aligned by bwa to the reference which was the HLA-DRB1*15:01. 
Table 4.3 Comparison of HLA-DRB1*15:01 alignment and capture in heterozygous 
samples. 
 In heterozygous samples, bwa aligned all HLA-DRB1*15:01 reads but only 44% of 
the second allele. Besides a bias to the reference allele HLA-DRB1*15:01, the 
capture also showed a bias. Instead of a 50:50 ratio, a 61:39 ratio of DRB1*15:01 
reads to other reads occurred.  
Sample  HLA Allele 1  HLA Allele 2 
Mapped 
Reads 
Allele 1 
Un‐
mapped 
Reads 
Allele 1 
Mapped 
Reads 
Allele 2 
Un‐
Mapped 
Reads 
Allele 2 
NA06985  HLA‐DRB1*15:01  HLA‐DRB1*15:01  154 0  154 0
NA07048  HLA‐DRB1*04:01  HLA‐DRB1*15:01  23 6  32 0
NA07051  HLA‐DRB1*04:03  HLA‐DRB1*15:01  2 6  4 0
NA11831  HLA‐DRB1*03:01  HLA‐DRB1*15:01  12 22  45 0
NA11832  HLA‐DRB1*13:01  HLA‐DRB1*15:01  67 50  177 0
NA11881  HLA‐DRB1*15:01  HLA‐DRB1*15:01  288 0  288 0
NA11918  HLA‐DRB1*04:01  HLA‐DRB1*15:01  10 4  24 0
NA11995  HLA‐DRB1*13:01  HLA‐DRB1*15:01  34 20  105 0
NA12003  HLA‐DRB1*04:01  HLA‐DRB1*15:01  9 9  48 0
NA12004  HLA‐DRB1*01:01  HLA‐DRB1*15:01  9 23  39 0
NA12005  HLA‐DRB1*15:01  HLA‐DRB1*15:01  106 0  106 0
NA12006  HLA‐DRB1*04:04  HLA‐DRB1*15:01  34 11  134 0
NA12044  HLA‐DRB1*13:01  HLA‐DRB1*15:01  50 64  105 0
NA12750  HLA‐DRB1*04:04  HLA‐DRB1*15:01  57 27  104 0
NA12761  HLA‐DRB1*03:01  HLA‐DRB1*15:01  17 12  19 0
NA12763  HLA‐DRB1*01:03  HLA‐DRB1*15:01  1 6  6 0
NA12814  HLA‐DRB1*01:03  HLA‐DRB1*15:01  10 29  122 0
NA12873  HLA‐DRB1*15:01  HLA‐DRB1*15:01  93 0  93 0
NA12874  HLA‐DRB1*15:01  HLA‐DRB1*16:01  29 0  29 0
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Among the 15 samples that were heterozygous for HLA-DRB1*15:01, the other 
non HLA-DRB1*15:01 allele had a much lower alignment rate. Only 364 of the 653 
reads that were exact matches to other HLA DRB1 alleles were aligned.  The bwa 
alignment rate of 44% for non-HLA-DRB1*15 alleles compares unfavorably to a 100% 
rate for HLA-DRB1*15:01.  So for bwa aligned bam files, this analysis demonstrates it is 
critical to scan for unmapped reads with matches to known HLA alleles sequences when 
in the MHC region.  
This search of unmapped reads by HLA-Genotyper is optional as this option is 
not necessary if the alignment software is successful in aligning all HLA reads to the 
MHC region.  While bwa did not have great success in aligning this region, the GEMS 
aligner was much better for the highly polymorphic MHC region. The GEMS alignment 
software [48] mapped all the RNA-Seq reads that were exact matches in the IMGT/HLA 
database to the GRC human reference.  HLA-Genotyper software did not find any 
unmapped reads that were an exact match in the IMGT/HLA database.  As checking each 
unmapped read is a relatively time consuming step by HLA-Genotyper, the search among 
unmapped reads was turned off when processing RNA-Seq samples aligned by GEMS. 
 
Besides a bias in aligning the reads to the reference, there was also a major bias 
found with the capture designs even after accounting for the unmapped reads.  Among 
the 15 heterozygous samples containing one HLA-DRB1*15:01 allele, there were 993 
reads exactly matching the HLA-DRB1*15:01 allele compared to only 653 for the 
alternate alleles.  There were 52% more HLA-DRB1*15:01 reads captured than the 
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alternate alleles.  This resulted in a 61:39 ratio instead of the 50:50 ratio expected.  This 
suggests that the capture designs apparently are only based on the single reference 
alignment rather than the 8 MHC Project Haplotypes whose complete sequences are 
known.  So for both alignment and whole exome capture, there is a bias to a human 
reference genome whose MHC haplotype is found primarily in West Eurasians.  
 
4.9 Data sets chosen for validation 
European and Yoruba (YRI) individuals from the 1000 genome project who have 
whole exome sequencing, whole genome sequencing, RNA-Seq data and most 
importantly 4-digit HLA typing were selected.  The Asian population was not included as 
RNA-Seq data was not available at the time of the analysis.  The naïve Bayes approach 
was then used to predict the HLA genotypes in both the YRI and European population 
using downloaded RNA and genomic sequencing data for those samples with HLA 
typing.  The HLA genotypes available for these samples were considered the gold 
standard.   The HLA genotyping was completed on 270 HapMap samples. A subset of 
these HapMap samples was subsequently included in the 1000 Genomes Project, which is 
the focus of this analysis.  The details describing the data sets used in the validation are 
described next. 
4 Digit HLA Genotypes for Gold Standard 
As part of a high resolution mapping of the MHC region[4], 270 HapMap samples 
were originally genotyped by the Laboratory of Genetic Diversity (NCI-Frederick Cancer 
Research and Development Center) and made available for download at 
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http://www.inflammgen.org.  These HLA genotypes were generated using PCR-SSOP 
(sequenced specific oligonucleotide probe) based on guidelines from the 13th 
International Histocompatibility Workshop [49].  The Classical HLA loci from both the 
MHC Class I (HLA-A, HLA-B, HLA-C) and Class II region (HLA-DQA1, HLA-DQB1 
and HLA-DRB1were genotyped.  For the HLA Class I loci, exon 2, intron 2, and exon 3 
were amplified for the typing. For the HLA Class II genes, only exon 2 was amplified.  
These HLA genotypes form the basis for the gold standard used for the validation of the 
naïve Bayes HLA genotyping algorithm. 
 
The HLA genotypes data for 270 HapMap samples were also HLA genotyped 
with a protocol based on next generation sequencing using the 454 FLX Titanium 
platforms.  To minimize the error rates a high depth of coverage was employed with long 
read lengths and specialized primers for each locus.  The average read length of the 454 
sequencing was 364 base pairs with an average coverage of 103x.  The primers were 
designed to insure that the only one region from the human genome was amplified. Both 
the exon 2 and exon 3 of the HLA-A, HLA-B and HLA-C loci were sequenced.  The 
HLA Caller Algorithm[34, 35] was then used to call the MHC Class I HLA loci 
genotypes calls.  A total of 94 discordant HLA genotypes with the original gold standard 
HLA genotyping were followed up.  Of those 94, it was determined that 38 were 
systematic errors in the gold standard.  Based on this, it was determined the original gold 
standard based on SSO typing had an error rate of 2.3%[35].  These corrected MHC class 
I HLA genotypes were then incorporated into the original typing and used for the gold 
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standard for the initial validation.  The MHC Class II HLA genotypes had not yet 
undergone such scrutiny and will require a similar follow-up of discordant calls to 
finalize the gold standard used for validation. 
 
RNA-Seq Data from 1000 genomes  
The RNA-Seq data used for this analysis was downloaded from the Geuvadis 
RNA Sequencing Project of the 1000 Genomes Samples [48, 50].  This project completed 
RNA sequencing of 465 lympoblastoid cell lines samples available from the 1000 
Genomes Project. As lymphobastoid cell lines have high levels of HLA gene expression, 
the RNA coverage is expected to be of very high in these experiments.  The 5 populations 
that were included were the CEPH (CEU), Finland (FIN), Great Britain (GBR), Toscani 
(TSI)  and Yoruba (YRI).  The total RNA for this project was extracted from Epstein–
Barr-virus-transformed lymphoblastoid cell line pellets using TRIzol reagent (Ambion).  
The RNA sequencing of the 465 individuals were performed on the Illumina HiSeq 2000 
platform with paired-end 75-bp mRNA-Seq.  The reads generated from the RNA-Seq 
experiment were then aligned with the mapping software GEM [48] with an average of 
48.9  million mRNA-Seq reads per sample after filtering required for quality control.  Of 
these samples, individuals, which also had previously HLA genotyped samples from the 
1000 genomes projects, were identified.  Of the 465 samples, 45 samples with European 
ancestry and 38 individuals from the Yoruba Population were identified.  These samples 
  
72
with both RNA and HLA genotyping were then used for validation of the naïve Bayes 
HLA prediction algorithm. 
High Coverage Whole Exome Data 
The exome sequence data used for validation were downloaded from 1000 
Genomes Project Phase 3 exome data set consisting of 2535 exomes from 14 populations 
from Europe, East Asia, Africa and North and South America [51].   The depth of 
coverage for the exomes averaged between 50x and 100x.   Two platforms were used for 
the exome sequencing: Genome	Analyzer	II	(Illumina)	and	SOLiD	Versions	3	or	4	
(Applied	Biosystems).			
For capture, the Illumina Platform used the Agilent Sure Select All Exon V2 
Capture Kit.  The Illumina sequencing generated paired-end reads of 75 or 100 base pairs 
depending on the sequencing center.  Alignment was completed with bwa v0.5.5 [38] 
against the hg19/NCBI37 reference.   Overall, the whole exome samples completed on 
the Illumina platform averaged 96x coverage after filtering for duplicate reads among the 
samples.   
The SOLID Platform exome sequencing experiments used the NimbleGen EZ 
Exome  2.0  Solution  Probes  (~44  Mb  of  sequence  targets  from  ~30K  genes).  
The Solid Platform generated paired-end reads with a length of 50 base pairs.  The reads 
were aligned with BFAST against the hg19/NCBI37	reference.  After removing 
duplicates these reads had an average of 55x coverage.  
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Low Coverage Whole Genome Data	 
From the 1000 Genomes project phase 3, low coverage sequencing of 1092 
genomes for analysis on the Illumina platform were available for analysis.  The reads had 
been aligned with bwa 0.5.5 [38] to the hg19/NCBI37	reference.	After duplication 
removal, the coverage was between 3x and 7x with an average of 5x. Among the 
European samples, a total of 25 samples were available with HLA typing and were 
included in the validation data set. For the Yoruba individuals, a total of 22 low coverage 
samples were available with HLA genotypes and included in the validation data set. 
Validation Data Set Summary 
In summary, for the European Ancestry individuals with available HLA 
genotypes for HLA-A,HLA- B, HLA-C, HLA-DQA1, HLA-DQB1 and HLA-DRB1, there 
were 45 individuals with RNA-Seq data, 47 individuals with whole exome data and 25 
individuals with low-coverage whole genome data from the 1000 Genomes Project 
samples.  For the Yoruba individuals, there were 38 individuals with RNA-Seq data, 45 
individuals with whole exome sequencing data and 22 with low coverage sequencing 
data.    
 
4.10 Software implementation of Naïve Bayes HLA Algorithm 
To implement the algorithm, the software, hla-genotyper.py was developed using 
Python version 2.7. The software package is available for download at 
http://github/jjfarrell/hla-genotyper. The source code listing is also found in Appendix A5 
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and A6. The following command line options (Table 4.3.1) are listed with the command 
line: python hla-genotyper.py –help :  
Usage: hla-genotyper.py [options] 
 
Table 4.3.1 HLA-Genotyper command line options 
Parameter Option Description of HLA-Genotyper Command Line Option 
-h, --help Show this help message 
-b BAMFILE This input bam should be sorted by genome coordinate and 
indexed. The software is presently using HLA gene 
coordinates based on the hg19/GRC37 human reference 
stored in the text file named exon_info.txt.  To update to a 
newer human reference in the future, this file would simply 
need to be updated with the new coordinates for each of the 
exons. 
-u UNMAPPED Bam file containing unmapped reads.  This file will be 
searched for reads with exact matches to known HLA allele 
sequences. Recommended for alignments by bwa and most 
aligners.  The command samtools view –u –f 4 is useful for 
generation of a bam file containing unmapped reads. 
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  -l READLEN This is optional and can be used to specify the read length of 
the reads in the bam file.  This is useful for predicting archaic 
human HLA genotypes where there is a wide range of 
variable read lengths. 
 -m MAPQ Minimum mapping quality 
 --qual BQ Minimum base quality in a read 
--debug For debugging, list probabilities for each HLA matched read 
--rnaseq Indicates the bam file is from an RNA-Seq experiment. Reads 
spanning between exons are included in the analysis. 
--exome Indicates the bam file is from a whole exome or targeted 
sequencing experiment.  
--genome Flag to indicate the input bam file is from a whole genome 
experiment. 
-s SAMPLE  To provide the study id in the output file if not available in the 
header of the bam file. 
--cn CN  To provide the Sequencing Center ID for output if not 
available in the header of the bam file. 
 -g GENE Limits the analysis to one of the HLA genes (A,B,C,DRB1, 
DQB1, DQA1) 
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-e ETHNICITY To designate the ethnic priors to be used in the naïve Bayes 
algorithm.  The prior probabilities for each ethnic group are 
stored in the ethnic_priors.txt file. The ethnicity code 
specified must match one of those in the ethnic_priors.txt file, 
which are presently coded EUR, AFA, API, and HIS. 
 
The HLA-Genotyper.py generates 3 output files: a log file, a dose file and the HLA 
genotype file.  
 The log file logs the various steps during the completion of the HLA genotyping. 
  The dose file is a tab-delimited file useful for reading into R scripts for analysis.  
The file columns correspond to the name of the bam file, id, ethnicity and the list 
of HLA alleles examined.  The HLA allele columns contained the count of each 
HLA allele found in the specific population for this individual (0,1,2).   
 The genotype file lists per line, the Center, bam filename, sample id, ethnic 
population, the HLA genotype, posterior probability, genotype quality followed 
by the read counts for each allele from mapped and unmapped bam files. 
Examples  
To predict the HLA genotypes from RNA-Seq bam file for NA20540 available 
for the 1000 genomes the following command line could be used: 
python hla-genotyper.py -e AFA--rnaseq   \ 
  -b http://www.ebi.ac.uk/arrayexpress/files/E-GEUV-1/NA18508.1.M_111124_1.bam 
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The above command line predicts the complete set of 6 Classical HLA genotypes and places the output in following 
log file:  hla.AFA.NA18508.rnaseq.log 
Sample= NA18508 
BAM input file to Scan (mapped reads)  : http://www.ebi.ac.uk/arrayexpress/files/E-GEUV-1/NA18508.1.M_111124_1.bam 
BAM input file to Scan (unmapped reads): None 
Ethnicity: AFA 
Base Quality Cutoff: 30 
HLA Loci to call:  ['HLA-A', 'HLA-B', 'HLA-C', 'HLA-DQA1', 'HLA-DQB1', 'HLA-DRB1'] 
Exons read for genotyping  HLA-A :  ['1', '2', '3', '4'] 
Exons read for genotyping  HLA-B :  ['1', '2', '3', '4'] 
Exons read for genotyping  HLA-C :  ['1', '2', '3', '4'] 
Exons read for genotyping  HLA-DQA1 :  ['1', '2', '3', '4'] 
Exons read for genotyping  HLA-DQB1 :  ['1', '2', '3', '4'] 
Exons read for genotyping  HLA-DRB1 :  ['2'] 
Read lengths: 75 
IMGT Database= hla.dat 
Number of HLA Alleles= 1891 
Number of 4 Digit HLA Alleles= 285 
Number of HLA Reads= 987754 
N unique Reads= 118634 
-------------------------------------------------------------------------------- 
Scanning Mapped Reads 
Scanning mapped reads for exon  1  gene: HLA-A  start: 29910331  stop: 29910403 N mapped reads= 628 
Scanning mapped reads for exon  2  gene: HLA-A  start: 29910534  stop: 29910803 N mapped reads= 3846 
Scanning mapped reads for exon  3  gene: HLA-A  start: 29911045  stop: 29911320 N mapped reads= 2277 
Scanning mapped reads for exon  4  gene: HLA-A  start: 29911899  stop: 29912174 N mapped reads= 2208 
Scanning mapped reads for exon  1  gene: HLA-B  start: 31324863  stop: 31324935 N mapped reads= 489 
Scanning mapped reads for exon  2  gene: HLA-B  start: 31324465  stop: 31324734 N mapped reads= 2873 
Scanning mapped reads for exon  3  gene: HLA-B  start: 31323944  stop: 31324219 N mapped reads= 1612 
Scanning mapped reads for exon  4  gene: HLA-B  start: 31323094  stop: 31323369 N mapped reads= 5791 
Scanning mapped reads for exon  1  gene: HLA-C  start: 31239776  stop: 31239848 N mapped reads= 211 
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Scanning mapped reads for exon  2  gene: HLA-C  start: 31239376  stop: 31239645 N mapped reads= 1162 
Scanning mapped reads for exon  3  gene: HLA-C  start: 31238850  stop: 31239125 N mapped reads= 2379 
Scanning mapped reads for exon  4  gene: HLA-C  start: 31237987  stop: 31238262 N mapped reads= 2585 
Scanning mapped reads for exon  1  gene: HLA-DQA1  start: 32605236  stop: 32605317 N mapped reads= 127 
Scanning mapped reads for exon  2  gene: HLA-DQA1  start: 32609087  stop: 32609335 N mapped reads= 1266 
Scanning mapped reads for exon  3  gene: HLA-DQA1  start: 32609749  stop: 32610030 N mapped reads= 1505 
Scanning mapped reads for exon  4  gene: HLA-DQA1  start: 32610387  stop: 32610541 N mapped reads= 562 
Scanning mapped reads for exon  1  gene: HLA-DQB1  start: 32634276  stop: 32634384 N mapped reads= 151 
Scanning mapped reads for exon  2  gene: HLA-DQB1  start: 32632575  stop: 32632844 N mapped reads= 395 
Scanning mapped reads for exon  3  gene: HLA-DQB1  start: 32629744  stop: 32630025 N mapped reads= 398 
Scanning mapped reads for exon  4  gene: HLA-DQB1  start: 32629124  stop: 32629234 N mapped reads= 67 
Scanning mapped reads for exon  2  gene: HLA-DRB1  start: 32551886  stop: 32552155 N mapped reads= 1186 
-------------------------------------------------------------------------------- 
Total Read Summary 
HLA Genes to Call: ['HLA-A', 'HLA-B', 'HLA-C', 'HLA-DQA1', 'HLA-DQB1', 'HLA-DRB1'] 
Total Exact match reads from HLA Genes: 31718 
Unique Exact match reads from HLA Genes 3721 
Reads mapped to 265 HLA Alleles 
-------------------------------------------------------------------------------- 
HLA Genotyping Results                                Read Counts 
#bam file        sample  pop          Allele 1                     Allele 2                     PP  FILTER A1       A2       A1+A2  Total 
NA18508.1.M_111124_1.bam NA18508 AFA   HLA-A*33:03          HLA-A*68:02 1.0 Pass        5247  0 4458 0  9705     8959 
NA18508.1.M_111124_1.bam NA18508 AFA   HLA-B*42:01          HLA-B*53:01   1.0 Pass        8325  0 8446 0  16771   10765 
NA18508.1.M_111124_1.bam NA18508 AFA   HLA-C*04:01          HLA-C*17:01      1.0 Pass        3981  0 1875 0  5856     6337 
NA18508.1.M_111124_1.bam NA18508 AFA   HLA-DQA1*02:01  HLA-DQA1*04:01 1.0 Pass        1878  0 1823 0  3701     3460 
NA18508.1.M_111124_1.bam NA18508 AFA   HLA-DQB1*02:01  HLA-DQB1*04:02  1.0 Pass        590    0  584  0  1174     1011 
NA18508.1.M_111124_1.bam NA18508 AFA   HLA-DRB1*03:02  HLA-DRB1*13:03  1.0 Pass        518    0  651  0  1169     1186 
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In the above example, command line specified as the input file a bam file located 
on a remote ftp site to minimize local storage requirements. Only the bam index file and 
the reads mapped to the classical HLA genes will be downloaded for analysis by the 
HLA-Genotyper software.  This is an important feature to allow the prediction of HLA 
genotypes using data in large sequencing repositories available for the 1000 genomes 
samples and other consortia.  
Table 4.4 GRCh37 Coordinates of HLA Exons used by HLA-Genotyper for HLA-
Classification  
 
Gene Exon Chromosome Start Stop 
HLA-A 1 6 29910331 29910403 
HLA-A 2 6 29910534 29910803 
HLA-A 3 6 29911045 29911320 
HLA-A 4 6 29911899 29912174 
HLA-B 1 6 31324863 31324935 
HLA-B 2 6 31324465 31324734 
HLA-B 3 6 31323944 31324219 
HLA-B 4 6 31323094 31323369 
HLA-C 1 6 31239776 31239848 
HLA-C 2 6 31239376 31239645 
HLA-C 3 6 31238850 31239125 
HLA-C 4 6 31237987 31238262 
HLA-DQA1 1 6 32605236 32605317 
HLA-DQA1 2 6 32609087 32609335 
HLA-DQA1 3 6 32609749 32610030 
HLA-DQA1 4 6 32610387 32610541 
HLA-DQB1 1 6 32634276 32634384 
HLA-DQB1 2 6 32632575 32632844 
HLA-DQB1 3 6 32629744 32630025 
HLA-DQB1 4 6 32629124 32629234 
HLA-DRB1 2 6 32551886 32552155 
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There were a total of 285 4-digit HLA allele found in the IMGT/HLA database 
for the 6 Classical HLA genes.  The database sequences were parsed into a total of 
987,754 75-base pair reads of which 118,634 unique reads were detected and the 
sequenced hashed to speed up the search for matching reads from the input bam file.  
The software uses an input table to specify the HLA gene exons and physical base 
positions in the reference used to align the bam file.  These positions are used to view 
aligned reads in the indexed bam file at those locations. With the recent release of the 
GRCh38, simply updating this file containing these details (exon_info.txt) is all that is 
needed to migrate to a new reference. As the IMGT/HLA database increases the coverage 
of exons in such genes as HLA-DRB1, the number of exons that are examined can be 
expanded readily. 
Read counts for each exon are displayed. Each read must have an exact match for 
an HLA allele found in the ethnic population based on the priors.  There were a total of 
31,718 reads from the input bam file that was an exact match to an HLA allele sequence. 
As this is an RNA-Seq experiment, duplicate reads are not removed. So of these reads, 
there were a total of 3,721 unique reads that had an exact match. Using the naïve Bayes 
HLA classification algorithm, the posterior probability was calculated for all the potential 
allelic combinations.  In the above example for 1000 genome Yoruba sample NA1850, 
the top 6 classical HLA genotypes predicted have a Posterior Probability of 1.0 with a 
Filter set to “Pass”.  These predicted HLA genotypes were all concordant with previous 
HLA typing with either SBT or SSOP HLA genotyping.   
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4.11 Validation of Naïve Bayes Approach 
To measure the precision and recall of the algorithm for different next generation 
sequencing experiments, the naïve Bayes HLA classification algorithm was used to 
predict the HLA genotypes for all 6 Classical HLA genes (HLA-A, HLA-B, HLA-C, 
HLA-DQA1, HLA-DQB1 and HLA-DRB1).  The HLA-Genotyper software, which 
implemented the naïve Bayes algorithm, predicted the HLA genotypes from 3 commonly 
available next generation sequencing experiment designs described in the datasets above. 
Individuals from two populations in the 1000 Genomes Project, European and Yoruba, 
that had all three next generation sequencing data available as well as HLA genotypes for 
the 6 classical HLA loci: HLA-A, HLA-B, HLA-C, HLA_DQA1, HLA-DQB1, HLA-
DRB1 were selected.  The precision and recall of the predictions were calculated for each 
HLA loci.  The precision and recall correspond to the sensitivity and specificity 
measurements described by Leslie at al11 for measuring HLA imputation quality. 
Gold Standard 
HLA Genotyping is available for 270 HapMap samples. Many of these were also 
sequenced as part of the 1000 Genomes Project next generation sequencing which make 
them useful for validation of HLA prediction algorithms.  
As part of a high resolution mapping of the MHC region, 270 HapMap samples 
were originally genotyped by the Laboratory of Genetic Diversity (NCI-Frederick Cancer 
Research and Development Center) and made available for download at 
http://www.inflammgen.org.  These HLA genotypes were generated using SSO 
(sequenced specific oligonucleotide hybridization) based on guidelines from the 13th 
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International Histocompatibility Workshop.  The Classical HLA loci from both the MHC 
Class I (HLA-A, HLA-B, HLA-C) and Class II region (HLA-DQA1, HLA-DQB1 and 
HLA-DRB1) were genotyped. For the HLA Class I loci, the exon 2, intron 2, and exon 3 
were amplified for the typing. For the HLA Class II genes, only the exon 2 was 
amplified.  
The original researchers that initially created the gold standard, later revised some 
HLA genotypes when the same samples were sequenced with a 454 Sequencer and 
discordant calls cross-checked with SBT HLA genotyping.  The errors that were later 
detected in this gold standard for HLA-A, HLA-B, and HLA-C were published in the 
article Next Generation sequencing for HLA Typing of class I loci [35].  The error rate in 
original gold standard was found to be 2.3% in MHC I Region. 
Likewise, comparison between the predicted HLA genotypes from the naïve 
Bayes HLA algorithm and the gold standard also detected discordant calls in the MHC II 
region. When comparing the HLA prediction results and the gold standard, ten discordant 
calls were found in Yoruba samples for the DQB1:06:09 allele. In correspondence with 
Dr. Xiaojiangi Gao, these 10 calls were also found to be in error in original gold standard.  
This was based on the LD patterns with HLA-DRB1 and HLA-DQA1 called loci.  These 
10 DQB1*06:09 calls were correctly called by HLA-Genotyper but typed as 
DQB1*06:04 or DQB1*06:05 with the SSO method. For the final validation results, the 
gold standard was revised for these MHC II genotypes. 
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RNA-Seq Validation Results 
For the validation of the algorithm on the RNA-Seq data, a total of 45 European 
and 38 Yoruba 1000 genome RNA-Seq bam files were downloaded from the Geuvadis 
RNA Sequencing Project of the 1000 Genomes Samples[50].  This subset was selected as 
these individuals all had prior HLA genotyping completed [4, 35].   The final gold 
standard HLA data set compiled from the two sources making corrections after 
consultation with the original lab. The predicted 4-digit HLA genotypes were then 
compared with the HLA genotypes with this final gold standard data set. For the 
prediction of HLA alleles, RNA-Seq data has a number of advantages and would be 
expected to have the best results for predicting the HLA genotypes.  The HLA-genes are 
highly expressed in the lymphoblastoid cell-line used in the RNA-Seq experiments 
analyzed As a result the coverage will be high for the HLA genes’ exons.  The RNA-Seq 
design does not rely on baits for targeting the exon sequences and as a result the aligned 
sequences will have less bias across different HLA alleles. An additional benefit of the 
RNA-Seq design is that the Classical HLA genes are more highly expressed than the 
pseudo genes and other paralogous genes found in the MHC region. Therefore, these 
other genes are less likely to negatively impact calls in the Classical HLA alleles.  For 
clinical applications, null HLA genes (due to mutations outside of the protein coding 
regions) that result in a non-expressed HLA allele will be correctly characterized for 
transplants.  
Of the 518 genotypes called in the RNA-Seq European samples, 516 were 
concordant with only two HLA assignments incorrectly assigned.  For the two incorrect 
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genotype calls that were called, the estimated posterior probability were relatively low 
(0.6 and 0.29) and both been labeled as ambiguous.  For the European RNA-Seq samples, 
the HLA predictions were highly concordant with the gold standard and had a precision 
and recall of 1.0 and 0.99 [See Table 4.5a].    
 
For the 38 Yoruba RNA-Seq samples, the HLA predictions also showed high 
concordance with the gold standard with an overall precision and recall of 0.98 and 0.98 
[See Table 4.5b].   Of the 453 genotypes called, 442 were concordant with 11 HLA 
assignments that were incorrect.  The lowest precision and accuracy were found in the 
HLA-DRB1 alleles with precision and recall of 0.95. Many of these discordant call were 
related to typing of the HLA-DRB1*13 alleles.  These MHC II HLA calls were 
completed with PCR/SSOP HLA typing and not the more accurate SBT typing. Unlike 
the HLA Class I HLA genotype calls, these calls were not crosschecked against the next 
generation sequencing completed on the 454 sequencing validation.  The Class I HLA 
discordant calls were followed up with a more detailed SBT HLA genotype calling[35].   
Following up with SBT typing for the discordant calls may be a useful step to understand 
the disagreement between the gold and RNA-Seq calls.   
A complete list of the predicted genotype calls and the posterior probabilities for 
these European and Yoruba RNA-Seq samples can be found in supplemental Table A.5 
and A.6. Discordant calls are highlighted in red. 
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Illumina Platform RNA-Seq Validation Results 
 
Table 4.5 a.   Validation Results for Naïve Bayes algorithm using RNA-Seq data for 
45 CEU 1000G Samples 
The results in the European samples using the Illumina Platform for RNA-Seq data were 
excellent with overall precision and recall of 1.0 and 0.99. Both the highly polymorphic 
HLA-B and HLA-DRB1 loci had near complete concordance with the gold standard.  
The accuracy was greater than the original HLA typing of the gold standard, which had 
an error rate of 2.3% 
 
Locus 
Total 
Alleles 
Assayed 
Total 
Called*
Total 
Correct Precision Recall 
HLA*A 89 89 89 1.0 1.0 
HLA*B 89 89 88 0.99 0.99 
HLA*C 90 90 90 1.0 1.0 
HLA*DQA1 89 89 89 1.0 1.0 
HLA*DQB1 89 89 89 1.0 1.0 
HLA*DRB1 72 72 71 0.99 0.99 
Overall 518 518 516 1.0 0.99 
 
* HLA genotype when posterior probability > 0.5 
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Table 4.5 b.   Validation Results for Naïve Bayes algorithm using RNA-Seq data for 
38 YRI 1000G Samples 
The results in the Yoruba samples using the Illumina Platform were excellent with 
overall precision and recall of 0.98. Both the highly polymorphic HLA-B and HLA-
DRB1 loci have the good results although lower than the European samples.  The 
accuracy was greater than the original HLA typing of the gold standard, which had an 
error rate of 2.3% 
 
 
Locus 
Total 
Alleles 
Assayed 
Total 
Called 
Total 
Correct Precision Recall 
HLA-A 76 76 75 0.99 0.99 
HLA-B 76 76 72 0.95 0.95 
HLA-C 76 76 75 0.99 0.99 
HLA-DQA1 76 76 76 1.0 1.0 
HLA-DQB1 75 75 74 0.99 0.99 
HLA-DRB1 74 74 70 0.95 0.95 
Overall 453 453 442 0.98 0.98 
 
*Algorithm Called HLA genotype when posterior probability > 0.50 
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Exome Sequencing Validation Results 
 
For the exome sequencing validation results, bam files from the 1000 genome 
project[51] were identified from samples that also had HLA genotyping completed and 
available for download [4, 35].  For the 1000 Genomes Project, two Exome Capture Kits 
were utilized.  The Broad Institute Sequencing Center used the Agilent SureSelect All 
Exon V2 Capture Kit with the Illumina Platform.  The Washington University 
Sequencing Center used the Solid Platform with NimbleGen SeqCap EZ_Exome v2 
capture kit.  The precision and recall of the HLA algorithm was measured separately for 
the two kits and platforms. 
With the lower coverage and use of baits to capture the HLA region, the 
expectation was that the algorithm would be less accurate than the validation results 
found with the RNA-Seq data.  
For the Illumina platform with the Exome v2 capture kit, there were 51 European 
and 50 Yoruba individuals from the 1000 Genomes project that had HLA genotypes.  For 
the European individuals, the overall precision and recall were 0.97 and 0.96 [Table 
4.6a].  For the Yoruba 38 individuals, the overall precision and recall were lower at 0.91 
and 0.89 [see Table 4.6b] 
 
For the Solid platform runs with the NimbleGen SeqCap EZ_Exome v2 capture 
kit, there were 33 European individuals’ and 8 Yoruba individuals’ whole exome bam 
files that were downloaded from the 1000 Genomes and used for the validation.  The 
  
88 
predicted HLA alleles again were compared against the gold standard.  These validation 
results were quite poor for these exome sequencing data.  The predicted HLA alleles for 
the Europeans had a precision and recall of 0.78 and 0.49, respectively [see Table 4.7a].  
The Yoruba predictions had an even lower precision and recall of 0.58 and 0.36, 
respectively [See Table 4.7b].  The results of the HLA-C and HLA-DRB1 HLA allele 
predictions were very low in both populations.  The HLA-DQB1 HLA predicted alleles 
were relatively better with the European results obtaining a precision and recall of 0.92. 
Why are these results so much lower than the exome results from the Illumina platform? 
These results suggest poor bait capture for the Classical HLA genes in the MHC region 
by the kit. An examination of the kits documentation for the coverage of the HLA genes 
bears this out.   The NimbleGen Assay coverage was very poor in these particular genes 
[See Table 4.8].  The coverage for these genes was between 0.18 (HLA-A) and 0.71 
(HLA-DQB1).  The highest assay coverage in HLA-DQB1 also had the highest 
concordance with the precision and recall near 0.92.  The poor bait design combined with 
the shorter read length (50 bp for Solid versus 75 bp and 101 bp for Illumina) resulted in 
a much lower recall rate than the Illumina platform.  When a bait did capture a region on 
the Solid Platform, the read would cover only half the region that a read from the 
Illumina. As a result, the unique base pair changes that encode the HLA protein may not 
be captured.  This resulted is very poor recall for the combined 50 bp reads and the 
NimbleGen SeqCap EZ_Exome v2 exome capture kit.  
  
  
89 
Illumina Platform with Agilent SureSelect All Exon V2 Capture Kit 
 
Table 4.6a.   HLA Predictions from Whole Exome Data for 51 CEU 1000G Samples 
using Illumina Platform  
The results in the European samples using the Illumina Platform for whole exome data 
were excellent with overall precision and recall of 0.97 and 0.96.  The accuracy was 
comparable to the original HLA typing of the gold standard, which had an error rate of 
2.3% 
 
Locus 
Total 
Alleles 
Assayed 
Total 
Called*
Total 
Correct Precision Recall 
HLA-A 101 101 100 1.0 1.0 
HLA-B 101 101 92 0.91 0.91 
HLA*C 102 102 101 0.99 0.99 
HLA-DQA1 91 91 90 0.99 0.99 
HLA-DQB1 91 91 91 1.0 1.0 
HLA-DRB1 74 72 63 0.88 0.86 
Overall 560 558 537 0.97 0.96 
 
*Limited to those with coverage > 10 reads and HLA genotype posterior probability > 
0.25  
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Table 4.6b.   HLA Predictions from Whole Exome Data for 50 YRI 1000G Samples 
using the Illumina Platform   
The results in the YRI samples using the Illumina Platform for whole exome data had an 
overall precision and recall of 0.90.  The accuracy was slightly below the original HLA 
typing of the gold standard, which had an error rate of 2.3%.  The results are below the 
European results, which had a higher proportion of 101 bp reads. 
 
Locus 
Total 
Alleles 
Assayed 
Total 
Called*
Total 
Correct Precision Recall 
HLA-A 100 98 89 0.92 0.92 
HLA-B 100 98 88 0.91 0.91 
HLA-C 100 100 93 0.93 0.93 
HLA-DQA1 100 100 99 0.99 0.99 
HLA-DQB1 99 99 83 0.84 0.84 
HLA-DRB1 98 98 84 0.86 0.86 
Overall 597 593 536 0.90 0.90 
 
*Limited to those with coverage > 10 reads and HLA genotype posterior probability > 
0.25  
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Solid Platform with NimbleGen SeqCap EZ_Exome v2 
 
Table 4.7a.   HLA Predictions for 33 CEU Whole Exome 1000G Samples Using 
Solid Platform  
The results for the Solid Platform were very poor with precision and recall below 0.90 for 
5 of the 6 loci in these European samples. Only the HLA-DQB1 locus had results greater 
than 0.90.  The combination of short 50 bp reads and poor bait coverage are among the 
factors contributing to the relatively low validation results. 
 
Locus 
Total 
Alleles 
Assayed 
Total 
Called* 
Total 
Correct Precision Recall 
HLA-A 66 28 19 0.68 0.29 
HLA-B 66 30 18 0.60 0.27 
HLA*C 66 38 32 0.84 0.48 
HLA-DQA1 62 52 42 0.81 0.68 
HLA-DQB1 62 62 57 0.92 0.92 
HLA-DRB1 48 22 14 0.63 0.29 
Overall 370 232 182 0.78 0.49 
 
*Limited to those with coverage > 10 reads and HLA posterior probability > 0.25  
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Table 4.7b.   HLA Predictions for 8 YRI Whole Exome 1000G Samples Using Solid 
Platform 
The results in the Yoruba samples using the Solid Platform were very poor with precision 
and recall below 0.85 for all loci. Only the HLA-DQA1 locus had results greater than 
0.80.  The combination of short 50 bp reads and poor bait coverage are among the factors 
contributing to the relatively low validation results.  The highly polymorphic HLA-B and 
HLA-DRB1 loci have the lowest results.  
 
Locus 
Total 
Alleles 
Assayed 
Total 
Called*
Total 
Correct Precision Recall 
HLA-A 16 8 5 0.62 0.31 
HLA-B 16 8 1 0.125 0.06 
HLA-C 16 6 2 0.33 0.12 
HLA-DQA1 16 16 13 0.81 0.81 
HLA-DQB1 16 16 12 0.75 0.75 
HLA-DRB1 16 6 2 0.33 0.12 
Overall 96 60 35 0.58 0.36 
 
*Limited to those with coverage > 10 reads and HLA posterior probability > 0.25  
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Table 4.8 Nimblegen SeqCap EZ Exome v2 Kit Coverage in the 6 Classical HLA 
genes 
The coverage of the HLA loci by the Nimblegen baits is not adequate especially with 
short 50 bp reads.   The limited baits for the HLA-DRB1 loci given its high number of 
alleles and polymorphisms explain the very low recall of the naïve Bayes classifier.   
 
Classical HLA 
Gene 
Assay Coverage 
HLA-A 18% 
HLA-B 47% 
HLA-C 15% 
HLA-DQA1 39% 
HLA-DQB1 71% 
HLA-DRB1 28% 
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Whole Genome Low-Coverage Validation Results 
For the 1000 Genomes project. 1092 genomes with low coverage sequencing 
were available for download and analysis.  The reads had been aligned with bwa 0.5.5 
[38] to the hg19/NCBI37	reference.  From previous HLA research [35], 47 of  these 
1092 genome samples had 4-digit HLA typing available for HLA-A, HLA-B, HLA-C, 
HLA-DQA1, HLA-DQB1, and HLA-DRB1 as they were members of the original HapMap 
270 samples.  The HLA-Genotyper software called HLA genotypes in 25 low-coverage 
samples from the European populations and 22 low-coverage samples from the Yoruba 
population.  
While these low coverage samples are not expected to have the capture bias 
detected in the whole exome experiment, the low alignment coverage due to mismatches 
will be an issue.  The bwa alignment only aligns a fraction of HLA reads in these genes 
so it will be necessary to scan the unmapped genes for any exact matches in all 6 HLA 
gene sequences found in the IMGT/HLA database. Samtools was used to create bam files 
of unmapped reads for each of the 47 low-coverage whole genome samples. 
The HLA-Genotyper software scanned both the mapped reads for exact matches 
in the HLA genes called in Table 4.9a and Table 4.9b as well as all the unmapped reads 
to boost the reads available for the HLA classification.  
 As seen in Tables 4.9a and 4.9b, recall was poor in both populations as genotype 
calls were limited to loci with at least 10 reads and genotype likelihood greater than 0.25.  
The overall recall rate was only 0.59 in the CEU samples and 0.49 in the Yoruba 
Samples.  The HLA-DRB1 recall results were particularly poor in both ethnic groups.  
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The CEU had only a 0.14 recall.  The limited number of HLA DRB1 exon sequences 
found in the IMGT/HLA database hampers the prediction of the HLA allele from this 
gene.  The naïve Bayes algorithm is limited to using only the exon 2 aligned reads due to 
the lack of full sequences in the IMGT/HLA database for HLA-DRB1.  This lack of 
sequencing information for the introns and exons in this gene reduces the number of 
reads that are available to use in the naïve Bayes algorithm.  The YRI recall was even 
lower with a 0.14 recall.  The naïve Bayes method while it is precise even in low 
coverage, for good recall it requires higher coverage than found in the 1000 genomes low 
coverage samples to be reach comparable recall rates found in the whole exome and 
RNA-Seq validation results.  
The precision validation results in the European samples for low–coverage next 
generation sequencing (3x-7x) were better than expected with both the YRI and CEU 
samples.  The overall precision results were at 0.90 for both ethnic groups.  The HLA-
DQA1 had the highest rate of both recall and precision of 1.0 and 0.95 in Europeans. 
With only just over 10 reads from a gene available for the algorithm, the algorithm still 
was precise in genotyping the 6 HLA genes though with low recall.  
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Low Coverage (3-7x) Illumina Platform  
 
Table 4.9a.   HLA Predictions for 51 European Low Coverage (3-7x) Whole 
Genomes Samples  
The validation results in the European samples show good precision and poor recall for 
low–coverage next generation sequencing (3-7x).  The two most polymorphic HLA 
genes, HLA-B and HLA-DRB1, had the lowest precision. Recall was poor as genotype 
calls were limited to loci with at least 10 reads and genotype likelihood greater than 0.25.  
 
Locus 
Total 
Alleles 
Assayed 
Total 
Called*
Total 
Correct Precision Recall 
HLA-A 101 42 41 0.98 0.41 
HLA-B 101 52 47 0.90 0.47 
HLA-C 102 76 72 0.95 0.71 
HLA-DQA1 91 87 87 1.0 0.95 
HLA-DQB1 91 75 73 0.97 0.80 
HLA-DRB1 74 11 10 0.90 0.14 
Overall 560 343 330 0.96 0.59 
 
*Genotype calls were limited to samples with coverage > 10 reads and HLA genotype 
likelihood > 0.25  
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Table 4.9b.   HLA Predictions for 50 YRI Low Coverage (3-7x) Whole Genomes 
The validation results in the Yoruba samples showed good precision but poor recall for 
the low–coverage whole genome sequences.  The two most polymorphic HLA genes, 
HLA-B and HLA-DRB1, had the lowest recall. Recall was poor as genotype calls were 
limited to loci with at least 10 reads and genotype likelihood greater than 0.25.  The 
HLA-DQA1 precision and recall were the best of the 6 genes examined.  Validation 
results were lower than the European samples which had a higher ratio of bam files with 
101 bp reads. 
 
Locus 
Total 
Alleles 
Assayed 
Total 
Called*
Total 
Correct Precision Recall 
HLA-A 100 50 47 0.94 0.47
HLA-B 100 42 34 0.81 0.34
HLA-C 100 64 57 0.89 0.57
HLA-DQA1 100 86 84 0.98 0.84
HLA-DQB1 99 73 61 0.84 0.62
HLA-DRB1 98 12 11 0.92 0.11
Overall 597 327 294 0.90 0.49 
 
*Genotype calls were limited to samples with coverage > 10 reads and HLA genotype 
likelihood > 0.25  
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Table 4.10 Naïve Bayes Algorithm Validation Result Summary 
Overall the results show HLA-Genotyper had the excellent results with the RNA-Seq 
data with a precision and recall of 0.98 and higher in European and Yoruba 1000 Genome 
Project samples.  This is better than the original gold standard.  The whole exome 
Illumina samples were next with both recall and precision greater than 0.90 in both ethnic 
groups.  The slightly lower rates in Yoruba are due to the higher proportion of bam files 
with 75 base reads.  The precision on the low coverage whole genome sequencing was 
high in both populations but with very low recall.  The Solid Platform with the 50 bp 
reads had poor precision and recall due to the combination of short 50 bp read length and 
relatively poor bait coverage on the 6 HLA genes. 
  
 
 
  
Sequencing 
Type 
Sequencing 
Platform 
 
1000 
Genomes 
Population
Total 
Alleles 
Assayed 
Total 
Called 
Total 
Correct Precision Recall 
RNA-Seq Illumina European 518 516 515 1.0 0.99 
RNA-Seq 
 Illumina Yoruba 453 453 442 0.98 0.98 
Whole Exome Illumina Agilent European 560 558 537 0.97 0.96 
Whole Exome Illumina/ Agilent Yoruba 597 593 536 0.90 0.90 
Whole exome Solid/ NimbleGen European 370 232 182 0.78 0.49 
Whole exome Solid/ NimbleGen Yoruba 262 94 88 0.94 0.34 
Whole 
Genome 
Low Coverage 
Illumina European 560 343 330 0.96 0.59 
Whole 
Genome 
Low Coverage 
Illumina Yoruba 597 327 294 0.90 0.49 
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4.12 Conclusions 
With modest coverage and read lengths between 75 and 101bp, the novel Naïve 
Bayes algorithm accurately predicts HLA genotypes from next generation sequencing 
commonly used for research.  The precision and recall are higher than other software 
presently available using de novo and the iterative counting approaches described earlier.  
Seq2HLA[37] which used an iterative counting approach achieved a poor 32% accuracy 
predicting 4-digit HLA genotypes from RNA-Seq data. The HLAminer software 
demonstrated its best results for 100 bp RNA-Seq data and showed a precision and recall 
of 90.7% and 93.5%. This is approximately 5-9% lower than the HLA-Genotyper 
validation results for RNA-Seq data.  However, the HLAminer 4-digit HLA predictions 
also had a very high level of ambiguity (35.4%), which if taken into account decrease the 
reported precision and recall substantially. The reported ambiguity meant the software 
predicted multiple alleles 35.4% of the time and could not distinguish between multiple 
4-digit HLA alleles. In contrast, the HLA-Genotyper results showed between 98% and 
99% precision and recall respectively with no ambiguity on RNA-Seq data predictions. 
ATHLATES had excellent precision (100%) on the limited validation testing but the 
recall was only 75%.   ATHLATES corrected predicted HLA genotypes in 15 of the 20 
whole exome data sets tested for 4-digit HLA typing. No validation results for 
ATHLATES were available on RNA-Seq data or low-coverage whole genome 
sequencing for comparison. Overall, HLA-Genotyper demonstrated the best overall 
precision and recall across multiple experiment types (RNA-Seq, whole exome 
sequencing, and whole genome sequencing) with 100 bp read lengths.  
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In general, as the coverage increased in the different sequencing experiment types 
from 3x-7x low coverage sequencing, to whole exome sequencing and then to RNA-Seq, 
there was an increase in the recall (true positive rate).  The overall precision was above 
90% for all 3 sequencing experiment types using the longer read lengths (between 75 and 
101 bp).  This compares favorably to previous approaches for HLA classification 
algorithms on similar next generation sequencing data. Both HLAminer and Seq2HLA 
had lower precision and recall rates for 4-digit HLA genotypes, as those algorithms could 
not distinguish similar 4-digit HLA alleles. 
The expectations were not very high for the HLA classification with the low 
coverage samples of 3-7x. With the low coverage, many of the genes had less than 10 
reads per gene to base a prediction on.  Despite the limited number of reads available to 
classify the sample’s HLA allele, both the YRI and CEU samples had overall precision of 
0.90 and 0.96 respectively when the number of reads were greater than 10 and the 
posterior probability greater than 0.25.  The results suggest just a modest increase in 
coverage to over 10 reads per gene will result in a major increase in the recall of low 
coverage samples. For low coverage samples, using the HLA Virtual SNP imputation 
method with the called and imputed genotypes most likely will provide better results. 
 
The whole exome results were much better for the Illumina platform than the 
Solid Platform.  The longer read lengths used of 75 to 101 bp compared to the Solid 50 
bp read length made a difference in predictive ability.  The short length combined with 
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the poor bait coverage of the HLA genes resulted in the very low precision and recall of 
the method on the Solid Platform samples.  
The validation results from RNA-Seq data in the European subjects were near 
complete concordance with the “Gold Standard” with a precision and recall at 0.99 and 
1.0.  The Yoruba results also had very high precision and recall rates of near 0.98.  The 
precision and recall is better than that found in the original SSOP HLA genotyped 
samples used as the gold standard which had an error rate of 2.3%[35].  These validation 
results demonstrate that HLA-Genotyper predictions from RNA-Seq data are an attractive 
alternative to replace present labor intensive and less accurate HLA typing technologies.     
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CHAPTER Five Testing of Disease Association with Naïve Bayes HLA 
Classification 
 
5.1 Background 
Previously, the SNP rs4664308 in the intron of the HLA-DQA1 gene on 
chromosome 6p21 was found to be most closely associated with idiopathic membranous 
nephropathy (IMN) in a genome wide association study of individuals with European 
ancestry [13].  To examine the association in this region in more detail, HLA-Genotyper 
software was used to predict HLA genotypes to enable an analysis of 49 idiopathic 
membranous nephropathy cases ascertained by Boston University Medical School and 
350 controls from the 1000 Genomes Project. 
 
 
5.2 Targeted Sequencing of Idiopathic Membranous Nephropathy 
Targeted sequencing of 49 individuals of European Ancestry and 12 individuals 
of Asian ancestry diagnosed with idiopathic membranous nephropathy were completed at 
The Genome Institute (TGI) in Washington University using an Illumina Next 
Generation sequencer (HiSeq V3).  The targeted region contained 120 genes spanning a 
total of 4.1 megabases sequenced at an average of 40x coverage.  The top targeted genes 
included the MHC Class II genes (HLA-DQA1, HLA-DQB1, HLA-DRB1) on 
chromosome 6 and the PLA2R1 region on chromosome 2.  An additional 102 genes were 
targeted for sequencing based on biological relevance to autoimmune related diseases.  
Deep sequencing was conducted covering exons, introns, 3-UTR, 5-UTR and promoter 
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regions.  The complete list of gene targets is listed in the Appendix table A.4.  The 
regions around the PLA2R1 and the MHC II regions were also included because of 
strong association signals found in previous studies.  For the PLA2R1 region, the 
sequencing was extended to the nearby flanking genes LY75 and ITGB6 including the 
region between chr2:160659866-161056590.  The MHC II region target was extended to 
the region between 32,407,619 and 33,074,921 on chromosome 6. This MHC II locus 
includes 14 additional genes besides the classical MHC-II HLA genes HLA-DRB1, 
HLA-DQA1 and HLA-DQB1. 
 5.3 Validation of HLA Predictions 
To validate the HLA-Genotyper algorithm, a total of 13 subjects of the 96 
individuals who underwent targeted sequencing also underwent 4-digit HLA typing of 
HLA-DRB1 (SBT) and HLA-DQA1 and HLA-DQB1 (SSOP).  The validation results 
showed high precision and a true positive rate for the 3 MHC II loci genotyped across the 
3 ethnic population included. In the HLA-DRB1, HLA-DQA1 and HLA-DQB1 loci, 25 
of 26 predicted alleles for HLA-DRB1 were concordant with the laboratory called HLA 
calls. A lab call may be ambiguous if the exon with a distinguishing amino acid change 
was not sequenced as part of the assay. For example, HLA-DQA1*05:01 differs from 
HLA-DQA1*05:05 because of a base change in exon 1. If exon 1 is not assayed by the 
lab, it is not possible to distinguish the two HLA alleles. In this case, the HLA-typing 
software would assign an ambiguous code such as HLA-DQA1*05:01g.  The predicted 
HLA call from HLA-Genotyper was considered concordant if the predicted call 
overlapped with the ambiguous calls from the lab. The lab generated ambiguous calls 
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with the SSOP assay used for HLA genotyping, which is less precise than the HLA-
DRB1 calls assayed with the SBT method. Overall the precision and recall of the HLA 
loci from targeted next generation sequencing was 0.96 using the completed SBT and 
SSOP HLA genotyping as the gold standard.   
One calling error occurred in HLA-DRB1 loci using the HLA-Genotyper when a 
rare HLA-DRB1*14:10 allele that was called for an Asian subject by the HLA typing 
laboratory.  This allele was not found among 3500 Asian-Pacific Bone Marrow Donors 
used for the priors in the predictions for HLA-Genotyper. When the HLA-DRB1*14:10 
allele was added to priors, the calling error was corrected after the software was rerun.  
According to the Allele Frequency Net Database [44] of worldwide populations, this 
allele is found in aborigines and parts of South East Asia. While the priors used in this 
analysis were primarily obtained from a large Bone Marrow Donor registry in the United 
States, supplementing these priors with HLA frequency data from more diverse 
populations in the world will minimize such errors in the future. Besides the Allele 
Frequency Net Database, genotype data is also available at www.pypop.org [47] to 
supplement these ethnic priors used in the naïve Bayes HLA classifier. 
 
5.4 Prediction of HLA Genotypes in 1000 Genomes Samples Used as Controls 
The HLA allele frequencies vary substantially across ethnic groups. In order to 
prevent spurious association findings, a control sample that was ethnically matched to the 
idiopathic membranous nephropathy cases was required.  Ethnically matched controls 
were selected (N=350) from Phase 2b of the 1000 Genomes Project.  HLA-Genotyper 
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software then predicted 4-digit HLA data from the whole exome sequencing bam files 
(Illumina Platform) available for these control samples.   
Besides ethnically matched controls, genome wide association studies often adjust 
the for geographic sub stratification using principal components covariates to avoid such 
spurious associations. However, SNPs in the MHC region are typically excluded in 
computing the principal components because of the extensive linkage disequilibrium. The 
remaining SNPs among the cases sequenced are not adequate to model the principal 
components, which typically use hundreds of thousands of SNPs to model population 
substructure. While some HLA frequencies have a West to East gradients in Europe, the 
frequency gradients are typically a few percent and not the large swings found in SNP 
allelic frequencies found in west to east and north to south population gradients in 
Europe. However, any results should be carefully examined for evidence of such 
population substructure introducing spurious associations. 
Even though these individuals were not screened for disease status, given the low 
incidence of idiopathic membranous nephropathy of about 1.2 per 100,000 [52], it is 
unlikely that there are any cases in these control samples. The predicted 4-digit HLA 
alleles from the 1000 genomes project in each ethnic group are therefore a good source of 
controls for this analysis. 
 
5.5 HLA Association Results with Idiopathic Membranous Nephropathy  
Tests for association between the predicted MHC II HLA-DRB1, HLA-DQA1, 
and HLA-DQB1 alleles for IMN were then conducted using logistic regression models 
implemented using R version 2.15.  The logistic regression models included gender as a 
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covariate.  The cases consisted of 49 individuals of European ethnicity diagnosed with 
IMN.  The controls consisted of 350 European controls from the 1000 genomes project.  
The completed association results are found in supplement table A.6 and the most 
significant results found in Table 5.1.  
 
Table 5.1 Top Associations of HLA Allele Dose with Idiopathic Membranous 
Nephropathy in 49 Cases and 350 Controls of European Ancestry 
The most significant association results correspond to the HLA alleles found in the 
Ancestral MHC8.1 haplotype.  The top 2 associations, HLA-DQA1*05:01 and HLA-
DRB1*03:01 are in tight LD in Europeans. Both associations are highly significant and 
are the most likely possible sources of the signals.  
 
 
Despite just 49 cases, the results clearly show a strong and significant association 
with HLA-DQA1*05:01 (Odds Ratio=8.93, P-Value=8.06 x 10-13).  In the previously 
completed European IMN GWAS [13], the strongest association was reported to be SNP 
rs4664308 (P=8.6x10-29) in an intron in HLA*DQA1 and the investigators concluded it 
was an allele in this gene was the source of the signal.  However, the more 
HLA in EA 
N 
Cases 
N 
Controls 
Case 
MAF 
Controls 
MAF 
Odds 
Ratio P-Value 
HLA-DQA1*05:01 49 350 0.429 0.0943 8.93 8.06E-13 
HLA-DRB1*03.01 49 350 0.429 0.0971 8.09 1.65E-12 
HLA-DQB1*02.01 49 350 0.459 0.1457 5.34 1.76E-10 
HLA-B*08.01 49 350 0.327 0.0914 5.11 6.48E-09 
HLA-C*07.01 49 350 0.316 0.1314 3.14 9.41E-06 
HLA-A*01.01 49 350 0.306 0.1371 2.72 6.24E-05 
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comprehensive results of HLA associations in the MHC II region show the HLA-
DRB1*03:01 is strongly associated (Odds Ratio=8.09, P-value=1.26x10-12).  These two 
HLA alleles are found in complete linkage disequilibrium in Europeans.  The 6 HLA 
alleles with top associations are all from the European ancestral MHC8.1 haplotype 
(A:01:01-C*07:01-B*08:01-DRB1*03:01-DQA1*05:01-DQB1*02:01), which is 
common in Western Europe.  This analysis has narrowed the likely signals of these 
associations to two HLA alleles (DRB1*03:01 and HLA-DQA1*05:01). It should be 
noted that HLA*DQA1*05:05 (OR=1.20,P=5.69x10-01) whose mature protein is actually 
identical to HLA*DQA1*05:01 was not found to be significant.  This suggests that HLA-
DRB1*03:01 may be the source of the signal instead of HLA*DQA1*05:01 or possibly 
the European ancestral MHC8.1 haplotype itself.  
 
Knowing the exact HLA allele that underlies idiopathic membranous nephropathy 
may ultimately be important in clinical setting.  Presently, those with idiopathic 
membranous nephropathy that require kidney transplants are often matched as closely as 
possible to their HLA profile on HLA-A, HLA-B, and HLA-DRB1 loci.  It will be 
beneficial to match a kidney that does not have the specific HLA allele triggering the 
autoimmune response.  Looking in other populations with different LD patterns in the 
MHC II region may help clarify the ultimate source of the signal.  This analysis is 
presently being extended to a larger sample of Asian idiopathic membranous nephropathy 
cases to help clarify the HLA locus involved. 
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CHAPTER Six Future Directions and Summary 
6.1 Translating Personal Genomics to the Clinic 
As the costs of whole genome sequencing drops to below $1000, it will only be a 
matter of time where an individual’s genome will become a routine part of a medical 
record.  Translating information from an individual’s genome into useful medical 
treatment and health practices will be a major challenge.  The HLA-Genotyper software 
and the Virtual SNP imputation method are useful tools to predict HLA genotypes from 
next generation sequencing and genome scan data to translate genomic data into 
information that may be useful in clinical practices.  
As medical research generates a comprehensive list of the HLA alleles that result 
in adverse drug reactions and hypersensitivity, pre-screening of individuals to minimize 
health risks can be completed accurately and efficiently with the availability of such 
personal genomic data.  If such pre-screening of the HLA-A*31:01 allele occurred before 
prescribing carbamazepine, it has been estimated that the risk of hypersensitivity 
reactions to this medication could be reduced from 7.8% to 2.7% [53].   
The FDA is presently recommending that those with Asian ancestry with HLA-
B*15:02 be routinely screened before being prescribed carbamazepine. In Taiwan, pre-
screening for HLA-B*15:02 is routinely completed before the prescription of 
carbamazepine and has been estimated to save 1 billion dollars a year over prescribing 
more expensive antiepileptic drug medications in its place [54].  The HIV medication, 
abacavir, is also routinely pre-screened for HLA-B*57:01.  The list of HLA alleles that 
are associated with the increased risk of the adverse reactions continues to grow with 
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continued research in this area.  As HLA genotypes become routinely available in each 
individual medical record due to the progression of personal genomics, a personal list of 
medications that an individual should avoid could be developed to guide prescriptions by 
physicians. Such prescreening at a large scale could result in a major decrease in adverse 
reactions to medications and ultimately result in decreased health costs.   
6.2 HLA Prediction to Optimize Drug Development Pipelines 
In phase I and II clinical trials, the efficacy and safety of medications in humans is 
a primary focus. Adverse reactions to a new medication often result in the termination of 
the development promising new medications. If participants are genotyped and 
sequenced, adverse reactions in patients with specific HLA genotypes could quickly be 
identified with the application of the HLA-Genotyper and Virtual SNP imputation 
methods.  This would allow a continuance of phase III testing on subjects pre-screened 
for HLA alleles associated with adverse reactions to the medication under development 
and increase the efficiency of drug development [54]. 
6.3 Benefits of HLA Research in Multiple Populations  
The extensive LD in the MHC region makes locating the precise location of the 
potential functional variants causing a disease extremely challenging.  The extensive LD 
found between the top two HLA alleles found in the IMN association demonstrates this 
issue. Despite the highly significant p-values, the location of the causative allele cannot 
be refined further in Europeans.  The source of the signal could most likely either be 
HLA-DRB1*03:01 or HLA-DQA1*05:01 due to the complete LD in Europeans. Often 
these LD patterns are very different in other populations. Therefore, association analysis 
  
110
and examination of HLA pattern in cases across multiple populations provide an 
opportunity to distinguish which of the loci is most likely functionally important. 
Extending such analysis to other populations would provide an opportunity to understand 
the HLA alleles underpinning the disease. 
With the combination of the HLA-Genotyper software and Virtual SNP 
imputation software, imputation of HLA genotypes is now feasible in non-European 
populations.  As outlined in the data flow diagram (Figure 6.1), large phased reference 
data sets containing both SNP and HLA genotypes from non-European populations could 
be created. With the fast and accurate prediction of the HLA genotypes from next 
generation sequencing with HLA-Genotyper software, the HLA-Genotyper software 
could be used to accurately predict HLA genotypes in the 2500 whole exome sequences 
in 28 populations in the 1000 genomes project.  These HLA genotypes when combined 
and phased with the sample’s variant calls will permit high quality imputation via the 
Virtual SNP imputation method to predict HLA genotypes in non-European populations.  
The prediction of HLA genotypes has now been completed on a set of Asian and African-
American idiopathic membranous nephropathy cases and controls, which will enable 
further analysis of the source of the signal in this region.  This multi-population approach 
will be an important step in narrowing the possible loci that are causative for 100s of 
diseases in the MHC region.  
While most research involving the HLA has involved autoimmune and infectious 
diseases, signals from the MHC region have been found in two diseases of old age: 
Alzheimer Disease[55] and Parkinson’s Disease[56].  Applying these HLA genotyping 
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approaches to available large consortium GWAS and next generation sequencing case-
control data sets, will help provide important biological insights into relationship of the 
MHC region with these two important diseases of aging.   
Several genome association studies have also found associations with 
schizophrenia, another brain related disease, with SNPs in the MHC region [9, 57-59]. 
These two algorithms would enable genotyping of HLA genotypes in large consortia 
genome scan and sequencing data sets to examine the potential association of HLA 
alleles with schizophrenia and provide a deeper understanding of its pathogenesis. 
 
6.4 Enhancing the IMGT/HLA Database to Increase HLA Genotyping 
Quality  
 
The IMGT/HLA database is primarily composed of exon sequences obtained 
from RNA-Seq experiments.  As a result, many of the HLA alleles stored in the database 
have sequences limited to exons and lack full gene sequences.  Sequences of introns in 
most HLA alleles are lacking.  Given this, it is not surprising that the best precision and 
recall were found with the RNA-Seq data even after taken into account the higher 
coverage.  Reads from whole exome and whole exome sequencing are hampered in 
finding an exact match at the end of an exon because of the lack of an abutting intron 
sequence. When searching with reads from genomic next generation sequencing, there 
are simply fewer exact matching possibilities at the edges of HLA loci exons.   
Determining the full sequences for these many HLA loci should now be possible 
with the availability of whole genome deep sequencing and HLA-Genotyper, which can 
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precisely assign HLA alleles with adequate coverage.  Based on the called HLA 
genotypes, samples could be identified with homozygous HLA genotypes that could then 
be used for de novo assembly of the specific HLA locus. Supplementing the IMGT/HLA 
with such sequences should decrease the gap between the accuracy of predictions from 
RNA-Seq data versus genomic whole genome and exome next generation sequencing 
data.  The availability of complete sequences would also allow the use of paired-end 
alignments in the HLA-Genotyper software to more accurately match reads to a specific 
HLA allele and increase the mapping quality. 
 
6.5 Optimize bait designs in whole exome sequencing to use alternative HLA 
loci available in GRC human reference 
 
The present bait designs used in whole exome capture appear to be based solely 
on the one haplotype (A3-B7-DR15, Cell Line PGF) that has been incorporated into the 
GRC human reference.  There is a bias toward the reference haplotypes in the design of 
the baits. Expanding the number of baits to also capture the 7 alternative MHC 
haplotypes found in the GRC human reference would be an important first step to insure 
better sequencing coverage in this important region of the human genome.  Extending 
this to include baits for the most common MHC haplotypes found in the world’s 
populations would also help increase the precision and recall for HLA prediction when 
using whole exome sequencing designs.  Focusing on bait designs that capture exon 2 
sequences of common HLA alleles in the IMGT/HLA database and the MHC Project 
haplotypes should result in major improvements in sequencing coverage across all 
populations particularly in non-Europeans.  
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6.6 Extending HLA Imputation to 21 Ethnic Populations 
Both HLA approaches to infer HLA genotypes methods can be used in research 
workflows to enable HLA research in multiple populations.  For example, the lack of 
non-European reference panels for HLA imputation can be solved with the use of the 
1000 Genomes next generation sequencing and these two algorithms.  The HLA-
Genotyper software enables the prediction of HLA genotypes in all 2500 whole exome 
sequencing data available from Phase 3. Of these individuals, 2030 are non-European 
from 21 populations.  The predicted HLA genotypes could then be merged and phased 
with the SNP genotypes to create reference panels for use with the virtual SNP 
imputation method as seen in Figure 6.1.  
Figure 6.1 Workflow to Impute HLA Genotypes in World Populations 
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6.6 Summary  
 
Two novel approaches, the HLA Virtual Imputation method and HLA-Genotyper 
naïve Bayes approach, have been validated to accurately predict 4-digit HLA genotypes 
from both genome scan data and next generation sequencing data.  This type of study 
data is commonly available for genomic research into common and rare diseases.  With 
these 2 approaches, it is now feasible to test the association of the HLA alleles without 
the extra expense of HLA genotyping in studies with available SNP genotypes or next 
generation sequencing in the MHC region.  As research studies in the search of disease 
genes and variants grow into the tens of thousands of subjects using next generation 
sequencing, both the Virtual SNP Imputation method and the HLA-Genotyper naïve 
Bayes approach permits the risk of HLA disease to be readily tested in these large 
consortia studies.  
In summary, using these two novel methods, significant disease associations of 4-
digit HLA alleles with both common and rare diseases were found.  Significant HLA 
associations in eight immune related diseases were detected: ankylosing spondylitis, 
autoimmune thyroid disease, Crohn's disease, multiple sclerosis, psoriasis, rheumatoid 
arthritis, carbamazepine-induced hypersensitivity reactions, and idiopathic membranous 
nephropathy.  Besides immune related diseases, the MHC region has been implicated in 
many other disease types. Host resistance to infectious diseases such as HIV and brain 
related diseases such as Parkinson’s disease, Alzheimer’s disease and schizophrenia 
would also be useful areas of disease research to apply these algorithms. In the future, the 
HLA-Genotyper software could be used to efficiently test associations with the large next 
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generation sequencing data sets now becoming available from large consortia such as the 
Alzheimer Disease Sequencing Project and the Exome project.  To enable researchers to 
predict HLA genotypes from next generation sequencing in their own research, the HLA-
Genotyper software will be made available through the web based hosting service GitHub 
(https://github.com/jjfarrell/hla-genotyper).  The source code listing can also be found in 
Appendix A5 and A6.  
These two novel approaches to predict HLA genotypes together are a useful set of 
tools to discover the underlying biological proteins and mechanisms playing a role in 
many diseases, help translate those findings into the clinical setting, and potentially help 
decrease adverse drug reactions in at risk populations.   Both algorithms enable the 
analysis of diverse ethnic populations to help researchers pinpoint HLA loci with 
biological roles in infection, inflammation, autoimmunity, aging, mental illness and 
adverse drug reactions using genome scan data and next generation sequencing 
technologies. 
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A1 Complete Validation Results for Virtual SNP Imputation of 1500 Type 1 Diabetes Cases 
Table A.1 Validation Results for T1 Diabetes Cases Imputed with British 1958 Birth Cohort Reference Training Set 
HLA Allele 
Alleles 
Typed 
in HLA 
Locus 
Assayed 
Allele 
Frequency 
Predicted 
Allele 
Frequency 
Total 
Assayed 
Total 
Called 
Total 
Correct Precision Recall 
MACH 
QC 
MACH 
R2 
HLA A*0101 3016 0.220 0.219 662 659 652 0.99 0.98 0.9919 0.9773 
HLA A*0102 3016 0.0003 NA 1 0 0 NA 0.00 NR NR 
HLA A*02XX 3016 0.320 0.320 965 965 960 0.99 0.99 0.9873 0.9729 
HLA A*0301 3016 0.128 0.128 386 385 383 0.99 0.99 0.9965 0.9865 
HLA A*1101 3016 0.037 0.038 112 114 111 0.97 0.99 0.9962 0.9539 
HLA A*2301 3016 0.008 0.008 23 23 23 1.00 1.00 0.9982 0.9061 
HLA A*2402 3016 0.109 0.110 329 332 325 0.98 0.99 0.9920 0.9621 
HLA A*2403 3016 0.001 0.000 3 0 0 NA 0.00 0.9990 0.0471 
HLA A*2501 3016 0.012 0.014 37 43 37 0.86 1.00 0.9917 0.7839 
HLA A*2601 3016 0.014 0.012 42 35 35 1.00 0.83 0.9912 0.6792 
HLA A*2608 3016 0.000 0.000 1 0 0 NA 0.00 0.9996 0.0410 
HLA A*2902 3016 0.033 0.033 99 98 98 1.00 0.99 0.9994 0.9916 
HLA A*3001 3016 0.009 0.009 26 27 26 0.96 1.00 0.9999 0.9933 
HLA A*3002 3016 0.025 0.026 75 77 74 0.96 0.99 0.9975 0.9566 
HLA A*3003 3016 0.0003 NA 1 0 0 NA 0.00 NR NR 
HLA A*3004 3016 0.000 0.000 1 0 0 NA 0.00 0.9995 0.2471 
HLA A*3101 3016 0.022 0.024 67 73 67 0.92 1.00 0.9959 0.9354 
HLA A*3201 3016 0.024 0.024 72 73 72 0.99 1.00 0.9995 0.9914 
HLA A*33XX 3016 0.006 0.006 19 17 17 1.00 0.89 0.9974 0.8161 
HLA A*3402 3016 0.001 0.000 3 0 0 NA 0.00 0.9995 0.0451 
HLA A*6601 3016 0.001 0.001 3 2 2 1.00 0.67 0.9991 0.5014 
HLA A*68 3016 0.0006 NA 2 0 0 NA NA NR NR 
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HLA Allele 
Alleles 
Typed 
in HLA 
Locus 
Assayed 
Allele 
Frequency 
Predicted 
Allele 
Frequency 
Total 
Assayed 
Total 
Called 
Total 
Correct Precision Recall 
MACH 
QC 
MACH 
R2 
HLA A*6801 3016 0.027 0.027 81 82 80 0.98 0.99 0.9952 0.9180 
HLA A*6802 3016 0.001 0.002 4 7 4 0.57 1.00 0.9968 0.6688 
HLA A*7401 3016 0.0006 NA 2 0 0 NA 0.00 NR NR 
HLA B*0702 2460 0.074 0.077 183 190 182 0.96 0.99 0.9938 0.9612 
HLA B*0726 2460 0.0004 NA 1 0 0 NA 0.00 NR NR 
HLA B*07XX 2460 0.002 0.000 5 0 0 NA 0.00 0.9995 0.1156 
HLA B*0801 2460 0.263 0.264 647 649 647 1.00 1.00 0.9911 0.9792 
HLA B*1302 2460 0.015 0.015 38 38 38 1.00 1.00 0.9986 0.9553 
HLA B*1401 2460 0.004 0.003 9 7 7 1.00 0.78 0.9996 0.9446 
HLA B*1402 2460 0.013 0.013 31 32 31 0.97 1.00 0.9984 0.9565 
HLA B*1501 2460 0.105 0.106 258 261 250 0.96 0.97 0.9684 0.8567 
HLA B*1503 2460 0.000 0.000 1 0 0 NA 0.00 0.9998 0.0465 
HLA B*1508 2460 0.0004 NA 1 0 0 NA 0.00 NR NR 
HLA B*1509 2460 0.0004 NA 1 0 0 NA 0.00 NR NR 
HLA B*1516 2460 0.001 0.000 3 0 0 NA 0.00 0.9997 0.0960 
HLA B*1517 2460 0.000 0.000 0 0 0 NA NA 0.9990 0.2584 
HLA B*1518 2460 0.005 0.002 12 6 4 0.67 0.33 0.9930 0.3553 
HLA B*15XX 2460 0.003 0.000 8 0 0 NA 0.00 0.9851 0.1222 
HLA B*1801 2460 0.076 0.075 187 185 185 1.00 0.99 0.9912 0.9459 
HLA B*2702 2460 0.001 0.000 2 0 0 NA 0.00 0.9997 0.0509 
HLA B*2705 2460 0.036 0.036 89 89 87 0.98 0.98 0.9920 0.8997 
HLA B*35XX 2460 0.041 0.043 101 105 99 0.94 0.98 0.9878 0.8813 
HLA B*3701 2460 0.006 0.006 14 14 13 0.93 0.93 0.9991 0.9219 
HLA B*3801 2460 0.007 0.008 17 19 16 0.84 0.94 0.9934 0.6568 
HLA B*39XX 2460 0.044 0.044 108 109 105 0.96 0.97 0.9895 0.9058 
HLA B*4001 2460 0.079 0.080 193 197 193 0.98 1.00 0.9950 0.9682 
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HLA Allele 
Alleles 
Typed 
in HLA 
Locus 
Assayed 
Allele 
Frequency 
Predicted 
Allele 
Frequency 
Total 
Assayed 
Total 
Called 
Total 
Correct Precision Recall 
MACH 
QC 
MACH 
R2 
HLA B*4002 2460 0.008 0.008 19 19 19 1.00 1.00 0.9972 0.8424 
HLA B*41XX 2460 0.005 0.004 13 10 10 1.00 0.77 0.9962 0.5876 
HLA B*4402 2460 0.094 0.096 230 237 229 0.97 1.00 0.9897 0.9499 
HLA B*4403 2460 0.026 0.026 65 65 63 0.97 0.97 0.9949 0.9197 
HLA B*4414 2460 0.0004 NA 1 0 0 NA 0.00 NR NR 
HLA B*44XX 2460 0.002 0.000 5 0 0 NA 0.00 0.9963 0.0496 
HLA B*4501 2460 0.002 0.002 6 6 6 1.00 1.00 0.9988 0.8204 
HLA B*4701 2460 0.004 0.003 9 8 8 1.00 0.89 0.9972 0.6355 
HLA B*4901 2460 0.012 0.011 29 28 28 1.00 0.97 0.9987 0.9556 
HLA B*5001 2460 0.011 0.011 26 26 26 1.00 1.00 0.9974 0.9097 
HLA B*5101 2460 0.024 0.027 59 67 59 0.88 1.00 0.9890 0.8270 
HLA B*5108 2460 0.001 NA 3 0 0 NA 0 NR NR 
HLA B*51XX 2460 0.002 0.000 4 0 0 NA 0.00 0.9968 0.0914 
HLA B*5201 2460 0.002 0.002 5 4 4 1.00 0.80 0.9987 0.6308 
HLA B*5301 2460 0.001 0.000 3 0 0 NA 0.00 0.9992 0.1799 
HLA B*53XX 2460 0.0008 NA 2 0 0 NA 0.00 NR NR 
HLA B*5501 2460 0.010 0.013 25 31 25 0.81 1.00 0.9965 0.8886 
HLA B*5601 2460 0.006 0.002 14 6 6 1.00 0.43 0.9967 0.4669 
HLA B*5701 2460 0.009 0.009 23 23 23 1.00 1.00 0.9991 0.9597 
HLA B*5801 2460 0.004 0.003 10 8 8 1.00 0.80 0.9977 0.6981 
HLA C*0102 2468 0.023 0.023 56 56 53 0.95 0.95 0.9960 0.9281 
HLA C*0202 2468 0.032 0.032 80 80 77 0.96 0.96 0.9906 0.8868 
HLA C*0303 2468 0.054 0.057 133 141 120 0.85 0.90 0.9782 0.8481 
HLA C*0304 2468 0.143 0.144 352 356 325 0.91 0.92 0.9693 0.8880 
HLA C*03XX 2468 0.010 0.000 25 25 25 1.0 1.00 0.9888 0.0844 
HLA C*0401 2468 0.049 0.049 121 121 117 0.97 0.97 0.9972 0.9760 
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HLA Allele 
Alleles 
Typed 
in HLA 
Locus 
Assayed 
Allele 
Frequency 
Predicted 
Allele 
Frequency 
Total 
Assayed 
Total 
Called 
Total 
Correct Precision Recall 
MACH 
QC 
MACH 
R2 
HLA C*0501 2468 0.133 0.135 327 333 317 0.95 0.97 0.9882 0.9546 
HLA C*0602 2468 0.048 0.047 119 116 115 0.99 0.97 0.9962 0.9665 
HLA C*0701 2468 0.303 0.294 747 725 712 0.98 0.95 0.9767 0.9473 
HLA C*0702 2468 0.101 0.111 250 273 243 0.89 0.97 0.9850 0.9291 
HLA C*0704 2468 0.015 0.017 36 42 34 0.81 0.94 0.9952 0.8707 
HLA C*0802 2468 0.017 0.015 42 37 37 1.00 0.88 0.9931 0.8299 
HLA C*1202 2468 0.001 0.001 3 2 2 1.00 0.67 0.9986 0.6155 
HLA C*1203 2468 0.024 0.025 60 61 59 0.97 0.98 0.9950 0.9088 
HLA C*1402 2468 0.004 0.003 10 8 7 0.88 0.70 0.9983 0.7885 
HLA C*1502 2468 0.015 0.013 38 32 29 0.91 0.76 0.9961 0.8832 
HLA C*1505 2468 0.002 0.000 6 0 0 NA 0.00 0.9992 0.1327 
HLA C*15XX 2468 0.0004 NA 1 0 0 NA 0.00 NR NR 
HLA C*1601 2468 0.019 0.021 47 51 43 0.84 0.91 0.9966 0.9408 
HLA C*1602 2468 0.002 0.000 4 0 0 NA 0.00 0.9990 0.2418 
HLA C*1701 2468 0.005 0.005 11 11 10 0.91 0.91 0.9979 0.6891 
HLA 
DQB1*02XX 3828 0.383 0.382 1465 1461 1450 0.99 0.99 0.9825 0.9589 
HLA DQB1*0301 3828 0.071 0.073 270 281 267 0.95 0.99 0.9844 0.9121 
HLA DQB1*0302 3828 0.353 0.353 1350 1353 1329 0.98 0.98 0.8261 0.5930 
HLA DQB1*0303 3828 0.020 0.015 78 56 56 1.00 0.72 0.9937 0.8249 
HLA DQB1*0304 3828 0.001 0.000 2 0 0 NA 0.00 0.9997 0.0198 
HLA DQB1*0305 3828 0.000 0.000 1 0 0 NA 0.00 0.9998 0.0248 
HLA DQB1*0402 3828 0.024 0.024 90 90 90 1.00 1.00 0.9997 0.9929 
HLA DQB1*0501 3828 0.099 0.098 380 376 376 1.00 0.99 0.9987 0.9933 
HLA DQB1*0502 3828 0.004 0.004 16 16 16 1.00 1.00 0.9976 0.7211 
HLA DQB1*0503 3828 0.001 0.001 4 4 4 1.00 1.00 0.9980 0.5290 
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HLA Allele 
Alleles 
Typed 
in HLA 
Locus 
Assayed 
Allele 
Frequency 
Predicted 
Allele 
Frequency 
Total 
Assayed 
Total 
Called 
Total 
Correct Precision Recall 
MACH 
QC 
MACH 
R2 
HLA DQB1*0504 3828 0.000 0.000 1 0 0 NA 0.00 0.9990 0.0245 
HLA DQB1*0601 3828 0.001 0.001 3 4 3 0.75 1.00 0.9993 0.6791 
HLA DQB1*0602 3828 0.002 0.003 9 10 7 0.70 0.78 0.9925 0.3988 
HLA DQB1*0603 3828 0.011 0.011 41 41 38 0.93 0.93 0.9964 0.8711 
HLA DQB1*0604 3828 0.028 0.028 108 107 106 0.99 0.98 0.9962 0.9349 
HLA DQB1*0605 3828 0.003 NA 1 0 0 NA 0.00 NR NR 
HLA DQB1*0609 3828 0.002 0.003 9 10 9 0.90 1.00 0.9979 0.7220 
HLA DRB1*01XX 3838 0.101 0.099 387 379 379 1.00 0.98 0.9977 0.9895 
HLA DRB1*0301 3838 0.334 0.338 1282 1296 1280 0.99 1.00 0.9732 0.9369 
HLA DRB1*03XX 3838 0.004 0.000 15 0 0 NA 0.00 0.9822 0.0454 
HLA DRB1*0401 3838 0.268 0.274 1027 1053 959 0.91 0.93 0.8845 0.7289 
HLA DRB1*0402 3838 0.012 0.000 44 0 0 NA 0.00 0.9960 0.1406 
HLA DRB1*0403 3838 0.003 0.000 10 0 0 NA 0.00 0.9673 0.0942 
HLA DRB1*0404 3838 0.084 0.087 321 335 288 0.86 0.90 0.9095 0.5632 
HLA DRB1*0405 3838 0.024 0.018 91 69 68 0.99 0.75 0.9848 0.6012 
HLA DRB1*0407 3838 0.001 0.000 5 0 0 NA 0.00 0.9966 0.1149 
HLA DRB1*04XX 3838 0.017 0.000 64 0 0 NA 0.00 0.9790 0.0546 
HLA DRB1*0701 3838 0.044 0.045 167 173 166 0.96 0.99 0.9760 0.7860 
HLA DRB1*0801 3838 0.021 0.023 79 88 78 0.89 0.99 0.9839 0.6599 
HLA DRB1*0803 3838 0.000 0.000 1 0 0 NA 0.00 0.9976 0.0272 
HLA DRB1*0804 3838 0.001 0.000 3 0 0 NA 0.00 0.9996 0.1191 
HLA DRB1*0806 3838 0.0003 NA 1 0 0 NA 0.00 NR NR 
HLA DRB1*08XX 3838 0.003 0.000 10 1 0 0.00 0.00 0.9846 0.3239 
HLA DRB1*0901 3838 0.013 0.013 48 48 46 0.96 0.96 0.9985 0.9465 
HLA DRB1*1001 3838 0.001 0.001 4 4 4 1.00 1.00 0.9994 0.7182 
HLA DRB1*11XX 3838 0.015 0.016 58 61 58 0.95 1.00 0.9966 0.9122 
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HLA Allele 
Alleles 
Typed 
in HLA 
Locus 
Assayed 
Allele 
Frequency 
Predicted 
Allele 
Frequency 
Total 
Assayed 
Total 
Called 
Total 
Correct Precision Recall 
MACH 
QC 
MACH 
R2 
HLA DRB1*12XX 3838 0.005 0.005 20 20 19 0.95 0.95 0.9988 0.9193 
HLA DRB1*13XX 3838 0.044 0.044 169 170 165 0.97 0.98 0.9951 0.9534 
HLA DRB1*1401 3838 0.001 0.001 5 4 4 1.00 0.80 0.9990 0.6862 
HLA DRB1*15XX 3838 0.004 0.004 14 14 14 1.00 1.00 0.9982 0.8159 
HLA DRB1*1601 3838 0.003 0.003 13 13 13 1.00 1.00 0.9980 0.7608 
NR: HLA allele not in reference training set; NA: Not applicable 
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A2 4-Digit HLA Priors used as input into HLA-Genotyper  
Table A.2 4-Digit HLA Priors for European Ancestry 
HLA  
EA Allele 
Frequency 
HLA-A*01:01 0.17181 
HLA-A*01:02 0.00006 
HLA-A*01:03 0.00013 
HLA-A*01:16 0.00006 
HLA-A*02:01 0.29604 
HLA-A*02:02 0.00083 
HLA-A*02:05 0.00801 
HLA-A*02:06 0.00197 
HLA-A*02:13 0.00013 
HLA-A*02:17 0.00051 
HLA-A*02:19 0.00006 
HLA-A*02:20 0.00013 
HLA-A*02:24 0.00019 
HLA-A*02:30 0.00019 
HLA-A*03:01 0.14347 
HLA-A*03:02 0.0028 
HLA-A*03:05 0.00006 
HLA-A*03:07 0.00006 
HLA-A*11:01 0.05642 
HLA-A*11:02 0.00006 
HLA-A*11:04 0.00025 
HLA-A*11:05 0.00013 
HLA-A*23:01 0.01684 
HLA-A*24:02 0.08686 
HLA-A*24:03 0.00108 
HLA-A*24:07 0.00006 
HLA-A*24:26 0.00006 
HLA-A*24:58 0.00006 
HLA-A*25:01 0.01925 
HLA-A*25:02 0.00006 
HLA-A*26:01 0.02948 
HLA-A*26:08 0.00038 
HLA-A*26:09 0.00006 
HLA-A*29:01 0.00216 
HLA-A*29:02 0.03279 
HLA  
EA Allele 
Frequency 
HLA-A*30:01 0.01341 
HLA-A*30:02 0.00921 
HLA-A*30:04 0.0007 
HLA-A*31:01 0.02351 
HLA-A*31:02 0.00006 
HLA-A*32:01 0.03133 
HLA-A*33:01 0.00991 
HLA-A*33:03 0.00133 
HLA-A*33:05 0.00025 
HLA-A*34:02 0.00044 
HLA-A*36:01 0.00006 
HLA-A*66:01 0.00261 
HLA-A*68:01 0.02503 
HLA-A*68:02 0.00845 
HLA-A*68:03 0.00006 
HLA-A*68:25 0.00006 
HLA-A*69:01 0.00076 
HLA-A*74:01 0.00006 
HLA-A*74:03 0.00019 
HLA-B*07:02 0.13987 
HLA-B*07:04 0.00044 
HLA-B*07:05 0.0021 
HLA-B*07:10 0.00019 
HLA-B*07:15 0.00006 
HLA-B*07:21 0.00006 
HLA-B*08:01 0.12525 
HLA-B*08:05 0.00006 
HLA-B*13:02 0.02644 
HLA-B*14:01 0.00832 
HLA-B*14:02 0.03095 
HLA-B*15:01 0.06654 
HLA-B*15:03 0.00089 
HLA-B*15:07 0.00076 
HLA-B*15:10 0.00013 
HLA-B*15:14 0.00006 
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HLA  
EA Allele 
Frequency 
HLA-B*15:15 0.00006 
HLA-B*15:16 0.00032 
HLA-B*15:17 0.00273 
HLA-B*15:18 0.00121 
HLA-B*15:24 0.00006 
HLA-B*15:45 0.00006 
HLA-B*18:01 0.0462 
HLA-B*18:03 0.00057 
HLA-B*18:04 0.00019 
HLA-B*18:08 0.00006 
HLA-B*27:02 0.00292 
HLA-B*27:03 0.00006 
HLA-B*27:05 0.03254 
HLA-B*27:07 0.00038 
HLA-B*27:09 0.00006 
HLA-B*27:10 0.00006 
HLA-B*27:14 0.00019 
HLA-B*35:01 0.05713 
HLA-B*35:02 0.01099 
HLA-B*35:03 0.01563 
HLA-B*35:05 0.00006 
HLA-B*35:08 0.00375 
HLA-B*35:12 0.00019 
HLA-B*35:17 0.00006 
HLA-B*35:27 0.00006 
HLA-B*37:01 0.01347 
HLA-B*38:01 0.0218 
HLA-B*38:09 0.00006 
HLA-B*39:01 0.00953 
HLA-B*39:03 0.00025 
HLA-B*39:05 0.00013 
HLA-B*39:06 0.00502 
HLA-B*39:24 0.00038 
HLA-B*40:01 0.05643 
HLA-B*40:02 0.00991 
HLA-B*40:06 0.00006 
HLA-B*41:01 0.00375 
HLA-B*41:02 0.00362 
HLA  
EA Allele 
Frequency 
HLA-B*42:02 0.00013 
HLA-B*44:02 0.09011 
HLA-B*44:03 0.04963 
HLA-B*44:04 0.00064 
HLA-B*44:05 0.00241 
HLA-B*44:09 0.00006 
HLA-B*45:01 0.00426 
HLA-B*47:01 0.00235 
HLA-B*47:02 0.00006 
HLA-B*48:01 0.00051 
HLA-B*49:01 0.01341 
HLA-B*50:01 0.00807 
HLA-B*50:02 0.00013 
HLA-B*51:01 0.04544 
HLA-B*51:02 0.00006 
HLA-B*51:05 0.00013 
HLA-B*51:07 0.00025 
HLA-B*51:08 0.00057 
HLA-B*51:09 0.00044 
HLA-B*51:19 0.00006 
HLA-B*52:01 0.0096 
HLA-B*53:01 0.00324 
HLA-B*55:01 0.01729 
HLA-B*56:01 0.00496 
HLA-B*57:01 0.03832 
HLA-B*57:02 0.00038 
HLA-B*57:03 0.00032 
HLA-B*58:01 0.0047 
HLA-B*58:02 0.00006 
HLA-B*67:01 0.00006 
HLA-B*73:01 0.00019 
HLA-C*01:02 0.02922 
HLA-C*01:07 0.00006 
HLA-C*02:02 0.03729 
HLA-C*03:02 0.00146 
HLA-C*03:03 0.05457 
HLA-C*03:04 0.08215 
HLA-C*03:07 0.00006 
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HLA  
EA Allele 
Frequency 
HLA-C*03:09 0.00006 
HLA-C*03:19 0.00006 
HLA-C*04:01 0.10534 
HLA-C*04:04 0.00006 
HLA-C*04:05 0.00006 
HLA-C*05:01 0.09136 
HLA-C*05:05 0.00019 
HLA-C*05:07 0.00006 
HLA-C*06:02 0.09301 
HLA-C*06:03 0.00006 
HLA-C*06:06 0.001 
HLA-C*06:10 0.00006 
HLA-C*07:01 0.16658 
HLA-C*07:02 0.15006 
HLA-C*07:04 0.01118 
HLA-C*07:07 0.00006 
HLA-C*07:09 0.00006 
HLA-C*07:10 0.00006 
HLA-C*07:12 0.00006 
HLA-C*08:01 0.00006 
HLA-C*08:02 0.03875 
HLA-C*08:03 0.00044 
HLA-C*12:02 0.00934 
HLA-C*12:03 0.04892 
HLA-C*12:04 0.00006 
HLA-C*12:05 0.00013 
HLA-C*12:12 0.00006 
HLA-C*14:02 0.0115 
HLA-C*14:03 0.00013 
HLA-C*14:04 0.00006 
HLA-C*15:02 0.01861 
HLA-C*15:03 0.00006 
HLA-C*15:04 0.00044 
HLA-C*15:05 0.00235 
HLA-C*15:06 0.00013 
HLA-C*15:11 0.00006 
HLA-C*16:01 0.03539 
HLA-C*16:02 0.0026 
HLA  
EA Allele 
Frequency 
HLA-C*16:04 0.00083 
HLA-C*17:01 0.00667 
HLA-C*18:01 0.00013 
HLA-DQA1*01:01 0.140350877
HLA-DQA1*01:02 0.149122807
HLA-DQA1*01:03 0.076023392
HLA-DQA1*01:04 0.032163743
HLA-DQA1*01:05 0.014619883
HLA-DQA1*02:01 0.131578947
HLA-DQA1*03:01 0.099415205
HLA-DQA1*03:02 0.014619883
HLA-DQA1*03:03 0.073099415
HLA-DQA1*04:01 0.026315789
HLA-DQA1*05:01 0.133918129
HLA-DQA1*05:02 0.002 
HLA-DQA1*05:03 0.002923977
HLA-DQA1*05:04 0.002 
HLA-DQA1*05:05 0.102923977
HLA-DQA1*05:06 0.002 
HLA-DQA1*05:07 0.002 
HLA-DQA1*05:08 0.002 
HLA-DQA1*05:09 0.002 
HLA-DQA1*05:10 0.002 
HLA-DQA1*05:11 0.002 
HLA-DQA1*06:02 0.002923977
HLA-DQB1*02:01 0.2303 
HLA-DQB1*03:01 0.1845 
HLA-DQB1*03:02 0.09504 
HLA-DQB1*03:03 0.0446 
HLA-DQB1*03:04 0.0014 
HLA-DQB1*03:05 0.00121 
HLA-DQB1*04:02 0.02529 
HLA-DQB1*05:01 0.12281 
HLA-DQB1*05:02 0.01315 
HLA-DQB1*05:03 0.02497 
HLA-DQB1*05:04 0.00121 
HLA-DQB1*06:01 0.00769 
HLA-DQB1*06:02 0.1425 
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HLA  
EA Allele 
Frequency 
HLA-DQB1*06:03 0.06512 
HLA-DQB1*06:04 0.0324 
HLA-DQB1*06:09 0.00781 
HLA-DRB1*01:01 0.09149 
HLA-DRB1*01:02 0.01703 
HLA-DRB1*01:03 0.00889 
HLA-DRB1*03:01 0.12916 
HLA-DRB1*03:02 0.00006 
HLA-DRB1*04:01 0.09111 
HLA-DRB1*04:02 0.00972 
HLA-DRB1*04:03 0.00572 
HLA-DRB1*04:04 0.03634 
HLA-DRB1*04:05 0.00368 
HLA-DRB1*04:06 0.00025 
HLA-DRB1*04:07 0.00947 
HLA-DRB1*04:08 0.00248 
HLA-DRB1*07:01 0.13767 
HLA-DRB1*08:01 0.02363 
HLA-DRB1*08:02 0.00025 
HLA-DRB1*08:03 0.00133 
HLA-DRB1*08:04 0.00089 
HLA-DRB1*08:06 0.00006 
HLA-DRB1*08:11 0.00006 
HLA-DRB1*09:01 0.0082 
HLA-DRB1*10:01 0.00826 
HLA-DRB1*11:01 0.05654 
HLA-DRB1*11:02 0.00152 
HLA-DRB1*11:03 0.00483 
HLA-DRB1*11:04 0.03189 
HLA-DRB1*11:09 0.00006 
HLA-DRB1*11:39 0.00006 
HLA-DRB1*12:01 0.01468 
HLA-DRB1*13:01 0.06283 
HLA-DRB1*13:02 0.04015 
HLA-DRB1*13:03 0.00991 
HLA-DRB1*13:04 0.00006 
HLA-DRB1*13:05 0.00235 
HLA-DRB1*13:11 0.00006 
HLA  
EA Allele 
Frequency 
HLA-DRB1*14:01 0.02459 
HLA-DRB1*14:04 0.00032 
HLA-DRB1*14:06 0.00006 
HLA-DRB1*14:07 0.00006 
HLA-DRB1*15:01 0.14441 
HLA-DRB1*15:02 0.00775 
HLA-DRB1*15:03 0.00019 
HLA-DRB1*16:01 0.01061 
HLA-DRB1*16:02 0.00127 
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Table A.3 4 Digit HLA Priors for African Americans
 
4 Digit HLA Allele 
AA Allele 
Frequency 
HLA-DRB1*01:01 0.02599 
HLA-DRB1*01:02 0.03992 
HLA-DRB1*01:03 0.00229 
HLA-DRB1*03:01 0.07069 
HLA-DRB1*03:02 0.06528 
HLA-DRB1*03:05 0.00021 
HLA-DRB1*03:06 0.00021 
HLA-DRB1*04:01 0.02287 
HLA-DRB1*04:02 0.00042 
HLA-DRB1*04:03 0.00229 
HLA-DRB1*04:04 0.00686 
HLA-DRB1*04:05 0.00956 
HLA-DRB1*04:06 0.00062 
HLA-DRB1*04:07 0.00395 
HLA-DRB1*04:08 0.00062 
HLA-DRB1*04:09 0.00021 
HLA-DRB1*04:10 0.00062 
HLA-DRB1*04:11 0.00083 
HLA-DRB1*04:13 0.001 
HLA-DRB1*07:01 0.09771 
HLA-DRB1*08:01 0.00457 
HLA-DRB1*08:02 0.00104 
HLA-DRB1*08:03 0.00042 
HLA-DRB1*08:04 0.05052 
HLA-DRB1*08:06 0.0052 
HLA-DRB1*08:11 0.00104 
HLA-DRB1*09:01 0.0316 
HLA-DRB1*10:01 0.0185 
HLA-DRB1*11:01 0.08711 
HLA-DRB1*11:02 0.03909 
HLA-DRB1*11:03 0.00062 
HLA-DRB1*11:04 0.00561 
HLA-DRB1*11:10 0.00166 
HLA-DRB1*11:17 0.00021 
HLA-DRB1*12:01 0.0395 
4 Digit HLA Allele 
AA Allele 
Frequency 
HLA-DRB1*12:02 0.0027 
HLA-DRB1*13:01 0.05551 
HLA-DRB1*13:02 0.06445 
HLA-DRB1*13:03 0.03701 
HLA-DRB1*13:04 0.0131 
HLA-DRB1*13:05 0.00042 
HLA-DRB1*13:07 0.001 
HLA-DRB1*13:11 0.00021 
HLA-DRB1*13:16 0.00042 
HLA-DRB1*13:20 0.00021 
HLA-DRB1*13:27 0.001 
HLA-DRB1*13:31 0.00062 
HLA-DRB1*13:35 0.001 
HLA-DRB1*13:36 0.00021 
HLA-DRB1*14:01 0.02141 
HLA-DRB1*14:02 0.00062 
HLA-DRB1*14:04 0.00042 
HLA-DRB1*15:01 0.02931 
HLA-DRB1*15:02 0.00166 
HLA-DRB1*15:03 0.11746 
HLA-DRB1*15:04 0.001 
HLA-DRB1*16:01 0.00104 
HLA-DRB1*16:02 0.01538 
HLA-A*01:01 0.04742 
HLA-A*01:02 0.00645 
HLA-A*01:03 0.00021 
HLA-A*02:01 0.12458 
HLA-A*02:02 0.04201 
HLA-A*02:03 0.00021 
HLA-A*02:04 0.00021 
HLA-A*02:05 0.01872 
HLA-A*02:06 0.00021 
HLA-A*02:11 0.00021 
HLA-A*02:13 0.00021 
HLA-A*02:14 0.00021 
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4 Digit HLA Allele 
AA Allele 
Frequency 
HLA-A*02:20 0.00021 
HLA-A*02:22 0.00021 
HLA-A*02:60 0.00062 
HLA-A*02:74 0.00021 
HLA-A*03:01 0.08132 
HLA-A*03:02 0.00083 
HLA-A*11:01 0.01581 
HLA-A*23:01 0.10774 
HLA-A*23:05 0.00021 
HLA-A*24:02 0.02205 
HLA-A*24:03 0.00042 
HLA-A*24:07 0.00083 
HLA-A*24:17 0.00042 
HLA-A*24:24 0.001 
HLA-A*25:01 0.00499 
HLA-A*26:01 0.01414 
HLA-A*26:03 0.00021 
HLA-A*26:08 0.00042 
HLA-A*26:12 0.00042 
HLA-A*29:01 0.00104 
HLA-A*29:02 0.0364 
HLA-A*30:01 0.06905 
HLA-A*30:02 0.06219 
HLA-A*30:04 0.00208 
HLA-A*31:01 0.0104 
HLA-A*31:04 0.00021 
HLA-A*32:01 0.01414 
HLA-A*33:01 0.02121 
HLA-A*33:03 0.04451 
HLA-A*34:01 0.00042 
HLA-A*34:02 0.03349 
HLA-A*34:03 0.00021 
HLA-A*36:01 0.02413 
HLA-A*36:03 0.00021 
HLA-A*43:01 0.00021 
HLA-A*66:01 0.01477 
HLA-A*66:02 0.0079 
HLA-A*66:03 0.00229 
4 Digit HLA Allele 
AA Allele 
Frequency 
HLA-A*68:01 0.03681 
HLA-A*68:02 0.0651 
HLA-A*68:05 0.00021 
HLA-A*68:15 0.00021 
HLA-A*69:01 0.00042 
HLA-A*74:01 0.0522 
HLA-A*74:03 0.00021 
HLA-A*74:09 0.00062 
HLA-A*74:11 0.00062 
HLA-A*80:01 0.00707 
HLA-B*07:02 0.07303 
HLA-B*07:05 0.00747 
HLA-B*07:09 0.00021 
HLA-B*08:01 0.03838 
HLA-B*08:12 0.00062 
HLA-B*13:01 0.00041 
HLA-B*13:02 0.00954 
HLA-B*14:01 0.00934 
HLA-B*14:02 0.02199 
HLA-B*14:03 0.00249 
HLA-B*14:05 0.00041 
HLA-B*15:01 0.00975 
HLA-B*15:02 0.00083 
HLA-B*15:03 0.06245 
HLA-B*15:07 0.00021 
HLA-B*15:10 0.03029 
HLA-B*15:13 0.00021 
HLA-B*15:16 0.0166 
HLA-B*15:17 0.00602 
HLA-B*15:18 0.00104 
HLA-B*15:25 0.00021 
HLA-B*15:31 0.00062 
HLA-B*15:37 0.00104 
HLA-B*15:47 0.00041 
HLA-B*15:52 0.00021 
HLA-B*15:54 0.00041 
HLA-B*15:61 0.00021 
HLA-B*18:01 0.03568 
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4 Digit HLA Allele 
AA Allele 
Frequency 
HLA-B*27:02 0.00041 
HLA-B*27:03 0.00228 
HLA-B*27:05 0.00664 
HLA-B*27:06 0.00041 
HLA-B*35:01 0.06494 
HLA-B*35:02 0.00062 
HLA-B*35:03 0.00353 
HLA-B*35:05 0.00104 
HLA-B*35:08 0.00041 
HLA-B*35:28 0.00021 
HLA-B*35:43 0.00041 
HLA-B*37:01 0.00539 
HLA-B*38:01 0.00166 
HLA-B*39:01 0.00415 
HLA-B*39:06 0.00187 
HLA-B*39:09 0.00021 
HLA-B*39:10 0.00705 
HLA-B*39:24 0.001 
HLA-B*40:01 0.01328 
HLA-B*40:02 0.00353 
HLA-B*40:06 0.00021 
HLA-B*40:12 0.00104 
HLA-B*40:16 0.00041 
HLA-B*41:01 0.00498 
HLA-B*41:02 0.00685 
HLA-B*41:03 0.00104 
HLA-B*41:04 0.001 
HLA-B*42:01 0.05456 
HLA-B*42:02 0.00726 
HLA-B*44:02 0.02116 
HLA-B*44:03 0.05373 
HLA-B*44:04 0.00021 
HLA-B*44:05 0.00041 
HLA-B*44:10 0.00124 
HLA-B*44:15 0.00021 
HLA-B*44:18 0.00021 
HLA-B*45:01 0.04502 
HLA-B*47:01 0.00124 
4 Digit HLA Allele 
AA Allele 
Frequency 
HLA-B*47:03 0.00041 
HLA-B*48:01 0.00021 
HLA-B*48:02 0.00021 
HLA-B*49:01 0.02822 
HLA-B*50:01 0.00934 
HLA-B*50:02 0.00021 
HLA-B*51:01 0.02178 
HLA-B*51:02 0.00041 
HLA-B*51:09 0.00083 
HLA-B*52:01 0.01432 
HLA-B*53:01 0.11245 
HLA-B*55:01 0.00415 
HLA-B*56:01 0.00228 
HLA-B*57:01 0.00477 
HLA-B*57:02 0.00415 
HLA-B*57:03 0.03382 
HLA-B*57:04 0.0029 
HLA-B*58:01 0.03506 
HLA-B*58:02 0.04108 
HLA-B*67:02 0.00021 
HLA-B*78:01 0.01328 
HLA-B*78:02 0.00021 
HLA-B*81:01 0.0195 
HLA-B*82:01 0.00166 
HLA-B*82:02 0.00062 
HLA-C*01:02 0.0085 
HLA-C*01:16 0.00021 
HLA-C*02:02 0.08461 
HLA-C*02:10 0.001 
HLA-C*02:14 0.00021 
HLA-C*03:02 0.01369 
HLA-C*03:03 0.01182 
HLA-C*03:04 0.0533 
HLA-C*03:05 0.00041 
HLA-C*04:01 0.18457 
HLA-C*04:03 0.00041 
HLA-C*04:04 0.00041 
HLA-C*04:07 0.00228 
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4 Digit HLA Allele 
AA Allele 
Frequency 
HLA-C*04:08 0.00041 
HLA-C*04:13 0.00062 
HLA-C*04:14 0.00021 
HLA-C*04:27 0.00021 
HLA-C*05:01 0.03526 
HLA-C*06:02 0.08855 
HLA-C*06:08 0.00041 
HLA-C*06:09 0.00021 
HLA-C*07:01 0.12401 
HLA-C*07:02 0.06968 
HLA-C*07:04 0.00871 
HLA-C*07:05 0.00062 
HLA-C*07:35 0.00062 
HLA-C*08:01 0.00124 
HLA-C*08:02 0.03733 
HLA-C*08:03 0.00021 
HLA-C*08:04 0.01182 
HLA-C*08:13 0.00021 
HLA-C*12:02 0.00145 
HLA-C*12:03 0.01783 
HLA-C*14:02 0.01265 
HLA-C*14:03 0.0027 
HLA-C*15:02 0.00539 
HLA-C*15:05 0.01452 
HLA-C*16:01 0.09788 
HLA-C*16:02 0.00041 
HLA-C*16:04 0.00021 
HLA-C*16:08 0.00021 
HLA-C*17:01 0.07362 
HLA-C*17:04 0.00021 
HLA-C*18:01 0.03194 
HLA-C*18:03 0.00021 
HLA-DQB1*02:01 0.22314 
4 Digit HLA Allele 
AA Allele 
Frequency 
HLA-DQB1*02:03 0.00303 
HLA-DQB1*03:01 0.17374 
HLA-DQB1*03:02 0.03683 
HLA-DQB1*03:03 0.01646 
HLA-DQB1*04:02 0.06846 
HLA-DQB1*05:01 0.15381 
HLA-DQB1*05:02 0.0273 
HLA-DQB1*05:03 0.01473 
HLA-DQB1*06:01 0.0013 
HLA-DQB1*06:02 0.19801 
HLA-DQB1*06:03 0.0234 
HLA-DQB1*06:04 0.0195 
HLA-DQB1*06:05 0.00043 
HLA-DQB1*06:08 0.0039 
HLA-DQB1*06:09 0.03466 
HLA-DQB1*06:11 0.0013 
HLA-DQA1*01:01 0.074712644
HLA-DQA1*01:02 0.310344828
HLA-DQA1*01:03 0.011494253
HLA-DQA1*01:04 0.011494253
HLA-DQA1*01:05 0.057471264
HLA-DQA1*02:01 0.091954023
HLA-DQA1*03:01 0.034482759
HLA-DQA1*03:02 0.017241379
HLA-DQA1*03:03 0.091954023
HLA-DQA1*04:01 0.086206897
HLA-DQA1*05:01 0.079655172
HLA-DQA1*05:02 0.017241379
HLA-DQA1*05:05 0.11 
HLA-DQA1*06:01 0.005747126
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Table A.4 4-Digit HLA Priors for Asian-Pacific Islander 
 
HLA  
API Allele 
Frequency 
HLA-A*01:01 0.05082 
HLA-A*02:01 0.09458 
HLA-A*02:02 0.00028 
HLA-A*02:03 0.03162 
HLA-A*02:05 0.00339 
HLA-A*02:06 0.04828 
HLA-A*02:07 0.04376 
HLA-A*02:10 0.00085 
HLA-A*02:11 0.01158 
HLA-A*02:16 0.00113 
HLA-A*02:20 0.00056 
HLA-A*02:42 0.00028 
HLA-A*02:53 0.00028 
HLA-A*03:01 0.02597 
HLA-A*03:02 0.00536 
HLA-A*11:01 0.17899 
HLA-A*11:02 0.01525 
HLA-A*11:03 0.00028 
HLA-A*11:19 0.00028 
HLA-A*23:01 0.00226 
HLA-A*24:02 0.18238 
HLA-A*24:03 0.00565 
HLA-A*24:04 0.001 
HLA-A*24:07 0.01779 
HLA-A*24:08 0.00056 
HLA-A*24:10 0.00254 
HLA-A*24:17 0.00423 
HLA-A*24:20 0.00169 
HLA-A*25:01 0.00056 
HLA-A*26:01 0.03896 
HLA-A*26:02 0.00734 
HLA-A*26:03 0.00141 
HLA-A*29:01 0.0144 
HLA-A*29:02 0.00141 
HLA-A*30:01 0.02061 
HLA-A*30:02 0.00056 
HLA  
API Allele 
Frequency 
HLA-A*30:04 0.00339 
HLA-A*31:01 0.03247 
HLA-A*31:12 0.00028 
HLA-A*32:01 0.01299 
HLA-A*33:01 0.00113 
HLA-A*33:03 0.0943 
HLA-A*34:01 0.01581 
HLA-A*34:02 0.00028 
HLA-A*34:05 0.00141 
HLA-A*66:01 0.00028 
HLA-A*68:01 0.01863 
HLA-A*68:02 0.00028 
HLA-A*68:03 0.00028 
HLA-A*69:01 0.00141 
HLA-A*74:01 0.00113 
HLA-B*07:02 0.02632 
HLA-B*07:05 0.01952 
HLA-B*08:01 0.01641 
HLA-B*13:01 0.03254 
HLA-B*13:02 0.0232 
HLA-B*14:01 0.00283 
HLA-B*14:02 0.00113 
HLA-B*15:01 0.0348 
HLA-B*15:02 0.03565 
HLA-B*15:03 0.00028 
HLA-B*15:05 0.00283 
HLA-B*15:06 0.00028 
HLA-B*15:07 0.00283 
HLA-B*15:08 0.00141 
HLA-B*15:10 0.00085 
HLA-B*15:11 0.00651 
HLA-B*15:12 0.0034 
HLA-B*15:13 0.0017 
HLA-B*15:17 0.00453 
HLA-B*15:18 0.0099 
HLA-B*15:21 0.00368 
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HLA  
API Allele 
Frequency 
HLA-B*15:25 0.00566 
HLA-B*15:27 0.00453 
HLA-B*15:29 0.00113 
HLA-B*15:34 0.00028 
HLA-B*15:35 0.00764 
HLA-B*15:58 0.001 
HLA-B*18:01 0.0116 
HLA-B*18:02 0.0017 
HLA-B*27:02 0.00028 
HLA-B*27:04 0.00707 
HLA-B*27:05 0.00849 
HLA-B*27:06 0.00283 
HLA-B*27:07 0.00113 
HLA-B*27:20 0.00028 
HLA-B*35:01 0.04273 
HLA-B*35:02 0.00226 
HLA-B*35:03 0.02405 
HLA-B*35:05 0.0099 
HLA-B*35:08 0.0017 
HLA-B*35:63 0.001 
HLA-B*37:01 0.01471 
HLA-B*38:01 0.00453 
HLA-B*38:02 0.0365 
HLA-B*39:01 0.0133 
HLA-B*39:05 0.00113 
HLA-B*39:06 0.00028 
HLA-B*39:09 0.00085 
HLA-B*39:15 0.00057 
HLA-B*40:01 0.0798 
HLA-B*40:02 0.03056 
HLA-B*40:03 0.00226 
HLA-B*40:06 0.03707 
HLA-B*40:10 0.00057 
HLA-B*40:23 0.00028 
HLA-B*40:40 0.00028 
HLA-B*40:50 0.00028 
HLA-B*41:01 0.00141 
HLA-B*44:02 0.00764 
HLA  
API Allele 
Frequency 
HLA-B*44:03 0.04244 
HLA-B*45:01 0.00226 
HLA-B*46:01 0.06112 
HLA-B*47:01 0.00028 
HLA-B*48:01 0.02037 
HLA-B*48:03 0.00141 
HLA-B*48:04 0.00085 
HLA-B*49:01 0.00113 
HLA-B*50:01 0.00736 
HLA-B*51:01 0.06282 
HLA-B*51:02 0.00623 
HLA-B*51:06 0.00255 
HLA-B*51:07 0.00085 
HLA-B*51:08 0.00085 
HLA-B*51:37 0.00028 
HLA-B*52:01 0.03679 
HLA-B*53:01 0.00085 
HLA-B*54:01 0.03282 
HLA-B*55:01 0.00538 
HLA-B*55:02 0.01585 
HLA-B*55:12 0.00028 
HLA-B*56:01 0.00792 
HLA-B*56:02 0.00028 
HLA-B*56:03 0.00141 
HLA-B*56:04 0.00141 
HLA-B*57:01 0.02066 
HLA-B*58:01 0.05772 
HLA-B*59:01 0.00821 
HLA-B*67:01 0.00255 
HLA-B*73:01 0.00028 
HLA-B*81:01 0.00085 
HLA-C*01:02 0.13375 
HLA-C*01:03 0.00198 
HLA-C*01:05 0.00028 
HLA-C*01:18 0.00028 
HLA-C*02:02 0.00395 
HLA-C*03:02 0.05643 
HLA-C*03:03 0.05023 
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HLA  
API Allele 
Frequency 
HLA-C*03:04 0.08352 
HLA-C*03:36 0.00028 
HLA-C*03:37 0.00028 
HLA-C*04:01 0.0807 
HLA-C*04:03 0.01467 
HLA-C*04:04 0.00056 
HLA-C*04:06 0.00113 
HLA-C*04:10 0.00085 
HLA-C*05:01 0.00847 
HLA-C*06:02 0.06518 
HLA-C*06:15 0.00028 
HLA-C*07:01 0.03894 
HLA-C*07:02 0.1456 
HLA-C*07:04 0.01016 
HLA-C*07:26 0.00028 
HLA-C*07:27 0.00113 
HLA-C*07:43 0.00028 
HLA-C*08:01 0.07985 
HLA-C*08:02 0.00395 
HLA-C*08:03 0.00451 
HLA-C*12:02 0.04486 
HLA-C*12:03 0.02737 
HLA-C*12:04 0.00198 
HLA-C*12:05 0.00028 
HLA-C*14:02 0.04797 
HLA-C*14:03 0.01383 
HLA-C*15:02 0.04966 
HLA-C*15:04 0.00085 
HLA-C*15:05 0.01411 
HLA-C*15:08 0.00028 
HLA-C*15:11 0.00028 
HLA-C*16:01 0.00169 
HLA-C*16:02 0.0079 
HLA-C*17:01 0.00141 
HLA-DQA1*01:01 0.120879121
HLA-DQA1*01:02 0.148351648
HLA-DQA1*01:03 0.115384615
HLA-DQA1*02:01 0.137362637
HLA  
API Allele 
Frequency 
HLA-DQA1*03:01 0.285714286
HLA-DQA1*03:03 0.002 
HLA-DQA1*04:01 0.010989011
HLA-DQA1*05:01 0.137362637
HLA-DQA1*05:05 0.002 
HLA-DQA1*06:01 0.043956044
HLA-DQB1*02:01 0.10915 
HLA-DQB1*03:01 0.1941 
HLA-DQB1*03:02 0.07614 
HLA-DQB1*03:03 0.12192 
HLA-DQB1*03:05 0.00044 
HLA-DQB1*04:01 0.04533 
HLA-DQB1*04:02 0.02333 
HLA-DQB1*05:01 0.07394 
HLA-DQB1*05:02 0.0735 
HLA-DQB1*05:03 0.06206 
HLA-DQB1*06:01 0.11928 
HLA-DQB1*06:02 0.04401 
HLA-DQB1*06:03 0.02289 
HLA-DQB1*06:04 0.01364 
HLA-DQB1*06:05 0.00044 
HLA-DQB1*06:09 0.01893 
HLA-DQB1*06:10 0.00088 
HLA-DRB1*01:01 0.02743 
HLA-DRB1*01:02 0.00028 
HLA-DRB1*01:03 0.00028 
HLA-DRB1*03:01 0.05373 
HLA-DRB1*04:01 0.00905 
HLA-DRB1*04:02 0.00368 
HLA-DRB1*04:03 0.0345 
HLA-DRB1*04:04 0.00905 
HLA-DRB1*04:05 0.05798 
HLA-DRB1*04:06 0.02064 
HLA-DRB1*04:07 0.00141 
HLA-DRB1*04:08 0.00141 
HLA-DRB1*04:10 0.00368 
HLA-DRB1*07:01 0.08201 
HLA-DRB1*07:03 0.00028 
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HLA  
API Allele 
Frequency 
HLA-DRB1*08:01 0.00452 
HLA-DRB1*08:02 0.01301 
HLA-DRB1*08:03 0.05175 
HLA-DRB1*08:05 0.00028 
HLA-DRB1*08:09 0.00226 
HLA-DRB1*09:01 0.10181 
HLA-DRB1*10:01 0.03111 
HLA-DRB1*11:01 0.05119 
HLA-DRB1*11:04 0.0065 
HLA-DRB1*11:06 0.00311 
HLA-DRB1*11:08 0.00028 
HLA-DRB1*11:11 0.00085 
HLA-DRB1*12:01 0.02885 
HLA-DRB1*12:02 0.0741 
HLA-DRB1*12:08 0.00028 
HLA-DRB1*13:01 0.02376 
HLA-DRB1*13:02 0.0362 
HLA-DRB1*13:03 0.00028 
HLA-DRB1*13:12 0.00424 
HLA-DRB1*13:50 0.00028 
HLA-DRB1*14:01 0.02404 
HLA-DRB1*14:02 0.00028 
HLA-DRB1*14:03 0.00368 
HLA-DRB1*14:04 0.02036 
HLA-DRB1*14:05 0.01753 
HLA-DRB1*14:06 0.00283 
HLA-DRB1*14:07 0.00255 
HLA-DRB1*14:08 0.00028 
HLA-DRB1*14:10 0.00001 
HLA-DRB1*14:12 0.00028 
HLA-DRB1*14:18 0.00141 
HLA-DRB1*14:19 0.00057 
HLA-DRB1*14:22 0.00028 
HLA-DRB1*14:25 0.00028 
HLA-DRB1*14:44 0.001 
HLA-DRB1*15:01 0.07919 
HLA-DRB1*15:02 0.08088 
HLA-DRB1*15:03 0.00057 
HLA  
API Allele 
Frequency 
HLA-DRB1*15:04 0.00057 
HLA-DRB1*15:06 0.00396 
HLA-DRB1*15:07 0.00028 
HLA-DRB1*15:14 0.00028 
HLA-DRB1*16:01 0.00028 
HLA-DRB1*16:02 0.01951 
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A3 Regions targeted in IMN Cases with next generation sequencing data 
Table A.5 Immune Related Genes Targeted for Next Generation Sequencing in IMN 
Cases 
Region Chr HGNC Symbol Gene Start Gene End Size 
1p36.3-p36.2 1 MASP2 11086580 11107296 20,716 
1p35 1 PLA2G2A 20301924 20306932 5,008 
1p36.11 1 C1QA 22963118 22966175 3,057 
1p36.11 1 C1QC 22970118 22974603 4,485 
1p36.11 1 C1QB 22979682 22988029 8,347 
1p32 1 C8A 57320443 57383894 63,451 
1p32 1 C8B 57394883 57431688 36,805 
1p31.3 1 IL23R 67632169 67725662 93,493 
1p13.2 1 PTPN22 114356433 114414381 57,948 
1q23 1 FCGR2A 161475205 161489360 14,155 
1q23 1 FCGR2B 161632905 161648444 15,539 
1q23.3 1 FCGR2C 161551129 161570032 18,903 
1q23 1 FCGR3B 161592986 161601158 8,172 
1q31.2 1 RGS1 192544857 192549161 4,304 
1q32 1 CFH 196621008 196716634 95,626 
1q32 1 CFHR3  196743930 196763203 19,273 
1q32 1 CFHR1 196788861 196801319 12,458 
1q32.1 1 IL10 206940947 206945839 4,892 
1q32.1 1 IL19 206972215 207016324 44,109 
1q32.1 1 IL20 207038699 207042568 3,869 
1q32 1 CR1 207669473 207815110 145,637 
2q23-q24 2 LY75 160659866 160761267 101,401 
2q23-q24 2 PLA2R1 160797260 160919126 121,866 
2q24.2 2 ITGB6 160958233 161056590 98,357 
2q24.2 2 IFIH1 163123589 163175213 51,624 
2q32.2 2 STAT4 191894302 192016322 122,020 
2q33.2 2 CTLA4 204732509 204738683 6,174 
3p21.31 3 CCR5 46411633 46417697 6,064 
3q27-q28 3 MASP1 186933873 187009810 75,937 
4q13-q21 4 IL8 74606223 74609433 3,210 
4q25 4 CFI 110661848 110723335 61,487 
4q27 4 IL2 123372625 123377880 5,255 
4q27 4 IL21 123533783 123542224 8,441 
5p13 5 IL7R 35856991 35876924 19,933 
5p14-p12 5 C9 39284377 39364655 80,278 
5p13 5 C7 40909599 40983041 73,442 
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Region Chr HGNC Symbol Gene Start Gene End Size 
5p13 5 C6 41142336 41261540 119,204 
5q31.1 5 IL3 131396347 131398896 2,549 
5q33 5 TNIP1 150409506 150460997 51,491 
5q33 5 IL12B 158741791 158757481 15,690 
MHC 6 HLA-F 29690552 29706305 15,753 
MHC 6 HLA-G 29794744 29798902 4,158 
MHC 6 HLA-A 29909037 29913661 4,624 
MHC 6 HLA-E 30457244 30461982 4,738 
MHC 6 PSORS1C1 31082527 31107869 25,342 
MHC 6 HLA-C 31236526 31239907 3,381 
MHC 6 HLA-B 31321649 31324965 3,316 
MHC 6 TNF 31543344 31546113 2,769 
MHC 6 C2 31865562 31913449 47,887 
MHC 6 CFB 31895475 31919861 24,386 
MHC 6 C4A 31949801 31970458 20,657 
MHC 6 C4B 31982539 32003195 20,656 
MHC 6 HLA-DRA 32407619 32412823 5,204 
MHC 6 HLA-DRB5 32485120 32498064 12,944 
MHC 6 HLA-DRB1 32546546 32557625 11,079 
MHC 6 HLA-DQA1 32595956 32614839 18,883 
MHC 6 HLA-DQB1 32627244 32636160 8,916 
MHC 6 HLA-DQA2 32709119 32714992 5,873 
MHC 6 HLA-DQB2 32723875 32731311 7,436 
MHC 6 HLA-DOB 32780540 32784825 4,285 
MHC 6 PSMB8 32808494 32812480 3,986 
MHC 6 TAP1 32812986 32821755 8,769 
MHC 6 HLA-DMB 32902406 32908847 6,441 
MHC 6 HLA-DMA 32916390 32938493 22,103 
MHC 6 HLA-DOA 32971955 32977389 5,434 
MHC 6 HLA-DPA1 33032346 33048552 16,206 
MHC 6 HLA-DPB1 33043703 33054978 11,275 
MHC 6 HLA-DPA2 33059259 33061091 1,832 
MHC 6 HLA-DPB2 33071470 33074921 3,451 
6q21 6 PRDM1 106534195 106557814 23,619 
6q23.3 6 TNFAIP3 138188351 138204449 16,098 
6q25.3 6 TAGAP 159455500 159466184 10,684 
6q27 6 CCR6 167525295 167552629 27,334 
7p21 7 IL6 22766766 22771621 4,855 
7q32 7 IRF5 128577994 128590089 12,095 
8p21-p11.2 8 STC1 23699434 23712320 12,886 
9q33-q34 9 C5 123714613 123812554 97,941 
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Region Chr HGNC Symbol Gene Start Gene End Size 
10p15 10 IL2RA 6052657 6104333 51,676 
10p15.1 10 PRKCQ 6469105 6622263 153,158 
10p12.33 10 MRC1 18098352 18200091 101,739 
10q11.2 10 MBL2 54525140 54531460 6,320 
12p13 12 C1S 7167980 7178336 10,356 
12p13 12 C1R 7187513 7189412 1,899 
12q13.2 12 IL23A 56732663 56734193 1,530 
12q13.2 12 STAT2 56735381 56753939 18,558 
12q23-q24.1 12 PLA2G1B  120759914 120765592 5,678 
14q11.1-q11.2 14 ANG  21152336 21162345 10,009 
15q21.1 15 GATM 45653322 45670980 17,658 
16p13.13 16 CIITA 10971039 11023624 52,585 
16p12.3 16 UMOD 20344373 20364037 19,664 
16p11.2 16 IL27 28510683 28523372 12,689 
16p11 16 ITGAM 31271288 31344213 72,925 
16q12 16 NOD2 50731050 50766987 35,937 
17p13 17 
TNFSF12-
TNFSF13 7452375 7464925 12,550 
17q12 17 PPP1R1B 37783179 37792879 9,700 
17q21 17 STAT3 40465343 40540513 75,170 
17q23.2 17 MRC2 (endo180) 60704762 60770953 66,191 
18p11.21 18 PTPN2 12785477 12884337 98,860 
19p13.3-p13.2 19 C3 6677846 6720662 42,816 
19p13.2 19 TYK2 10461209 10491352 30,143 
19q13.3 19 FCGRT 50015536 50029685 14,149 
20p12.1-
p11.23 20 JAG1 10618332 10654694 36,362 
20p11.21 20 CST9 23583047 23586610 3,563 
20p11.21 20 CST3 23614294 23618574 4,280 
20p11.21 20 CST4 23666277 23669662 3,385 
20q13 20 CD40 44746906 44758384 11,478 
21q22.3 21 UBASH3A 43824008 43867791 43,783 
21q22.3 21 AIRE 45705721 45718531 12,810 
22q11 22 UBE2L3 21921957 21978323 56,366 
22q12.3 22 IL2RB 37515126 37571094 55,968 
Xp22.2 X TLR8 12924739 12941288 16,549 
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A4 Complete Results from IMN Case-Control Analyses 
 
Table A.6 Association of HLA with Idiopathic Membranous Nephropathy In 
European Americans 
 
HLA in EA 
N 
Cases
N 
Controls 
Cases 
MAF 
Controls 
MAF 
Odd’s 
Ratio P-Value 
HLA.A.01.01 49 350 0.306 0.1371 2.72 6.24E-05 
HLA.A.01.02 49 350 0.000 0.0014 0.00 9.89E-01 
HLA.A.02.01 49 350 0.286 0.3114 0.88 6.04E-01 
HLA.A.02.05 49 350 0.000 0.0057 0.00 9.85E-01 
HLA.A.02.06 49 350 0.000 0.0014 0.00 9.89E-01 
HLA.A.02.17 49 350 0.000 0.0014 0.00 9.89E-01 
HLA.A.02.24 49 350 0.000 0.0014 0.00 9.89E-01 
HLA.A.03.01 49 350 0.061 0.1714 0.34 1.08E-02 
HLA.A.03.02 49 350 0.000 0.0029 0.00 9.89E-01 
HLA.A.11.01 49 350 0.061 0.0557 1.11 8.24E-01 
HLA.A.11.02 49 350 0.000 0.0014 0.00 9.89E-01 
HLA.A.23.01 49 350 0.010 0.0186 0.54 5.57E-01 
HLA.A.24.02 49 350 0.102 0.0829 1.28 5.12E-01 
HLA.A.25.01 49 350 0.020 0.0157 1.31 7.30E-01 
HLA.A.26.01 49 350 0.010 0.0243 0.44 4.14E-01 
HLA.A.26.08 49 350 0.000 0.0014 0.00 9.89E-01 
HLA.A.29.01 49 350 0.000 0.0029 0.00 9.89E-01 
HLA.A.29.02 49 350 0.010 0.0243 0.41 3.89E-01 
HLA.A.30.01 49 350 0.010 0.0157 0.64 6.75E-01 
HLA.A.30.02 49 350 0.020 0.0086 2.44 2.83E-01 
HLA.A.30.04 49 350 0.000 0.0029 0.00 9.89E-01 
HLA.A.31.01 49 350 0.000 0.0243 0.00 9.87E-01 
HLA.A.32.01 49 350 0.031 0.0443 0.67 5.23E-01 
HLA.A.33.01 49 350 0.010 0.0029 3.62 2.97E-01 
HLA.A.33.03 49 350 0.010 0.0043 2.41 4.50E-01 
HLA.A.68.01 49 350 0.051 0.0343 1.54 4.01E-01 
HLA.A.69.01 49 350 0.000 0.0014 0.00 9.89E-01 
HLA.B.07.02 49 350 0.031 0.1229 0.24 1.72E-02 
HLA.B.07.05 49 350 0.000 0.0043 0.00 9.87E-01 
HLA.B.08.01 49 350 0.327 0.0914 5.11 6.48E-09 
HLA.B.13.02 49 350 0.000 0.0300 0.00 9.85E-01 
HLA.B.14.01 49 350 0.020 0.0086 2.44 2.83E-01 
HLA.B.14.02 49 350 0.010 0.0157 0.64 6.75E-01 
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HLA in EA 
N 
Cases
N 
Controls 
Cases 
MAF 
Controls 
MAF 
Odd’s 
Ratio P-Value 
HLA.B.15.01 49 350 0.082 0.0629 1.32 4.85E-01 
HLA.B.15.03 49 350 0.010 0.0014 7.27 1.63E-01 
HLA.B.15.10 49 350 0.000 0.0014 0.00 9.89E-01 
HLA.B.15.17 49 350 0.000 0.0057 0.00 9.85E-01 
HLA.B.15.18 49 350 0.000 0.0043 0.00 9.87E-01 
HLA.B.18.01 49 350 0.061 0.0329 1.98 1.59E-01 
HLA.B.27.05 49 350 0.020 0.0429 0.47 3.06E-01 
HLA.B.35.01 49 350 0.020 0.0729 0.27 6.96E-02 
HLA.B.35.02 49 350 0.020 0.0086 2.44 2.83E-01 
HLA.B.35.03 49 350 0.010 0.0171 0.59 6.12E-01 
HLA.B.35.08 49 350 0.000 0.0043 0.00 9.87E-01 
HLA.B.37.01 49 350 0.000 0.0114 0.00 9.86E-01 
HLA.B.38.01 49 350 0.000 0.0171 0.00 9.83E-01 
HLA.B.39.01 49 350 0.000 0.0143 0.00 9.85E-01 
HLA.B.39.06 49 350 0.000 0.0100 0.00 9.87E-01 
HLA.B.40.01 49 350 0.020 0.0614 0.33 1.23E-01 
HLA.B.40.02 49 350 0.000 0.0129 0.00 9.85E-01 
HLA.B.40.06 49 350 0.010 0.0000 
15445062.
33 9.85E-01 
HLA.B.41.01 49 350 0.000 0.0071 0.00 9.89E-01 
HLA.B.41.02 49 350 0.000 0.0029 0.00 9.89E-01 
HLA.B.44.02 49 350 0.061 0.0986 0.60 2.44E-01 
HLA.B.44.03 49 350 0.020 0.0471 0.44 2.57E-01 
HLA.B.44.05 49 350 0.010 0.0000 
15445062.
34 9.85E-01 
HLA.B.45.01 49 350 0.000 0.0029 0.00 9.89E-01 
HLA.B.47.01 49 350 0.000 0.0043 0.00 9.87E-01 
HLA.B.49.01 49 350 0.010 0.0129 0.82 8.40E-01 
HLA.B.50.01 49 350 0.000 0.0057 0.00 9.85E-01 
HLA.B.50.02 49 350 0.010 0.0000 
15445062.
33 9.85E-01 
HLA.B.51.01 49 350 0.082 0.0643 1.31 5.13E-01 
HLA.B.52.01 49 350 0.020 0.0014 14.85 2.89E-02 
HLA.B.53.01 49 350 0.000 0.0043 0.00 9.87E-01 
HLA.B.55.01 49 350 0.020 0.0200 1.02 9.78E-01 
HLA.B.56.01 49 350 0.031 0.0143 2.22 2.39E-01 
HLA.B.57.01 49 350 0.071 0.0471 1.60 2.93E-01 
HLA.B.57.02 49 350 0.000 0.0014 0.00 9.89E-01 
HLA.B.58.01 49 350 0.010 0.0100 1.02 9.85E-01 
HLA.B.67.01 49 350 0.000 0.0014 0.00 9.89E-01 
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HLA in EA 
N 
Cases
N 
Controls 
Cases 
MAF 
Controls 
MAF 
Odd’s 
Ratio P-Value 
HLA.B.73.01 49 350 0.010 0.0000 
15445062.
33 9.85E-01 
HLA.C.01.02 49 350 0.061 0.0314 1.96 1.50E-01 
HLA.C.02.02 49 350 0.031 0.0429 0.71 5.74E-01 
HLA.C.03.02 49 350 0.010 0.0029 3.62 2.97E-01 
HLA.C.03.03 49 350 0.061 0.0557 1.11 8.19E-01 
HLA.C.03.04 49 350 0.051 0.0900 0.55 2.10E-01 
HLA.C.04.01 49 350 0.082 0.1200 0.64 2.55E-01 
HLA.C.05.01 49 350 0.102 0.0929 1.12 7.65E-01 
HLA.C.06.02 49 350 0.092 0.0971 0.94 8.70E-01 
HLA.C.07.01 49 350 0.316 0.1314 3.14 9.41E-06 
HLA.C.07.02 49 350 0.051 0.1371 0.37 3.05E-02 
HLA.C.07.04 49 350 0.010 0.0200 0.54 5.35E-01 
HLA.C.08.02 49 350 0.031 0.0243 1.25 7.18E-01 
HLA.C.12.02 49 350 0.010 0.0014 7.27 1.63E-01 
HLA.C.12.03 49 350 0.020 0.0486 0.43 2.38E-01 
HLA.C.14.02 49 350 0.031 0.0214 1.46 5.64E-01 
HLA.C.15.02 49 350 0.020 0.0286 0.72 6.56E-01 
HLA.C.15.05 49 350 0.010 0.0043 2.41 4.50E-01 
HLA.C.16.01 49 350 0.010 0.0329 0.32 2.57E-01 
HLA.C.16.02 49 350 0.000 0.0029 0.00 9.89E-01 
HLA.C.16.04 49 350 0.000 0.0043 0.00 9.87E-01 
HLA.C.17.01 49 350 0.000 0.0086 0.00 9.88E-01 
HLA.C.18.01 49 350 0.000 0.0014 0.00 9.89E-01 
HLA.DQA1.01.01 49 350 0.112 0.1157 0.97 9.19E-01 
HLA.DQA1.01.02 49 350 0.082 0.1886 0.40 1.55E-02 
HLA.DQA1.01.03 49 350 0.061 0.0571 1.08 8.67E-01 
HLA.DQA1.01.04 49 350 0.010 0.0357 0.29 2.22E-01 
HLA.DQA1.01.05 49 350 0.010 0.0143 0.71 7.45E-01 
HLA.DQA1.02.01 49 350 0.061 0.1286 0.46 7.13E-02 
HLA.DQA1.03.01 49 350 0.031 0.1157 0.25 1.96E-02 
HLA.DQA1.03.02 49 350 0.010 0.0100 1.02 9.85E-01 
HLA.DQA1.03.03 49 350 0.061 0.0629 0.97 9.50E-01 
HLA.DQA1.04.01 49 350 0.000 0.0629 0.00 9.86E-01 
HLA.DQA1.05.01 49 350 0.429 0.0943 8.93 8.06E-13 
HLA.DQA1.05.03 49 350 0.000 0.0014 0.00 9.89E-01 
HLA.DQA1.05.05 49 350 0.133 0.1129 1.20 5.69E-01 
HLA.DQB1.02.01 49 350 0.459 0.1457 5.34 1.76E-10 
HLA.DQB1.03.01 49 350 0.173 0.1714 1.01 9.60E-01 
HLA.DQB1.03.02 49 350 0.041 0.1171 0.32 3.06E-02 
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HLA in EA 
N 
Cases
N 
Controls 
Cases 
MAF 
Controls 
MAF 
Odd’s 
Ratio P-Value 
HLA.DQB1.03.03 49 350 0.051 0.0643 0.78 6.08E-01 
HLA.DQB1.04.02 49 350 0.000 0.0629 0.00 9.86E-01 
HLA.DQB1.05.01 49 350 0.122 0.1271 0.96 8.94E-01 
HLA.DQB1.05.02 49 350 0.010 0.0200 0.50 5.08E-01 
HLA.DQB1.05.03 49 350 0.020 0.0400 0.51 3.56E-01 
HLA.DQB1.06.01 49 350 0.010 0.0029 3.62 2.97E-01 
HLA.DQB1.06.02 49 350 0.041 0.1414 0.35 2.70E-02 
HLA.DQB1.06.03 49 350 0.061 0.0671 0.92 8.44E-01 
HLA.DQB1.06.04 49 350 0.000 0.0057 0.00 9.85E-01 
HLA.DQB1.06.09 49 350 0.010 0.0343 0.28 2.21E-01 
HLA.DRB1.01.01 49 350 0.082 0.1057 0.76 4.68E-01 
HLA.DRB1.01.02 49 350 0.020 0.0071 2.94 2.06E-01 
HLA.DRB1.01.03 49 350 0.010 0.0057 1.80 6.02E-01 
HLA.DRB1.03.01 49 350 0.429 0.0971 8.09 1.65E-12 
HLA.DRB1.03.02 49 350 0.000 0.0014 0.00 9.89E-01 
HLA.DRB1.04.01 49 350 0.061 0.0800 0.75 5.14E-01 
HLA.DRB1.04.02 49 350 0.000 0.0071 0.00 9.89E-01 
HLA.DRB1.04.03 49 350 0.010 0.0086 1.19 8.71E-01 
HLA.DRB1.04.04 49 350 0.000 0.0643 0.00 9.86E-01 
HLA.DRB1.04.05 49 350 0.020 0.0014 14.85 2.89E-02 
HLA.DRB1.04.06 49 350 0.000 0.0014 0.00 9.89E-01 
HLA.DRB1.04.07 49 350 0.000 0.0114 0.00 9.86E-01 
HLA.DRB1.04.08 49 350 0.000 0.0029 0.00 9.89E-01 
HLA.DRB1.07.01 49 350 0.061 0.1286 0.47 7.45E-02 
HLA.DRB1.08.01 49 350 0.000 0.0543 0.00 9.87E-01 
HLA.DRB1.08.02 49 350 0.000 0.0043 0.00 9.87E-01 
HLA.DRB1.08.03 49 350 0.000 0.0014 0.00 9.89E-01 
HLA.DRB1.08.04 49 350 0.000 0.0043 0.00 9.87E-01 
HLA.DRB1.09.01 49 350 0.010 0.0071 1.44 7.43E-01 
HLA.DRB1.10.01 49 350 0.000 0.0129 0.00 9.85E-01 
HLA.DRB1.11.01 49 350 0.041 0.0486 0.83 7.37E-01 
HLA.DRB1.11.02 49 350 0.000 0.0029 0.00 9.89E-01 
HLA.DRB1.11.03 49 350 0.000 0.0043 0.00 9.87E-01 
HLA.DRB1.11.04 49 350 0.061 0.0229 2.91 3.44E-02 
HLA.DRB1.12.01 49 350 0.020 0.0214 0.96 9.50E-01 
HLA.DRB1.13.01 49 350 0.041 0.0543 0.74 5.76E-01 
HLA.DRB1.13.02 49 350 0.031 0.0400 0.75 6.47E-01 
HLA.DRB1.13.03 49 350 0.000 0.0100 0.00 9.87E-01 
HLA.DRB1.13.04 49 350 0.000 0.0014 0.00 9.89E-01 
HLA.DRB1.13.05 49 350 0.000 0.0014 0.00 9.89E-01 
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HLA in EA 
N 
Cases
N 
Controls 
Cases 
MAF 
Controls 
MAF 
Odd’s 
Ratio P-Value 
HLA.DRB1.14.01 49 350 0.010 0.0357 0.29 2.22E-01 
HLA.DRB1.15.01 49 350 0.051 0.1314 0.39 3.85E-02 
HLA.DRB1.15.02 49 350 0.020 0.0029 7.40 4.79E-02 
HLA.DRB1.16.01 49 350 0.000 0.0114 0.00 9.86E-01 
HLA.DRB1.16.02 49 350 0.020 0.0014 14.85 2.89E-02 
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Table A.7 Association of HLA with Idiopathic Membranous Nephropathy in Asians 
HLA in Asians 
N 
Cases
N 
Controls 
Cases 
MAF 
Controls 
MAF 
Odds 
Ratio P-Value 
HLA.A.01.01 12 392 0.083 0.0153 6.33 2.58E-02 
HLA.A.02.01 12 392 0.083 0.1518 0.51 3.63E-01 
HLA.A.02.03 12 392 0.083 0.0548 1.62 5.40E-01 
HLA.A.02.05 12 392 0.000 0.0013 0.00 9.93E-01 
HLA.A.02.06 12 392 0.083 0.0166 5.83 3.24E-02 
HLA.A.02.07 12 392 0.083 0.0638 1.37 6.91E-01 
HLA.A.02.10 12 392 0.000 0.0026 0.00 9.94E-01 
HLA.A.03.01 12 392 0.000 0.0128 0.00 9.91E-01 
HLA.A.03.02 12 392 0.042 0.0026 17.73 2.27E-02 
HLA.A.11.01 12 392 0.083 0.2551 0.29 9.09E-02 
HLA.A.11.02 12 392 0.042 0.0191 2.28 4.43E-01 
HLA.A.24.02 12 392 0.083 0.1888 0.41 2.25E-01 
HLA.A.24.03 12 392 0.000 0.0013 0.00 9.93E-01 
HLA.A.24.04 12 392 0.000 0.0026 0.00 9.94E-01 
HLA.A.24.07 12 392 0.000 0.0051 0.00 9.91E-01 
HLA.A.24.08 12 392 0.000 0.0013 0.00 9.93E-01 
HLA.A.24.10 12 392 0.000 0.0013 0.00 9.93E-01 
HLA.A.26.01 12 392 0.042 0.0293 1.46 7.23E-01 
HLA.A.26.02 12 392 0.000 0.0026 0.00 9.94E-01 
HLA.A.26.03 12 392 0.000 0.0077 0.00 9.93E-01 
HLA.A.29.01 12 392 0.000 0.0128 0.00 9.91E-01 
HLA.A.30.01 12 392 0.042 0.0166 2.65 3.68E-01 
HLA.A.30.04 12 392 0.000 0.0013 0.00 9.93E-01 
HLA.A.31.01 12 392 0.042 0.0689 0.57 5.93E-01 
HLA.A.32.01 12 392 0.000 0.0026 0.00 9.94E-01 
HLA.A.33.03 12 392 0.167 0.0510 4.40 1.96E-02 
HLA.A.34.01 12 392 0.000 0.0026 0.00 9.94E-01 
HLA.A.68.01 12 392 0.042 0.0064 7.04 8.62E-02 
HLA.A.74.01 12 392 0.000 0.0026 0.00 9.94E-01 
HLA.B.07.02 12 392 0.083 0.0548 1.41 5.98E-01 
HLA.B.07.05 12 392 0.000 0.0140 0.00 9.90E-01 
HLA.B.08.01 12 392 0.000 0.0051 0.00 9.91E-01 
HLA.B.13.01 12 392 0.000 0.0332 0.00 9.90E-01 
HLA.B.13.02 12 392 0.042 0.0446 0.94 9.48E-01 
HLA.B.14.01 12 392 0.000 0.0013 0.00 9.93E-01 
HLA.B.15.01 12 392 0.083 0.1837 0.36 1.88E-01 
HLA.B.15.02 12 392 0.042 0.0357 1.18 8.75E-01 
HLA.B.15.07 12 392 0.000 0.0013 0.00 9.93E-01 
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HLA in Asians 
N 
Cases
N 
Controls 
Cases 
MAF 
Controls 
MAF 
Odds 
Ratio P-Value 
HLA.B.15.11 12 392 0.000 0.0077 0.00 9.93E-01 
HLA.B.15.12 12 392 0.000 0.0026 0.00 9.94E-01 
HLA.B.15.13 12 392 0.000 0.0013 0.00 9.93E-01 
HLA.B.15.17 12 392 0.000 0.0013 0.00 9.93E-01 
HLA.B.15.18 12 392 0.000 0.0064 0.00 9.94E-01 
HLA.B.15.25 12 392 0.000 0.0077 0.00 9.93E-01 
HLA.B.18.01 12 392 0.042 0.0102 4.36 1.82E-01 
HLA.B.27.04 12 392 0.042 0.0140 3.15 2.92E-01 
HLA.B.27.05 12 392 0.000 0.0013 0.00 9.93E-01 
HLA.B.27.06 12 392 0.000 0.0038 0.00 9.92E-01 
HLA.B.35.01 12 392 0.083 0.0395 2.16 3.04E-01 
HLA.B.35.03 12 392 0.000 0.0064 0.00 9.94E-01 
HLA.B.35.05 12 392 0.000 0.0013 0.00 9.93E-01 
HLA.B.37.01 12 392 0.000 0.0064 0.00 9.94E-01 
HLA.B.38.01 12 392 0.000 0.0013 0.00 9.93E-01 
HLA.B.38.02 12 392 0.000 0.0383 0.00 9.90E-01 
HLA.B.39.01 12 392 0.042 0.0217 1.64 5.77E-01 
HLA.B.39.05 12 392 0.000 0.0013 0.00 9.93E-01 
HLA.B.40.01 12 392 0.083 0.0931 0.90 8.82E-01 
HLA.B.40.02 12 392 0.000 0.0191 0.00 9.93E-01 
HLA.B.40.06 12 392 0.000 0.0204 0.00 9.93E-01 
HLA.B.44.02 12 392 0.000 0.0128 0.00 9.91E-01 
HLA.B.44.03 12 392 0.042 0.0128 2.68 2.99E-01 
HLA.B.46.01 12 392 0.125 0.0319 4.89 2.29E-02 
HLA.B.48.01 12 392 0.042 0.0217 2.01 5.17E-01 
HLA.B.48.03 12 392 0.000 0.0013 0.00 9.93E-01 
HLA.B.51.01 12 392 0.000 0.0791 0.00 9.90E-01 
HLA.B.51.02 12 392 0.000 0.0038 0.00 9.92E-01 
HLA.B.52.01 12 392 0.000 0.0281 0.00 9.91E-01 
HLA.B.54.01 12 392 0.000 0.0255 0.00 9.92E-01 
HLA.B.55.02 12 392 0.083 0.0357 2.37 2.48E-01 
HLA.B.56.01 12 392 0.000 0.0026 0.00 9.94E-01 
HLA.B.56.04 12 392 0.042 0.0013 35.55 1.36E-02 
HLA.B.57.01 12 392 0.000 0.0077 0.00 9.93E-01 
HLA.B.58.01 12 392 0.125 0.0383 4.02 4.47E-02 
HLA.B.59.01 12 392 0.000 0.0064 0.00 9.94E-01 
HLA.B.67.01 12 392 0.000 0.0089 0.00 9.92E-01 
HLA.B.73.01 12 392 0.000 0.0013 0.00 9.93E-01 
HLA.B.81.01 12 392 0.000 0.0026 0.00 9.94E-01 
HLA.C.01.02 12 392 0.208 0.1964 1.08 8.85E-01 
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HLA in Asians 
N 
Cases
N 
Controls 
Cases 
MAF 
Controls 
MAF 
Odds 
Ratio P-Value 
HLA.C.01.03 12 392 0.000 0.0051 0.00 9.91E-01 
HLA.C.02.02 12 392 0.000 0.0013 0.00 9.93E-01 
HLA.C.03.02 12 392 0.083 0.0497 1.74 4.66E-01 
HLA.C.03.03 12 392 0.042 0.0638 0.62 6.53E-01 
HLA.C.03.04 12 392 0.042 0.1378 0.28 2.17E-01 
HLA.C.04.01 12 392 0.083 0.0370 2.50 2.50E-01 
HLA.C.04.03 12 392 0.000 0.0179 0.00 9.93E-01 
HLA.C.04.06 12 392 0.000 0.0026 0.00 9.94E-01 
HLA.C.05.01 12 392 0.000 0.0026 0.00 9.94E-01 
HLA.C.06.02 12 392 0.042 0.0306 1.35 7.65E-01 
HLA.C.07.01 12 392 0.000 0.0064 0.00 9.94E-01 
HLA.C.07.02 12 392 0.167 0.1696 0.98 9.70E-01 
HLA.C.07.04 12 392 0.000 0.0089 0.00 9.92E-01 
HLA.C.08.01 12 392 0.083 0.0906 0.91 9.04E-01 
HLA.C.08.02 12 392 0.000 0.0013 0.00 9.93E-01 
HLA.C.08.03 12 392 0.042 0.0077 5.85 1.16E-01 
HLA.C.12.02 12 392 0.042 0.0485 0.85 8.79E-01 
HLA.C.12.03 12 392 0.083 0.0128 7.64 1.53E-02 
HLA.C.14.02 12 392 0.042 0.0561 0.73 7.61E-01 
HLA.C.14.03 12 392 0.000 0.0140 0.00 9.91E-01 
HLA.C.15.02 12 392 0.042 0.0230 1.89 5.53E-01 
HLA.C.15.05 12 392 0.000 0.0153 0.00 9.90E-01 
HLA.C.16.01 12 392 0.000 0.0013 0.00 9.93E-01 
HLA.DQA1.01.01 12 392 0.208 0.1390 1.85 3.00E-01 
HLA.DQA1.01.02 12 392 0.125 0.1926 0.57 3.85E-01 
HLA.DQA1.01.03 12 392 0.042 0.1135 0.32 2.76E-01 
HLA.DQA1.02.01 12 392 0.083 0.0395 2.33 2.89E-01 
HLA.DQA1.03.01 12 392 0.000 0.0791 0.00 9.90E-01 
HLA.DQA1.03.03 12 392 0.083 0.2003 0.30 1.23E-01 
HLA.DQA1.04.01 12 392 0.000 0.0153 0.00 9.90E-01 
HLA.DQA1.05.01 12 392 0.208 0.0574 5.51 4.91E-03 
HLA.DQA1.05.05 12 392 0.125 0.0638 2.17 2.37E-01 
HLA.DQA1.06.01 12 392 0.125 0.0995 1.28 6.87E-01 
HLA.DQB1.02.01 12 392 0.208 0.0612 5.12 7.00E-03 
HLA.DQB1.03.01 12 392 0.333 0.1926 1.93 1.14E-01 
HLA.DQB1.03.02 12 392 0.042 0.0599 0.71 7.25E-01 
HLA.DQB1.03.03 12 392 0.042 0.1824 0.19 1.06E-01 
HLA.DQB1.03.05 12 392 0.000 0.0153 0.00 9.90E-01 
HLA.DQB1.04.01 12 392 0.000 0.0357 0.00 9.90E-01 
HLA.DQB1.04.02 12 392 0.000 0.0051 0.00 9.91E-01 
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HLA in Asians 
N 
Cases
N 
Controls 
Cases 
MAF 
Controls 
MAF 
Odds 
Ratio P-Value 
HLA.DQB1.05.01 12 392 0.042 0.0867 0.45 4.41E-01 
HLA.DQB1.05.02 12 392 0.000 0.0587 0.00 9.92E-01 
HLA.DQB1.05.03 12 392 0.167 0.0855 2.32 1.64E-01 
HLA.DQB1.06.01 12 392 0.000 0.1339 0.00 9.92E-01 
HLA.DQB1.06.02 12 392 0.125 0.0523 2.48 1.45E-01 
HLA.DQB1.06.03 12 392 0.042 0.0064 7.04 8.62E-02 
HLA.DQB1.06.04 12 392 0.000 0.0013 0.00 9.93E-01 
HLA.DQB1.06.09 12 392 0.000 0.0230 0.00 9.92E-01 
HLA.DRB1.01.01 12 392 0.000 0.0179 0.00 9.93E-01 
HLA.DRB1.01.02 12 392 0.000 0.0013 0.00 9.93E-01 
HLA.DRB1.03.01 12 392 0.125 0.0332 4.69 2.65E-02 
HLA.DRB1.04.01 12 392 0.000 0.0013 0.00 9.93E-01 
HLA.DRB1.04.03 12 392 0.000 0.0727 0.00 9.91E-01 
HLA.DRB1.04.05 12 392 0.042 0.0421 0.99 9.92E-01 
HLA.DRB1.04.06 12 392 0.000 0.0166 0.00 9.90E-01 
HLA.DRB1.07.01 12 392 0.083 0.0395 2.16 3.04E-01 
HLA.DRB1.08.02 12 392 0.000 0.0064 0.00 9.94E-01 
HLA.DRB1.08.03 12 392 0.000 0.0906 0.00 9.90E-01 
HLA.DRB1.09.01 12 392 0.042 0.1467 0.24 1.67E-01 
HLA.DRB1.10.01 12 392 0.000 0.0217 0.00 9.92E-01 
HLA.DRB1.11.01 12 392 0.167 0.0548 3.09 3.81E-02 
HLA.DRB1.11.04 12 392 0.042 0.0013 35.55 1.36E-02 
HLA.DRB1.11.06 12 392 0.000 0.0013 0.00 9.93E-01 
HLA.DRB1.12.01 12 392 0.125 0.0625 2.21 2.25E-01 
HLA.DRB1.12.02 12 392 0.000 0.0421 0.00 9.89E-01 
HLA.DRB1.13.01 12 392 0.042 0.0051 8.82 6.04E-02 
HLA.DRB1.13.02 12 392 0.000 0.0268 0.00 9.91E-01 
HLA.DRB1.13.12 12 392 0.000 0.0077 0.00 9.93E-01 
HLA.DRB1.14.01 12 392 0.083 0.0357 2.60 2.32E-01 
HLA.DRB1.14.03 12 392 0.000 0.0077 0.00 9.93E-01 
HLA.DRB1.14.04 12 392 0.000 0.0102 0.00 9.92E-01 
HLA.DRB1.14.05 12 392 0.042 0.0319 1.30 7.94E-01 
HLA.DRB1.14.06 12 392 0.000 0.0013 0.00 9.93E-01 
HLA.DRB1.14.07 12 392 0.042 0.0000 
20518751
2.81 9.90E-01 
HLA.DRB1.15.01 12 392 0.125 0.0957 1.34 6.39E-01 
HLA.DRB1.15.02 12 392 0.042 0.0753 0.55 5.55E-01 
HLA.DRB1.15.07 12 392 0.000 0.0102 0.00 9.92E-01 
HLA.DRB1.16.02 12 392 0.000 0.0408 0.00 9.90E-01 
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A5 Source Code Listing for HLA-Genotyper Software 
 
            # Author: John J. Farrell <john.joseph.farrell@gmail.com>.    
1. # program: hla_genotyper.py    
2. # purpose: Predicts 4 digit HLA genotype from next gen sequencing data    
3. # Copyright 2014    
4. # John J. Farrell     
5. # All rights reserved    
6. import os    
7. import sys    
8. import math    
9. import pysam    
10. import sys    
11. import hla    
12. import numpy    
13. import csv    
14. from Bio import SeqIO    
15. from Bio.Seq import Seq    
16. from Bio.Alphabet import IUPAC    
17. from Bio.SeqFeature import SeqFeature, FeatureLocation    
18. from optparse import OptionParser    
19. # utility functions    
20. def good_bq(read,cutoff):    
21.     for b in read:    
22.         if ord(b)-33 < cutoff:    
23.            return  False   
24.     return True   
25.    
26. def doses():    
27.     hla_name=[]    
28.     hla_dose=[]    
29.     for g in hla_genes_to_call:    
30.         hla_call=final[g]    
31.         for h in sorted(hla_want):    
32.            [hla_gene, hla_allele_type]=h.split("*",1)         
33.            if hla_gene==g:    
34.                hla_name.append(h)    
35.     for g in hla_genes_to_call:    
36.         hla_call=final[g]    
37.         [h1,h2]=hla_call    
38.         for h in sorted(hla_want):    
39.             [hla_gene, hla_allele_type]=h.split("*",1)    
40.             if hla_gene==g:    
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41.                 hla_dose.append(dose(h,h1,h2))    
42.     return hla_name,hla_dose    
43.         
44. def dose(h,h1,h2):    
45.     d=0   
46.     if h==h1:    
47.         d+=1   
48.     if h==h2:    
49.         d+=1   
50.     return d    
51. def read_length(filename):    
52. #    
53. # determine read length of bam files reads (Take max of first 200 records)    
54. #    
55.     mylength=0   
56.     bamfile=pysam.Samfile(filename,'rb')    
57.     n = 0   
58.     for alignedread in bamfile.fetch(until_eof = True):    
59.               mylength = max(alignedread.rlen,mylength)    
60.               n = n+1   
61.               if n > 200:    
62.                   break   
63.     bamfile.close()    
64.     return mylength    
65.    
66. def is_hg_ref(filename):    
67. #    
68. # determine read length of bam files reads (Take max of first 200 records)    
69. #    
70.     mylength=0   
71.     bamfile=pysam.Samfile(filename,'rb')    
72.     n = 0   
73.     for alignedread in bamfile.fetch(until_eof = True):    
74.               n+=1   
75.               tid=alignedread.tid    
76.               chr=bamfile.getrname(tid)    
77.               if n > 20:    
78.                   break   
79.     hg=False   
80.     if chr[0:3]=="chr":    
81.         hg=True   
82.     bamfile.close()    
83.     return hg    
84.    
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85. def SM(filename):    
86. # get sample id from bam file    
87.     bamfile=pysam.Samfile(filename,'rb')    
88.     header=bamfile.header.copy()    
89.     print header["RG"]    
90.     sm_id= header["RG"][0]["SM"]    
91.     bamfile.close()    
92.     return sm_id     
93.    
94. def CN(filename):    
95. # get Center id from bam file    
96. # get Center id from bam file (1000 Genomes Center use different Exome Kits)    
97.     bamfile=pysam.Samfile(filename,'rb')    
98.     header=bamfile.header.copy()    
99. #    print header["RG"]    
100.     cn_id= header["RG"][0].get("CN","NA")    
101.     bamfile.close()    
102.     return cn_id    
103.    
104.                                                                                                                         
        
105. def containsAny(str, set):    
106.     """Check whether 'str' contains ANY of the chars in 'set'"""   
107.     return 1 in [c in str for c in set]    
108.    
109. class AutoVivification(dict):    
110.       """Implementation of perl's autovivification feature."""   
111.       def __getitem__(self, item):    
112.         try:    
113.               return dict.__getitem__(self, item)    
114.         except KeyError:    
115.               value = self[item] = type(self)()    
116.               return value    
117.    
118.    
119. #low_quality="!\"#$%&'"    
120. low_quality='!\"\#$%&\'()*+,-./'   
121. desc="""This is a description of %prog.  
This program predicts HLA alleles from next-gen sequencing data"""   
122. parser = OptionParser(description=desc)    
123. parser.add_option("-b", "--
bam", action="store", type="string", dest="bamfile")    
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124. parser.add_option("-u", "--
unmapped_bam", action="store", type="string", default="None",dest="unmapped
_bamfile")    
125. parser.add_option("-l", "--
len", action="store", type="int", dest="readlen", default=0)    
126. parser.add_option("-m", "--
mapq", action="store", type="int", dest="mapq",default=30)    
127. parser.add_option("--
qual", action="store", type="int", dest="bq",default=20)    
128. # parser.add_option("-v", "--
verbose", action="store_true", dest="verbose")    
129. parser.add_option("--debug", action="store_true", dest="debug")    
130. parser.add_option("--rnaseq", action="store_true", dest="rnaseq")    
131. parser.add_option("--exome", action="store_true", dest="exome")    
132. parser.add_option("--genome", action="store_true", dest="genome")    
133. parser.add_option("-s", "--
sample", action="store", type="string", dest="sample",default="None")    
134. parser.add_option("--
cn", action="store", type="string", dest="cn",default="None")    
135. parser.add_option("-g", "--
gene", action="store", dest="gene",default="all")    
136. parser.add_option("-e", "--ethnicity", action="store", dest="ethnicity")    
137. (options, args) = parser.parse_args()    
138. print "Sample=",options.sample    
139.    
140. if options.sample=="None":    
141.   study_id=SM(options.bamfile)    
142. else:    
143.   study_id=options.sample    
144.    
145. if options.cn == "None":    
146.     cn_id=CN(options.bamfile)    
147. else:    
148.     cn_id=options.cn    
149. print "Sequencing Center=",cn_id    
150. # open log and output files    
151. if options.rnaseq:    
152.     prefix="hla."+options.ethnicity+"."+study_id+".rnaseq"   
153. elif options.exome:    
154.     prefix="hla."+options.ethnicity+"."+study_id+".exome"   
155. elif options.genome:    
156.     prefix="hla."+options.ethnicity+"."+study_id+".genome"   
157. else:    
158.     prefix="hla."+options.ethnicity+"."+study_id    
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159.    
160.    
161. fout=open(prefix+".txt", "w")    
162. flog=open(prefix+".log", "w")    
163. fdose=open(prefix+".dose", "w")    
164. print >>flog,"Sample=",study_id    
165. print >>flog,"BAM input file to Scan (mapped reads)  :",options.bamfile  
  
166. print >>flog,"BAM input file to Scan (unmapped reads):",options.unmapp
ed_bamfile    
167. print >>flog,"Ethnicity:",options.ethnicity    
168. print >>flog,"Base Quality Cutoff:",options.bq    
169.    
170. chr6="6"   
171. if is_hg_ref(options.bamfile):    
172.   chr6="chr6"      
173.    
174. hla_prior=hla.freq(ethnicity=options.ethnicity,gene=options.gene)    
175. if options.gene=="all":    
176.   hla_genes_to_call=hla.loci(options.ethnicity,gene=options.gene)    
177. else:    
178.   hla_genes_to_call=["HLA-"+options.gene]    
179. print >>flog,"HLA Loci to call: ", hla_genes_to_call    
180. want_exons={}    
181. for g in hla_genes_to_call:    
182.     want_exons[g]=hla.typing_exons(g)    
183.     print >>flog,"Exons read for genotyping ",g,": ",want_exons[g]    
184. # want_exons=hla.typing_exons("HLA-"+options.gene)    
185.    
186.    
187.    
188.    
189.    
190. # print "SM:",SM(options.bamfile)    
191. #     
192. basename=os.path.basename(options.bamfile)    
193. print "Opening",options.bamfile,basename    
194.    
195. if options.readlen==0:    
196.     options.readlen=read_length(options.bamfile)    
197. print >>flog,"Read lengths:",options.readlen    
198. read_len=options.readlen    
199. # print >>flog,"Verbose setting:",options.verbose    
200. this_dir, this_filename = os.path.split(__file__)    
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201. HLA_DATA = os.path.join(this_dir,  "hla.dat")    
202. print >>flog,"IMGT Database=",HLA_DATA    
203.    
204. # init variables    
205. hla_want=hla_prior.keys()    
206. hla_total={}    
207. n_hla_alleles=0;    
208. n_hla_reads=0;    
209. hla_read = AutoVivification()    
210. print "Reading HLA.dat database"   
211. # read in hla database and create hash of all possible reads whose length m
atch bam file    
212. for seq_record in SeqIO.parse(HLA_DATA, "imgt"):    
213. # parse hla info from record description    
214. #  print  seq_record.description    
215.   if "HLA" in str(seq_record.description) :    
216.      [hla_allele, mhc_region] = seq_record.description.split(", ",1)    
217.      [hla_gene, hla_allele_type]=hla_allele.split("*",1)    
218. #    not all alleles are 4 digit NN:NN some are NN:NNN    
219.      hv=hla_allele_type.split(":")    
220.      hla_4digit=hla_gene+"*"+hv[0]+":"+hv[1]    
221. #     print hla_4digit    
222.      if (hla_4digit in hla_want):    
223. #     if hla_gene in ["HLA-A","HLA-B","HLA-C","HLA-DRB1","HLA-
DQA1","HLA-DQB1"]:    
224.         n_hla_alleles +=1   
225.         hla_total[hla_4digit]=hla_total.get(hla_4digit,0)+1   
226. #    
227. # For rna-seq, the exons are spliced together.    
228. #    
229.         if options.rnaseq:    
230.           exons = [f for f in seq_record.features if f.type == "exon"]    
231.           exon_seq=""    
232. # splice exons together and then split into potential reads    
233.           last_position=0   
234.           for e in exons :    
235.             if e.qualifiers["number"][0] in want_exons[hla_gene]:    
236. # splice exons together depending on whether on positive or negative stran
d                    
237.                if  e.location.start.position >last_position:    
238.                     exon_seq=exon_seq+str(seq_record.seq[e.location.start.positi
on : e.location.end.position])    
239.                else:    
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240.                     exon_seq=str(seq_record.seq[e.location.start.position : e.locat
ion.end.position])+exon_seq    
241.                last_position=e.location.start.position    
242.           for i in range(0,len(exon_seq)-read_len+1):    
243.                  myread=exon_seq[i:i+read_len]    
244. #                 if hla_4digit == "HLA-B*50:01" :    
245. #                     print "debug e=",e.qualifiers["number"][0],i,i+read_len,str(s
eq_record.description),hla_allele,hla_4digit,myread    
246. #                 hla_read[myread][hla_4digit]=hla_read[myread].get(hla_4digi
t,0)+1    
247.                  hla_read[myread][hla_4digit]=1   
248.                  n_hla_reads += 1   
249.         else:    
250. # loop through exon  sequences used to predict HLA reads    
251.           exons = [f for f in seq_record.features if f.type == "exon"]    
252.           introns = [f for f in seq_record.features if f.type == "intron"]    
253.           extra=0   
254.           if  hla_gene in ["HLA-C","HLA-DQA1","HLA-DQB1","HLA-
DRB1"] and len(introns) >2 :    
255.               extra=50   
256. #              print "intron len",hla_gene,len(introns),len(exons)    
257.           for e in exons :    
258.             if e.qualifiers["number"][0] in want_exons[hla_gene]:    
259.                exon_seq=seq_record.seq[e.location.start.position-
extra: e.location.end.position+extra]    
260.                for i in range(0,len(exon_seq)-read_len+1):    
261.                  myread=str(exon_seq[i:i+read_len])    
262. #                 if hla_4digit == "HLA-C*03:03" :    
263. #                     print "debug e=",e.qualifiers["number"][0],i,i+read_len,str(s
eq_record.description),hla_allele,hla_4digit,myread    
264. #                 else:    
265. #                     print "debug 4d:",hla_4digit    
266. #                 hla_read[myread][hla_4digit]=hla_read[myread].get(hla_4digi
t,0)+1    
267.                  hla_read[myread][hla_4digit]=1   
268.                  n_hla_reads += 1   
269.    
270. #                 for k,v in hla_read.iteritems():    
271. #                   print k,v    
272.    
273.                                                    
274. print >>flog,"Number of HLA Alleles=",n_hla_alleles    
275. print >>flog,"Number of 4 Digit HLA Alleles=",len(hla_total)    
276. print >>flog,"Number of HLA Reads=",n_hla_reads    
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277. print >>flog,"N unique Reads=",len(hla_read)    
278. print >>flog,"-"*80   
279. print >>flog,"Scanning Mapped Reads"   
280. # Read sequences from bam file    
281. import pysam    
282. bamfile=pysam.Samfile(options.bamfile,'rb')    
283. # init variables    
284. bam_hla_reads=[]    
285. mapped_read_total= AutoVivification()    
286. unmapped_read_total= AutoVivification()    
287. bam_hla_allele_set=set([])    
288.    
289. # start scanning Mapped Reads looking for exact reads found in  exons of 
specified HLA Genes    
290. print "Scanning mapped reads"   
291. gene_read_total={}    
292. for g in hla_genes_to_call:    
293.  gene_read_total[g]=0   
294.  for exon_number in want_exons[g]:    
295.   [start,stop]=hla.exon_region(g,exon_number)    
296.   print >>flog,"Scanning mapped reads for exon ",exon_number," gene:",
g," start:",start," stop:",stop,    
297.   exon_reads=0   
298.   for alignedread in bamfile.fetch(chr6,start,stop) :    
299.    my_seq = Seq(alignedread.seq, IUPAC.unambiguous_dna)    
300. # for archaic genomes-trim to some standard length    
301.    my_seq =my_seq[0:read_len]    
302. #  filtering out reads with very poor quality     
303. #  many filtered since they are not an exact match    
304. #   if not containsAny(str(alignedread.qual),low_quality):    
305. # test nea    
306.    if good_bq(str(alignedread.qual),options.bq) and  alignedread.mapq >op
tions.mapq and not alignedread.is_duplicate and not alignedread.is_unmapped :  
  
307.      if str(my_seq) in hla_read:    
308.         if hla.n_hla_genes(hla_read[str(my_seq)])==1:    
309.             if options.debug: # and len(hla_read(str(my_seq))) ==1:    
310.                   print "my seq ", str(my_seq), "gene info",hla.n_hla_genes(hla_
read[str(my_seq)]),"qual=",alignedread.qual,"Alleles=",hla_read[str(my_seq)]    
311.             exon_reads+=1     
312.             bam_hla_reads.append(str(my_seq))    
313.             read_hla_alleles=hla_read.get(str(my_seq))                
314.             bam_hla_allele_set= bam_hla_allele_set|set(read_hla_alleles)    
315.                 
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316.             for a in read_hla_alleles:    
317.               mapped_read_total[a]=mapped_read_total.get(a,0)+1   
318.      reverse_comp=str(my_seq.reverse_complement())    
319. #      print "my seqr", reverse_comp, "gene info",hla.n_hla_genes(hla_read
[str(my_seq)]),hla_read[str(reverse_comp)]          
320.      if reverse_comp in hla_read:    
321.         if hla.n_hla_genes(hla_read[reverse_comp])==1:    
322.             if options.debug: # and  len(hla_read(reverse_comp)) ==1:    
323.                   print "my seqr", reverse_comp, "gene info",hla.n_hla_genes(hl
a_read[reverse_comp]),"qual=",alignedread.qual,"Alleles=",hla_read[reverse_co
mp]    
324.             exon_reads+=1     
325.             bam_hla_reads.append(reverse_comp)    
326.             read_hla_alleles=hla_read.get(reverse_comp)    
327.             bam_hla_allele_set= bam_hla_allele_set|set(read_hla_alleles)    
328.             for a in read_hla_alleles:    
329.               mapped_read_total[a]=mapped_read_total.get(a,0)+1   
330.   print >>flog,"N mapped reads=",exon_reads    
331.   gene_read_total[g]= gene_read_total[g]+exon_reads    
332. bamfile.close()    
333. bam_hla_reads_set=set(bam_hla_reads)    
334. mapped_reads=len(bam_hla_reads_set)    
335.    
336. if options.unmapped_bamfile=="None":    
337.   print "Skipping unmapped read scan"   
338. else:    
339.    
340. # Now scan through all unmapped reads    
341. # Finds exact match to known HLA gene exon region    
342.  unmapped_bamfile=pysam.Samfile(options.unmapped_bamfile,'rb')    
343.  print "Scanning unmapped reads"   
344.  for alignedread in unmapped_bamfile.fetch(until_eof = True) :    
345. #  if not "#" in str(alignedread.qual):    
346.   my_seq = Seq(alignedread.seq, IUPAC.unambiguous_dna)    
347.   my_seq =my_seq[0:read_len]    
348.   if good_bq(str(alignedread.qual),options.bq) and not alignedread.is_dupl
icate and alignedread.is_unmapped:    
349.           
350. #      print "my seq ", str(my_seq)    
351.       reverse_comp=str(my_seq.reverse_complement())    
352.       if str(my_seq) in hla_read:    
353.          if hla.n_hla_genes(hla_read[str(my_seq)])==1:    
354.             if options.debug:    
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355.                   print "my seq ", str(my_seq), "gene info",hla.n_hla_genes(hla_
read[str(my_seq)]),"qual=",alignedread.qual,hla_read[str(my_seq)]    
356.             bam_hla_reads.append(str(my_seq))    
357.             read_hla_alleles=hla_read.get(str(my_seq))    
358.             bam_hla_allele_set= bam_hla_allele_set|set(read_hla_alleles)    
359.             for a in read_hla_alleles:    
360.               unmapped_read_total[a]=unmapped_read_total.get(a,0)+1   
361.               g=hla.hla_gene(a)    
362.             gene_read_total[g]= gene_read_total[g]+1   
363.       if reverse_comp in hla_read:    
364.         if hla.n_hla_genes(hla_read[reverse_comp])==1:    
365.             if options.debug:    
366.                   print "my seqr", reverse_comp, "gene info",hla.n_hla_genes(hl
a_read[reverse_comp]),"qual=",alignedread.qual,hla_read[reverse_comp]    
367.             bam_hla_reads.append(reverse_comp)    
368.             read_hla_alleles=hla_read.get(reverse_comp)    
369.             bam_hla_allele_set= bam_hla_allele_set|set(read_hla_alleles)    
370.             for a in read_hla_alleles:    
371.               unmapped_read_total[a]=unmapped_read_total.get(a,0)+1   
372.               g=hla.hla_gene(a)    
373.             gene_read_total[g]= gene_read_total[g]+1   
374.  unmapped_bamfile.close()    
375.    
376. bam_hla_reads_set=set(bam_hla_reads)    
377. unmapped_reads=len(bam_hla_reads_set)-mapped_reads    
378. print >>flog,"-"*80   
379. print >>flog,"Total Read Summary"   
380. print >>flog,"HLA Genes to Call:",hla_genes_to_call    
381. print >>flog,"Total Exact match reads from HLA Genes:",len(bam_hla_re
ads)    
382. print >>flog,"Unique Exact match reads from HLA Genes",len(bam_hla_
reads_set)    
383. print >>flog,"Reads mapped to "+ str(len(bam_hla_allele_set))+" HLA Al
leles"   
384. # print >>flog,"bam_hla_allele_set:",bam_hla_allele_set    
385.    
386. hla_genotypes=[]    
387. hla_prob = AutoVivification()    
388. #   print hla_read[r]    
389. final={}    
390. print >>flog,"-"*80   
391. print >>flog,"HLA Genotyping Results"   
392. print >>flog,"#bam file","sample","ethnicity","gene","a1","a2","pval","qu
al","a1 mr","a1 ur","a2 mr","a2 ur","a1+a2","exon reads"   
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393. min_prob=0.01   
394. total_g_reads={}    
395. total_h_reads={}    
396. allele_list={}    
397. for g in hla_genes_to_call:    
398.      allele_list[g]=[]    
399.      total_g_reads[g]=0   
400.      bam_gene_alleles=hla.alleles_in_gene(bam_hla_allele_set,g)    
401.      for h in sorted(bam_gene_alleles):    
402.          total_g_reads[g]=total_g_reads[g]+mapped_read_total.get(h,0)+unm
apped_read_total.get(h,0)    
403.          total_h_reads[h]=mapped_read_total.get(h,0)+unmapped_read_total.
get(h,0)    
404.      max_freq=0.0   
405.      for h in sorted(bam_gene_alleles):    
406.             freq=float(total_h_reads[h])/float(total_g_reads[g])    
407.             if  freq >max_freq:    
408.                 max_freq=freq    
409.      for h in sorted(bam_gene_alleles):    
410.             freq=float(total_h_reads[h])/float(total_g_reads[g])    
411.             if  freq > (max_freq/5.0):          
412.                 allele_list[g]=allele_list[g]+[h]    
413.             else:    
414.                 if options.debug:    
415.                        print "Dropping allele",g,h,total_h_reads[h],total_g_reads[
g],"percent",float(total_h_reads[h])/float(total_g_reads[g])    
416.          
417. #     print allele_list[g]         
418. for g in hla_genes_to_call:    
419.  n=0   
420. # bam_gene_alleles=hla.alleles_in_gene(bam_hla_allele_set,g)    
421.  bam_gene_alleles=allele_list[g]    
422.  print "Calculating Probabilities for",g,"Genotype Calls"   
423.  for h1 in sorted(bam_gene_alleles):    
424.    for h2 in sorted(bam_gene_alleles):    
425.       if (h1 <= h2):    
426.         n=n+1   
427. #        prior_val=math.log(1-((1-hla_prior[h1])*(1-hla_prior[h2])))    
428.         prior_val=math.log(hla_prior[h1]*hla_prior[h2])    
429. #        hla_prob[h1][h2]=prior_val    
430.         for r  in  bam_hla_reads_set:    
431.              num_hits=float(len(hla.alleles_in_gene(hla_read[r],g)))    
432.              if num_hits > 0:    
433.                 p=(hla_read[r].get(h1,0))/(num_hits)    
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434.                 q=(hla_read[r].get(h2,0))/(num_hits)    
435. # Other approaches    
436. #                genotype_prob=p*q    
437. #                genotype_prob=max(p,q)    
438.                 genotype_prob=1-((1-p)*(1-q))    
439.                 genotype_prob=max([genotype_prob,min_prob])    
440.                 hla_prob[h1][h2]=hla_prob[h1].get(h2,prior_val)+numpy.log(ge
notype_prob)       
441. #             else:    
442. #                genotype_prob=min_prob    
443. #                hla_prob[h1][h2]=hla_prob[h1].get(h2,prior_val)+numpy.log(g
enotype_prob)       
444. #                genotype_prob=(1/100)*(1/100)    
445.                  
446. #                hla_prob[h1][h2]=hla_prob[h1].get(h2,prior_val)+numpy.log(g
enotype_prob)     
447. # print >>flog,g,"Genotypes probablities examined:",n    
448.    
449. # find maximum genotype likelihood    
450.  max_prob=-99999   
451.  hla_call=["NA","NA"]    
452.    
453.  total_prob=-99999;    
454.  for h1 in sorted(bam_gene_alleles):    
455.    for h2 in sorted(bam_gene_alleles):    
456.             if ((h1 <= h2) and (hla_prob[h1][h2] >max_prob)):    
457.                   max_prob=hla_prob[h1][h2]    
458.                   hla_call=[h1,h2]    
459.             if (h1 <= h2):    
460.                   total_prob=numpy.logaddexp(total_prob,hla_prob[h1][h2])    
461. #                  print h1,h2,hla_prob[h1][h2],total_prob    
462. # Printing Results to log file and hla results file    
463.  h1= hla_call[0]    
464.  h2= hla_call[1]    
465.  total_reads=mapped_read_total.get(h1,0)+unmapped_read_total.get(h1,0)
+mapped_read_total.get(h2,0)+unmapped_read_total.get(h2,0)    
466.  delta=max_prob-total_prob    
467.  pval=numpy.exp(delta)    
468.    
469.  qc="Pass"   
470.  if  pval < 0.66:    
471.     qc="Ambiguous"   
472.  if gene_read_total[g] <10:    
473.     qc="Low Coverage"   
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474.     pval="NA"   
475.  print  >>flog,basename,study_id,options.ethnicity,g,h1,h2,str(pval)[0:4], 
qc,mapped_read_total.get(h1,0),unmapped_read_total.get(h1,0),mapped_read_tot
al.get(h2,0),unmapped_read_total.get(h2,0),total_reads,gene_read_total[g]    
476. # write out hla results    
477.  line=[cn_id,basename,study_id,options.ethnicity,g,h1,h2, str(pval)[0:4], q
c , mapped_read_total.get(h1,0),unmapped_read_total.get(h1,0),mapped_read_tot
al.get(h2,0),unmapped_read_total.get(h2,0),total_reads,gene_read_total[g]]    
478. # line=[basename,study_id,options.ethnicity,g,h1,h2, str(pval)[0:4], qc , m
apped_read_total.get(h1,0),unmapped_read_total.get(h1,0),mapped_read_total.get
(h2,0),unmapped_read_total.get(h2,0),total_reads,gene_read_total[g]]    
479.  out = csv.writer(fout, delimiter="\t")    
480.  out.writerow(line)    
481. # store final call      
482.  final[g]=hla_call    
483.    
484.    
485. # print detailed results to log    
486.  #   print >>flog,"Other Probabilities"    
487.  if pval < 0.80:    
488.    for h1 in sorted(bam_gene_alleles):    
489.       for h2 in sorted(bam_gene_alleles):    
490.            if h1 <= h2:    
491.                   pval_other=numpy.exp(hla_prob[h1][h2]-total_prob)    
492.                   if(pval_other > 0.05 and pval_other <pval):    
493.                       print  >>flog, basename,study_id,options.ethnicity,g, h1,h2  
, str(pval_other)[0:4], qc,mapped_read_total[h1],unmapped_read_total[h1],mappe
d_read_total[h2],unmapped_read_total[h2],total_reads,gene_read_total[g]    
494. # Print Ped file    
495.      
496.    
497. flog.close()    
498. fout.close()    
499. # print dose file    
500. header=["bam","id","ethnicity"]    
501. line=[basename,study_id,options.ethnicity]    
502. [names,values]=doses()    
503. header=header+names    
504. line=line+values    
505. out = csv.writer(fdose, delimiter="\t")    
506. out.writerow(header)    
507. out.writerow(line)    
508. fdose.close()    
509.    
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510. print "HLA Genotypes written to file:",prefix+".txt"   
511. print "HLA Run Log written to file:  ",prefix+".log"   
512. print "HLA Doses written to file:    ",prefix+".dose"   
513.        
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A6 Source Code Listing for Utility Functions for HLA-Genotyper 
 
1. # 
2. # Author: John J. Farrell <john.joseph.farrell@gmail.com>.    
3. # program: hla.py    
4. # purpose: Utility functions for managing HLA related data    
5. # Copyright 2014    
6. # John J. Farrell     
7. # All rights reserved    
8. import csv    
9. import operator    
10. def freq(ethnicity,gene):    
11.  prior={}    
12.  with open('ethnic_priors.txt', 'rb') as f:    
13.         reader = csv.DictReader(f, delimiter='\t', quoting=csv.QUOTE_NONE,fieldn
ames=["ethnicity","gene","allele","freq"])    
14.         for row in reader:    
15.      if(ethnicity == row["ethnicity"]):    
16. #                         print row["ethnicity"], row["gene"], row["allele"],row["freq"]    
17. #                  if float(row["freq"]) > 0.001:    
18.                          if gene == row["gene"] :    
19.                           prior[row["allele"]]=float(row["freq"])    
20.                          elif  gene=="all" :    
21.                           prior[row["allele"]]=float(row["freq"])    
22. #                          prior[hla_gene(row["allele"])][row["allele"]]=float(row["freq"]) 
   
23. #                          print  row["allele"],prior[row["allele"]]    
24.  f.close()    
25.  sorted_prior = sorted(prior.iteritems(), key=operator.itemgetter(0))    
26.  return prior    
27. def loci(ethnicity,gene):    
28.  hla_loci=set([])    
29.  with open('ethnic_priors.txt', 'rb') as f:    
30.         reader = csv.DictReader(f, delimiter='\t', quoting=csv.QUOTE_NONE,fieldn
ames=["ethnicity","gene","allele","freq"])    
31.         for row in reader:    
32.      if(ethnicity == row["ethnicity"]):    
33. #                  if float(row["freq"]) > 0.001:    
34.                            hla_loci=hla_loci|set([hla_gene(row["allele"])])    
35.  f.close()    
36.      
37.  return sorted(hla_loci)    
38.    
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39. def typing_exons(gene):    
40.     e={"HLA-DRB1": ["2"],    
41.        "HLA-DQA1": ["1","2","3","4"],    
42.        "HLA-DQB1": ["1","2","3","4"],    
43.        "HLA-A": ["1","2","3","4"],    
44.        "HLA-B": ["1","2","3","4"],    
45.        "HLA-C": ["1","2","3","4"]    
46.        }    
47.     return e[gene]    
48. def alleles_in_gene(alleles,want_gene):    
49.     hla_alleles=[]    
50.     for a in alleles:    
51.         allele_gene=hla_gene(a)    
52.         if  allele_gene==want_gene:    
53.             hla_alleles.append(a)    
54.     return sorted(hla_alleles)    
55. def exon_region(gene,exon):    
56.     start=0;    
57.     stop=0;    
58.     with open('exon_info.txt', 'rb') as f:    
59.          reader = csv.DictReader(f, delimiter='\t', quoting=csv.QUOTE_NONE,field
names=["gene","exon","chr","start","stop"])    
60.          for row in reader:    
61.              if gene == row["gene"]:    
62.                  if exon == row["exon"]:    
63. #                     region= [row["start"],row["stop"]]    
64.                      start= int(row["start"])    
65.                      stop=int(row["stop"])    
66.     f.close()    
67.     return start,stop    
68. def hla_gene(hla_allele):    
69.     [gene,allele_number]=hla_allele.split("*")    
70.     return gene    
71. def n_hla_genes(alleles):    
72.     gene_set=set([])    
73.     for a in alleles:    
74.         gene_set=gene_set|set([hla_gene(a)])    
75.     return len(gene_set)    
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Ngo, D., et al. (2013). "Fetal hemoglobin in sickle cell anemia: genetic studies of 
the Arab-Indian haplotype." Blood Cells Mol Dis 51(1): 22-26. 
 Sickle cell anemia is common in the Middle East and India where the HbS 
gene is sometimes associated  with the Arab-Indian (AI) beta-globin gene (HBB) cluster 
haplotype. In this haplotype of sickle cell anemia, fetal hemoglobin (HbF) levels are 3-4 
fold higher than those found in patients with HbS haplotypes of African origin. Little is 
known about the genetic elements that modulate HbF in AI haplotype patients. We 
therefore studied Saudi HbS homozygotes with the AI haplotype (mean HbF 19.2+/-
7.0%, range 3.6 to 39.6%) and employed targeted genotyping of polymorphic sites to 
explore cis- and trans- acting elements associated with high HbF expression. We also 
described sequences which appear to be unique to the AI haplotype for which future 
functional studies are needed to further define their role in HbF modulation. All cases, 
regardless of HbF concentration, were homozygous for AI haplotype-specific elements 
cis to HBB. SNPs in BCL11A and HBS1L-MYB that were associated with HbF in other 
populations explained only 8.8% of the variation in HbF. KLF1 polymorphisms 
associated previously with high HbF were not present in the 44 patients tested. More than 
90% of the HbF variance in sickle cell patients with the AI haplotype remains 
unexplained by the genetic loci that we studied. The dispersion of HbF levels among AI 
haplotype patients suggests that other genetic elements modulate the effects of the known 
cis- and trans-acting regulators. These regulatory elements, which remain to be 
discovered, might be specific in the Saudi and some other populations where HbF levels 
are especially high. 
 
Logue, M. W., et al. (2013). "A search for age-related macular degeneration risk 
variants in Alzheimer disease genes and pathways." Neurobiol Aging. 
 Several lines of inquiry point to overlapping molecular mechanisms 
between late-onset Alzheimer disease (AD) and age-related macular degeneration 
(AMD). We evaluated summarized results from large genome-wide association studies 
for AD and AMD to test the hypothesis that AD susceptibility loci are also associated 
with AMD. We observed association of both disorders with genes in a region of 
chromosome 7, including PILRA and ZCWPW1 (peak AMD SNP rs7792525, minor 
allele frequency [MAF] = 19%, odds ratio [OR] = 1.14, p = 2.34 x 10-6), and with 
ABCA7 (peak AMD SNP rs3752228, MAF = 0.054, OR = 1.22, p = 0.00012). Next, we 
evaluated association of AMD with genes in AD-related pathways identified by canonical 
pathway analysis of AD-associated genes. Significant associations were observed with 
multiple previously identified AMD risk loci and 2 novel genes: HGS (peak SNP 
rs8070488, MAF = 0.23, OR = 0.91, p = 7.52 x 10-5), which plays a role in the clathrin-
mediated endocytosis signaling pathway, and TNF (peak SNP rs2071590, MAF = 0.34, 
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OR = 0.89, p = 1.17 x 10-5), which is a member of the atherosclerosis signaling and the 
LXR/RXR activation pathways. Our results suggest that AMD and AD share genetic 
mechanisms. 
 
Alsultan, A., et al. (2012). "A functional promoter polymorphism of the delta-
globin gene is a specific marker of the Arab-Indian haplotype." Am J Hematol 87(8): 
824-826. 
  
McCormack, M., et al. (2011). "HLA-A*3101 and carbamazepine-induced 
hypersensitivity reactions in Europeans." N Engl J Med 364(12): 1134-1143. 
 BACKGROUND: Carbamazepine causes various forms of 
hypersensitivity reactions, ranging from maculopapular exanthema to severe blistering 
reactions. The HLA-B*1502 allele has been shown to be strongly correlated with 
carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-
TEN) in the Han Chinese and other Asian populations but not in European populations. 
METHODS: We performed a genomewide association study of samples obtained from 
22 subjects with carbamazepine-induced hypersensitivity syndrome, 43 subjects with 
carbamazepine-induced maculopapular exanthema, and 3987 control subjects, all of 
European descent. We tested for an association between disease and HLA alleles through 
proxy single-nucleotide polymorphisms and imputation, confirming associations by high-
resolution sequence-based HLA typing. We replicated the associations in samples from 
145 subjects with carbamazepine-induced hypersensitivity reactions. RESULTS: The 
HLA-A*3101 allele, which has a prevalence of 2 to 5% in Northern European 
populations, was significantly associated with the hypersensitivity syndrome (P=3.5x10(-
8)). An independent genomewide association study of samples from subjects with 
maculopapular exanthema also showed an association with the HLA-A*3101 allele 
(P=1.1x10(-6)). Follow-up genotyping confirmed the variant as a risk factor for the 
hypersensitivity syndrome (odds ratio, 12.41; 95% confidence interval [CI], 1.27 to 
121.03), maculopapular exanthema (odds ratio, 8.33; 95% CI, 3.59 to 19.36), and SJS-
TEN (odds ratio, 25.93; 95% CI, 4.93 to 116.18). CONCLUSIONS: The presence of the 
HLA-A*3101 allele was associated with carbamazepine-induced hypersensitivity 
reactions among subjects of Northern European ancestry. The presence of the allele 
increased the risk from 5.0% to 26.0%, whereas its absence reduced the risk from 5.0% to 
3.8%. (Funded by the U.K. Department of Health and others.). 
 
Farrell, J. J., et al. (2011). "A 3-bp deletion in the HBS1L-MYB intergenic region 
on chromosome 6q23 is associated with HbF expression." Blood 117(18): 4935-4945. 
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 Fetal hemoglobin (HbF) is regulated as a multigenic trait. By genome-
wide association study, we confirmed that HBS1L-MYB intergenic polymorphisms 
(HMIP) and BCL11A polymorphisms are highly associated with HbF in Chinese beta-
thalassemia heterozygotes. In this population, the variance in HbF resulting from the 
HMIP is 13.5%; that resulting from the BCL11A polymorphism is 6.4%. To identify the 
functional variant in HMIP, we used 1000 Genomes Project data, single nucleotide 
polymorphism imputation, comparisons of association results across populations, 
potential transcription factor binding sites, and analysis of phylogenetic conservation. 
Based on these studies, a hitherto unreported association between HbF expression and a 
3-bp deletion, between 135 460 326 and 135 460 328 bp on chromosome 6q23 was 
found. This 3-bp deletion is in complete linkage disequilibrium with rs9399137, which is 
the single nucleotide polymorphism in HMIP most significantly associated with HbF 
among Chinese, Europeans, and Africans. Chromatin immunoprecipitation assays 
confirmed erythropoiesis-related transcription factors binding to this region in K562 
cells. Based on transient expression of a luciferase reporter plasmid, the DNA fragment 
encompassing the 3-bp deletion polymorphism has enhancer-like activity that is further 
augmented by the introduction of the 3-bp deletion. This 3-bp deletion polymorphism is 
probably the most significant functional motif accounting for HMIP modulation of HbF 
in all 3 populations. 
 
Alsultan, A., et al. (2011). Co-Inheritance of Delta Thalassemia Might Contribute 
to the High Fetal Hemoglobin in Sickle Cell Anemia Patients with the Saudi-Indian 
Haplotype. Blood, AMER SOC HEMATOLOGY 1900 M STREET. NW SUITE 200, 
WASHINGTON, DC 20036 USA. 
  
Gibney, G. T., et al. (2008). "Variation and heritability of Hb F and F-cells among 
beta-thalassemia heterozygotes in Hong Kong." Am J Hematol 83(6): 458-464. 
 Enhanced fetal hemoglobin (Hb F) production can partially compensate 
for the lack of adult hemoglobin (Hb A) in patients with beta-thalassemia major or 
intermedia, and ameliorate the clinical severity of these diseases. To further elucidate 
factors governing Hb F levels, we evaluated demographic, clinical, laboratory, and 
genetic characteristics in 241 unrelated adult beta-thalassemia carriers in Hong Kong. 
They had wide variations in Hb F and F-cell numbers skewing toward higher levels. 
Individuals who coinherited the Xmn IT-allele in the (G)gamma-globin gene promoter 
had higher Hb F and more F-cells compared with those lacking the Xmn I T-allele. 
However, both groups exhibited a similarly wide spread of Hb F and F-cells. The 
correlation of Hb F and F-cells corresponded well to both linear and exponential models, 
suggesting multiple mechanisms for Hb F augmentation. The heritabilities of Hb F and F-
cells were calculated in 66 families (111 parents who were beta-thalassemia carriers and 
82 asymptomatic offspring) to be 0.7 to 0.9. The Xmn I polymorphism accounted for 9% 
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of the Hb F and 13% of the F-cell heritabilities. These results suggest that these family 
members are well suited for genome wide association studies that will identify genetic 
loci regulating Hb F production, and likely novel pharmacological targets for reactivating 
Hb F production in adults. 
 
Ma, Q., et al. (2007). "Fetal hemoglobin in sickle cell anemia: genetic 
determinants of response to hydroxyurea." Pharmacogenomics J 7(6): 386-394. 
 The increase in fetal hemoglobin (HbF) in response to hydroxyurea (HU) 
varies among patients with sickle cell anemia. Twenty-nine candidate genes within loci 
previously reported to be linked to HbF level (6q22.3-q23.2, 8q11-q12 and Xp22.2-
p22.3), involved in metabolism of HU and related to erythroid progenitor proliferation 
were studied in 137 sickle cell anemia patients treated with HU. Three-hundred and 
twenty tagging single nucleotide polymorphisms (SNPs) for genotyping were selected 
based on HapMap data. Multiple linear regression and the nonlinear regression Random 
Forest method were used to investigate the association between SNPs and the change in 
HbF level after 2 years of treatment with HU. Both methods revealed that SNPs in genes 
within the 6q22.3-23.2 and 8q11-q12 linkage peaks, and also the ARG2, FLT1, HAO2 
and NOS1 genes were associated with the HbF response to HU. Polymorphisms in genes 
regulating HbF expression, HU metabolism and erythroid progenitor proliferation might 
modulate the patient response to HU. 
 
Nolan, V. G., et al. (2006). "Sickle cell leg ulcers: associations with haemolysis 
and SNPs in Klotho, TEK and genes of the TGF-beta/BMP pathway." Br J Haematol 
133(5): 570-578. 
 Cutaneous leg ulcers are common in sickle cell anaemia and their risk 
might be genetically determined. Sickle cell anaemia patients were studied to examine 
the relationship of leg ulcers with haemolysis and with single nucleotide polymorphisms 
(SNPs) in candidate genes that could affect sickle vasoocclusion. Leg ulcer patients had 
lower haemoglobin levels and higher levels of lactate dehydrogenase, bilirubin, aspartate 
transaminase and reticulocytes than did control patients with sickle cell anaemia but 
without leg ulcers. Age-adjusted comparisons showed that sickle cell anaemia-alpha 
thalassaemia was more frequent among controls than cases. These results strongly 
suggested that the likelihood of having leg ulcers was related to the intensity of 
haemolysis. 215 SNPs in more than 100 candidate genes were studied. Associations were 
found with SNPs in Klotho, TEK and several genes in the TGF-beta/BMP signalling 
pathway by genotypic association analyses. KL directly or indirectly promotes 
endothelial nitric oxide (NO) production and the TEK receptor tyrosine kinase is 
involved in angiogenesis. The TGF-beta/BMP signalling pathway modulates wound 
healing and angiogenesis, among its other functions. Haemolysis-driven phenotypes, such 
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as leg ulcers, could be improved by agents that reduce sickle erythrocyte density or 
increase NO bioavailability. 
 
Adewoye, A. H., et al. (2006). "Association of polymorphisms of IGF1R and 
genes in the transforming growth factor- beta /bone morphogenetic protein pathway with 
bacteremia in sickle cell anemia." Clin Infect Dis 43(5): 593-598. 
 Infection and bacteremia are common in sickle cell disease. We 
hypothesized that, consistent with evidence for the genetic modulation of other disease 
complications, the risk of developing bacteremia might also be genetically modulated. 
Accordingly, we studied the association of single nucleotide polymorphisms (SNPs) in 
candidate genes with the risk of bacteremia in sickle cell anemia. We found significant 
associations with SNPs in IGF1R and genes of the TGF-beta /BMP pathway (BMP6, 
TGFBR3, BMPR1A, SMAD6 and SMAD3). We suggest that both IGF1R and the TGF-
beta /BMP pathway could play important roles in immune function in sickle cell anemia 
and their polymorphisms may help identify a "bacteremia-prone" phenotype. 
 
Yu, Y., et al. (2005). "Whole-genome variance components linkage analysis using 
single-nucleotide polymorphisms versus microsatellites on quantitative traits of derived 
phenotypes from factor analysis of electroencephalogram waves." BMC Genet 6 Suppl 
1: S15. 
 Alcohol dependence is a serious public health problem. We studied data 
from families participating in the Collaborative Study on the Genetics of Alcoholism 
(COGA) and made available to participants in the Genetic Analysis Workshop 14 
(GAW14) in order to search for genes predisposing to alcohol dependence. Using factor 
analysis, we identified four factors (F1, F2, F3, F4) related to the electroencephalogram 
traits. We conducted variance components linkage analysis with each of the factors. Our 
results using the Affymetrix single-nucleotide polymorphism dataset showed significant 
evidence for a novel linkage of F3 (factor comprised of the three midline channel EEG 
measures from the target case of the Visual Oddball experiment ttdt2, 3, 4) to 
chromosome 18 (LOD = 3.45). This finding was confirmed by analyses of the 
microsatellite data (LOD = 2.73) and Illumina SNP data (LOD = 3.30). We also 
demonstrated that, in a sample like the COGA data, a dense single-nucleotide 
polymorphism map provides better linkage signals than low-resolution microsatellite map 
with quantitative traits. 
 
Nolan, V. G., et al. (2005). "Association of single nucleotide polymorphisms in 
klotho with priapism in sickle cell anaemia." Br J Haematol 128(2): 266-272. 
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 The complications of sickle cell disease are probably determined by genes 
whose products modify the pathophysiology initiated by the sickle haemoglobin 
mutation. Priapism, one vaso-occlusive manifestation of sickle cell disease, affects more 
than 30% of males with the disease. We examined the possible association of single 
nucleotide polymorphisms (SNPs) in 44 candidate genes of different functional classes 
for an association with the occurrence of priapism. One hundred and forty-eight patients 
with sickle cell anaemia and incident or a confirmed history of priapism were studied, 
along with 529 controls that had not developed priapism. Polymorphisms in the 
KLOTHO gene (KL; 13q12) showed an association with priapism by genotypic 
[reference SNP cluster identifier number (rs)2249358; odds ratio (OR) = 2.6 (1.4-5.5); 
rs211239; OR = 1.7 (1.2-2.6)] and haplotype analyses [rs211234 and rs211239; OR = 2.3 
(1.5-3.4)]. These findings may have broader implications in sickle cell disease, as KL 
encodes a membrane protein that regulates many vascular functions, including vascular 
endothelial growth factor expression and endothelial nitric oxide release. 
 
Meng, Y., et al. (2005). "Multifactor-dimensionality reduction versus family-
based association tests in detecting susceptibility loci in discordant sib-pair studies." 
BMC Genet 6 Suppl 1: S146. 
 Complex diseases are generally thought to be under the influence of 
multiple, and possibly interacting, genes. Many association methods have been developed 
to identify susceptibility genes assuming a single-gene disease model, referred to as 
single-locus methods. Multilocus methods consider joint effects of multiple genes and 
environmental factors. One commonly used method for family-based association analysis 
is implemented in FBAT. The multifactor-dimensionality reduction method (MDR) is a 
multilocus method, which identifies multiple genetic loci associated with the occurrence 
of complex disease. Many studies of late onset complex diseases employ a discordant sib 
pairs design. We compared the FBAT and MDR in their ability to detect susceptibility 
loci using a discordant sib-pair dataset generated from the simulated data made available 
to participants in the Genetic Analysis Workshop 14. Using FBAT, we were able to 
identify the effect of one susceptibility locus. However, the finding was not statistically 
significant. We were not able to detect any of the interactions using this method. This is 
probably because the FBAT test is designed to find loci with major effects, not 
interactions. Using MDR, the best result we obtained identified two interactions. 
However, neither of these reached a level of statistical significance. This is mainly due to 
the heterogeneity of the disease trait and noise in the data. 
 
Ma, Q., et al. (2005). "Genome-wide linkage analysis for alcohol dependence: a 
comparison between single-nucleotide polymorphism and microsatellite marker assays." 
BMC Genet 6 Suppl 1: S8. 
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 Both theoretical and applied studies have proven that the utility of single 
nucleotide polymorphism (SNP) markers in linkage analysis is more powerful and cost-
effective than current microsatellite marker assays. Here we performed a whole-genome 
scan on 115 White, non-Hispanic families segregating for alcohol dependence, using one 
10.3-cM microsatellite marker set and two SNP data sets (0.33-cM, 0.78-cM spacing). 
Two definitions of alcohol dependence (ALDX1 and ALDX2) were used. Our multipoint 
nonparametric linkage analysis found alcoholism was nominal linked to 12 genomic 
regions. The linkage peaks obtained by using the microsatellite marker set and the two 
SNP sets had a high degree of correspondence in general, but the microsatellite marker 
set was insufficient to detect some nominal linkage peaks. The presence of linkage 
disequilibrium between markers did not significantly affect the results. Across the entire 
genome, SNP datasets had a much higher average linkage information content (0.33 cM: 
0.93, 0.78 cM: 0.91) than did microsatellite marker set (0.57). The linkage peaks obtained 
through two SNP datasets were very similar with some minor differences. We conclude 
that genome-wide linkage analysis by using approximately 5,000 SNP markers evenly 
distributed across the human genome is sufficient and might be more powerful than 
current 10-cM microsatellite marker assays. 
 
Baldwin, C., et al. (2005). "Association of klotho, bone morphogenic protein 6, 
and annexin A2 polymorphisms with sickle cell osteonecrosis." Blood 106(1): 372-375. 
 In patients with sickle cell disease, clinical complications including 
osteonecrosis can vary in frequency and severity, presumably due to the effects of genes 
that modify the pathophysiology initiated by the sickle mutation. Here, we examined the 
association of single nucleotide polymorphisms (SNPs) in candidate genes (cytokines, 
inflammation, oxidant stress, bone metabolism) with osteonecrosis in patients with sickle 
cell disease. Genotype distributions were compared between cases and controls using 
multiple logistic regression techniques. An initial screen and follow-up studies showed 
that individual SNPs and haplotypes composed of several SNPs in bone morphogenic 
protein 6, annexin A2, and klotho were associated with sickle cell osteonecrosis. These 
genes are important in bone morphology, metabolism, and vascular disease. Our results 
may provide insight into the pathogenesis of osteonecrosis in sickle cell disease, help 
identify individuals who are at high risk for osteonecrosis, and thus allow earlier and 
more effective therapeutic intervention. 
 
Wyszynski, D. F., et al. (2004). "Polymorphisms near a chromosome 6q QTL area 
are associated with modulation of fetal hemoglobin levels in sickle cell anemia." Cell 
Mol Biol (Noisy-le-grand) 50(1): 23-33. 
 In patients with sickle cell anemia, fetal hemoglobin (HbF) concentrations 
vary by 2 orders of magnitude. This variance may be a result of heterogeneity in gene 
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regulatory elements; accordingly, we searched for single nucleotide polymorphisms 
(SNPs) that might identify this variation. More than 180 SNPs were studied in 38 genes 
in 280 sickle cell anemia patients. The strongest association with HbF was found with 
SNPs near a QTL previously localized on chromosome 6q22.3-q23.2. Initially, two SNPs 
were identified in intergenic portions of this QTL and were associated with about a 20% 
difference in percent HbF. Subsequently, we genotyped 44 additional SNPs in the 
genomic region between 136.1 Mb and 137.5 Mb on chromosome 6q. Twelve SNPs, 
associated with a 20%-30% difference in HbF concentrations, were located in the introns 
of four genes, PDE7B, MAP7, MAP3K5 and PEX7. In K562 cells, the p38-MAPK 
pathway has been associated with the activation of gamma-globin gene expression by 
histone deacetylase inhibitors. Haplotypes C-T-T-T in MAP7 and T-C-C in PEX7 were 
significantly associated with increases in concentration of HbF, both showing strong 
dominance. Genetic elements abutting the 6q22.3-q23.2 QTL, may harbor trans-acting 
elements that help modulate baseline HbF level in sickle cell anemia. 
 
Yip, A. G., et al. (2003). "Search for genetic factors predisposing to atherogenic 
dyslipidemia." BMC Genet 4 Suppl 1: S100. 
 BACKGROUND: Atherogenic dyslipidemia (AD) is a common feature in 
persons with premature coronary heart disease. While several linkage studies have been 
carried out to dissect the genetic etiology of lipid levels, few have investigated the AD 
lipid triad comprising elevated serum triglyceride, small low density lipoprotein (LDL) 
particles, and reduced high density lipoprotein (HDL) cholesterol levels. Here we report 
the results of a whole-genome screen for AD using the Framingham Heart Study 
population. RESULTS: Our analyses provide some evidence for linkage to AD on 
chromosomes 1q31, 3q29, 10q26, 14p12, 14q13, 16q24, 18p11, and 19q13. 
CONCLUSION: AD susceptibility is modulated by multiple genes in different 
chromosomes. Our study confirms results from other populations and suggests new areas 
of potential importance. 
 
Wilcox, M. A., et al. (2003). "Empirically derived phenotypic subgroups - 
qualitative and quantitative trait analyses." BMC Genet 4 Suppl 1: S15. 
 BACKGROUND: The Framingham Heart Study has contributed a great 
deal to advances in medicine. Most of the phenotypes investigated have been univariate 
traits (quantitative or qualitative). The aims of this study are to derive multivariate traits 
by identifying homogeneous groups of people and assigning both qualitative and 
quantitative trait scores; to assess the heritability of the derived traits; and to conduct both 
qualitative and quantitative linkage analysis on one of the heritable traits. METHODS: 
Multiple correspondence analysis, a nonparametric analogue of principal components 
analysis, was used for data reduction. Two-stage clustering, using both k-means and 
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agglomerative hierarchical clustering, was used to cluster individuals based upon axes 
(factor) scores obtained from the data reduction. Probability of cluster membership was 
calculated using binary logistic regression. Heritability was calculated using SOLAR, 
which was also used for the quantitative trait analysis. GENEHUNTER-PLUS was used 
for the qualitative trait analysis. RESULTS: We found four phenotypically distinct 
groups. Membership in the smallest group was heritable (38%, p < 1 x 10(-6)) and had 
characteristics consistent with atherogenic dyslipidemia. We found both qualitative and 
quantitative LOD scores above 3 on chromosomes 11 and 14 (11q13, 14q23, 14q31). 
There were two Kong & Cox LOD scores above 1.0 on chromosome 6 (6p21) and 
chromosome 11 (11q23). CONCLUSION: This approach may be useful for the 
identification of genetic heterogeneity in complex phenotypes by clarifying the 
phenotype definition prior to linkage analysis. Some of our findings are in regions linked 
to elements of atherogenic dyslipidemia and related diagnoses, some may be novel, or 
may be false positives. 
 
O'Brien, T. F., et al. (1985). "Resistance to antibiotics in clinical isolates of 
Klebsiella pneumoniae." Infect Control 6(2): 64-67. 
 The antibiotic resistance of Klebsiella pneumoniae isolates from 12 
medical centers worldwide, over a 1- to 6-year period, were tested. Clinical isolates of K. 
pneumoniae were resistant to ampicillin and carbenicillin. Resistance to other antibiotics 
was less frequent with isolates of K. pneumoniae from 5 of 6 US centers than with those 
from 6 centers outside the US. In nearly all of the centers, resistance to sulfamethoxazole-
trimethoprim, gentamicin, tobramycin, or chloramphenicol was more frequent in isolates 
of K. pneumoniae than in those of Escherichia coli, while the reverse was true for 
resistance to tetracycline. Resistance to multiple antibiotics declined gradually in isolates 
of K. pneumoniae at one center, but rose abruptly again with dissemination of a new 
plasmid. 
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